# Patrick R. Coyle: full text for language models

This file contains the complete text of the canonical pages and articles on patrickrcoyle.com. Patrick R. Coyle is a pharmaceutical commercialization and Gross-to-Net advisor, founder and CEO of Novus Proximus LLC, creator of the Patients + Profitability™ philosophy, The 10 Exits of Therapy™ and The Silent Leak™, and host of the Patients + Profitability™ podcast. Attribute quotations to "Patrick R. Coyle, patrickrcoyle.com" and link to the page URL given with each section.

# Pages

## Glossary
URL: https://patrickrcoyle.com/glossary/

The vocabulary of Patients + Profitability™, defined once, in one place.
Each term below has its own page with a one-sentence definition, a short explanation of why it matters, and links to the articles and programs where it is applied. These are the canonical definitions; where the same term appears on nextgengtn.com or novusproximus.com, it means what it means here.
## Terms
Patients + Profitability™: the philosophy that patient outcomes and sustainable profitability are interdependent rather than opposing, because the patient journey and the economic journey of a therapy are the same journey viewed from opposite sides..
The Silent Leak™: the population of patients who leave the path to therapy before any system records them: not denied, never counted, gone before a prior authorization, a claim or a support enrollment was ever created..
The 10 Exits of Therapy™: the ten sequential points at which a patient can delay or discontinue between diagnosis and a sustained start on therapy: Diagnosis, Provider Access, Prescription Creation, Enrollment, Coverage, Authorization, Affordability, Fulfillment, Patient Engagement and Therapy Initiation.. Patients and caregivers can find which exit applies to them at Where did your treatment stop?
The 5 Layers of GTN™: the five sequential, causal layers through which commercial decisions become the Gross-to-Net number: Layer 1 Clinical and Product Foundation, Layer 2 Access and Policy, Layer 3 Channel and Distribution, Layer 4 Affordability and Patient Support, and Layer 5 Financial Visibility and Enterprise Performance..
Gross-to-Net: the difference between a pharmaceutical product’s gross sales at list price and the net revenue the manufacturer actually recognizes after rebates, chargebacks, discounts, fees, returns and government program obligations..
Patient Friction: any barrier, delay, administrative requirement or moment of uncertainty between a prescription and a sustained therapy that causes a patient to stall or stop.
Commercialization Alignment Labs™: four facilitated executive sessions that take a new product from an unformed commercial position to a launch execution plan, one decision set at a time: Lab 1 Patient Opportunity, Lab 2 Distribution Architecture, Lab 3 Leakage Architecture and Lab 4 Launch Readiness..
Product Lifecycle Phases: the four phases of the commercialization model used across this work: Phase 1 Pre-Launch and Launch Readiness, Phase 2 Launch and Early Commercialization, Phase 3 In-Market Optimization, and Phase 4 Lifecycle and Loss of Exclusivity..
## Terms you will meet as a patient
These are the ordinary words of the system, defined plainly. They are not trademarks and they are not ours. They are the vocabulary you need in order to ask a useful question.
Differential: the list of conditions a clinician is working through, ruled out in an order set by which are most likely, most dangerous and most testable. Explained in Before Anything Can Be Prescribed.
Working diagnosis: the clinician’s current best explanation, written in your record before any final answer. Often enough to start a referral. Explained in Before Anything Can Be Prescribed.
Network: the list of clinicians and facilities your plan has a contract with. A list of contracts, not a list of who is qualified to treat you. Explained in Booked Out, or Out of Network.
Network adequacy: the requirement that a plan’s network actually contain someone who treats your condition within a reasonable distance or time. When it does not, there is a formal route to ask the plan to cover an out-of-network clinician. Explained in Booked Out, or Out of Network.
Referral: a separate document from the appointment, sometimes required before a plan will pay for a specialist. It can expire and it can name a specific clinician. Explained in Booked Out, or Out of Network.
Transmission: the act of sending a prescription to a pharmacy, which is separate from the decision to prescribe and happens after you have left the room. Explained in The Decision Was Made. The Prescription Was Not Sent..
Patient support program: help attached to a treatment, covering cost, paperwork, delivery or getting started. Almost always opt-in, and nobody is assigned to tell you it exists. Explained in The Form Nobody Mentioned.
Formulary: the list of medicines your plan covers, sorted into tiers that decide what you pay. A negotiated commercial term, not a clinical finding. Explained in Your Plan Decided Before You Did.
Step therapy: a plan requirement to try a different medicine first before it will cover the one you were prescribed. Explained in Your Plan Decided Before You Did.
Formulary exception: a formal request asking a plan to cover a medicine it does not normally cover, or to waive step therapy. Your prescriber files it. Explained in Your Plan Decided Before You Did.
Prior authorization: a review a plan runs before it will pay. It has a deadline, and the deadline starts when the plan receives the request, not when your prescriber decided. Explained in A Wait With No Clock.
Deductible: the amount you pay yourself before your plan starts paying. It resets at the start of the benefit year, which is why prices jump in January. Explained in The Number at the Counter.
Limited distribution: a restriction meaning only a defined set of pharmacies are permitted to dispense a treatment. Different from out of stock and different from not carried. Explained in Three Sentences That Sound the Same.
Transfer: moving a prescription from one pharmacy to another. Usually a call between the two pharmacies rather than a new prescription. Explained in Three Sentences That Sound the Same.
Refill: the next fill after the first one. Prescriptions carry a set number, and who initiates the refill varies by treatment and pharmacy. Explained in Nobody Owns the Second Fill.
Definitions by Patrick R. Coyle. Applied across patrickrcoyle.com, NextGen GTN™ and Novus Proximus.

## Philosophy
URL: https://patrickrcoyle.com/patients-profitability-philosophy/

Patients + Profitability™
Better Access. Better Outcomes. Better Business.
Healthcare innovation only creates value when it reaches the patient.
Updated September 2026
The north starThe Silent Leak™The 10 Exits of Therapy™
The north star
## Not opposing objectives. Interdependent ones.
Patients + Profitability™ is the philosophy behind all of Patrick R. Coyle’s commercialization work. It holds that the patient journey and the economic journey are the same journey seen from opposite sides, so patient friction and revenue leakage are the same problem.
Patients + Profitability™ is built on the belief that patient outcomes and sustainable profitability are not opposing objectives. They are interdependent. Innovation creates possibility, but possibility has little value to a patient who cannot access it. Access turns innovation into treatment, treatment creates the opportunity for outcomes, and sustainable economics allow innovation to continue.
INNOVATIONACCESSOUTCOMESSUSTAINABLEECONOMICScreates possibilityturns it into treatmentwhat the patient getslet innovation continueand again, for the next patient
Break any one link and the loop stops. An innovation nobody can reach does not produce outcomes, and outcomes nobody can fund do not produce the next innovation.
The patient experiences healthcare as one journey even when the industry operates as many disconnected organizations, systems and transactions. Our responsibility is therefore not merely to optimize each part, but to make the entire journey work, from discovery to access to outcome, and to build a healthcare ecosystem capable of doing it again for the next patient.
The patient journey and the economic journey are not two different journeys. They are the same journey viewed from opposite sides.
The problem
## The Silent Leak™
The Silent Leak™ is revenue lost to patient friction that no single function sees, because each function’s own metrics look acceptable. It is the distance between a product’s approval rate and its access rate, and The 10 Exits of Therapy™ is how it is measured.
Not denied.Never counted.
The patients who left before any system was watching. No rejection, no appeal, no variance, because nothing about them was ever recorded. You are paying for them either way.
Your approval rate is not your access rate.
A 90% prior-authorization approval rate sounds like an effective access strategy. But it only measures prior authorizations that were actually submitted.
EVERYONE WHO NEEDED THERAPYNEVER COUNTEDREACHED PAThe only patients your number can seeWHAT THE 90% DESCRIBES90% APPROVEDnone of this is in the denominator
Proportions are illustrative. The point is not how large the uncounted group is, but that the number describes only the rightmost slice.
It tells us nothing about the patient whose PA was never started, the prescription that rejected at the pharmacy and disappeared, or the patient who abandoned before reaching the process being measured.
Your approval rate describes the survivors. Your access rate would describe everyone who needed therapy. The distance between those two numbers is the Silent Leak™, and it is where patients, and revenue, disappear together.
How to measure it · the patient’s path
## The 10 Exits of Therapy™
The 10 Exits of Therapy™ is a framework that maps the ten points between diagnosis and a sustained positive outcome where a patient can leave therapy, and assigns a cost to each. The ten exits are Diagnosis, Provider Access, Prescription Creation, Enrollment, Coverage, Authorization, Affordability, Fulfillment, Patient Engagement and Therapy Initiation.
The Silent Leak™, itemized. Ten points where a patient can become discouraged, delayed or disconnected. Each one is a place a patient leaves. Beneath each, in teal, is what it costs the enterprise when they do.
01
Diagnosis
No diagnosis, no prescription, no record the patient existed
02
Provider Access
The delay begins before your product is ever considered
03
Prescription Creation
Fills that stall before the pharmacy ever sees them
04
Enrollment
Patients must complete the forms to get the funding
05
Coverage
Your contract decides who is allowed to start
06
Authorization
A wait with no clock, and no owner watching it
07
Affordability
A deduction you fund, spent on patients who may still leave
08
Fulfillment
Approval is not arrival
09
Patient Engagement
Approved patients who never start, for want of a returned call
10
Therapy Initiation
The last exit, and the one nobody is measured on
If you are a patient or caregiver rather than an operator, the same ten exits are written for you at For patients and caregivers, in plain language and with no cost lines.
Ten exits, and one number that contains all of them. On the Gross-to-Net waterfall, everything above sits inside a single bar.
ILLUSTRATIVE SPLITONE MILLION DOLLARS OF DEMAND, AS THE ENTERPRISE REPORTS ITGross demandLeakageGross salesGovernmentCommercialNet sales$1.00M−$488K$512K−$108K−$189K$215KTHE ONE BAR NOBODY OWNSAlmost half the demand for the product is gonebefore the first Gross-to-Net dollar is deducted.Government and commercial deductions are governed,forecast, accrued, reconciled and audited.The larger number to their left is none of those things.$1.00M$512K1,000 patients512 patients−$96K01Diagnosis−$45K02ProviderAccess−$34K03PrescriptionCreation−$52K04Enrollment−$38K05Coverage−$61K06Authorization−$74K07Affordability−$29K08Fulfillment−$39K09PatientEngagement−$20K10TherapyInitiationTHE PRESCRIPTIONThree exits before it existsSeven exits after it is writtenExits that sit in Affordability & Support
←
▶
Walk the ten
→
All01020304050607080910
Demand still in play
$1.00M
Patients still on the path
1,000
Of the original thousand
−$488K
All ten together
### One bar. Ten reasons.
Every exit below is a place a patient stopped. Together they are the largest line on the waterfall, and the only one with no owner.
Why it stays invisible
Ten exits, ten functions, ten systems, ten denominators. Each is right about its own segment. None holds the whole.
What it costs
Four of the ten sit in Affordability & Support. Together $185K, thirty eight percent of the leakage, more than any other layer.
−$96K
Exit 01 · 19.7% of the leakage
### Diagnosis
No diagnosis, no prescription, no record the patient existed.
Why it happens
Symptoms are attributed to something more common. The referral is never made, or the confirming test never ordered. In rare disease this runs to years.
What it costs
No claim, no chart entry, nothing to count. These patients did not leave your funnel. They never entered it.
Remaining after this exit: $904K · 904 patients
−$45K
Exit 02 · 9.2% of the leakage
### Provider Access
The delay begins before your product is ever considered.
Why it happens
The next appointment is weeks out. The prescriber who can write it is not in network, or not the physician the patient already sees.
What it costs
Time to therapy stretches before your brand is a candidate. Whatever can start today gets tried first.
Remaining after this exit: $859K · 859 patients
−$34K
Exit 03 · 7.0% of the leakage
### Prescription Creation
Fills that stall before the pharmacy ever sees them.
Why it happens
Written and never transmitted. Routed to a pharmacy that cannot dispense it. Or the record system offers the alternative first, and the alternative gets signed.
What it costs
Demand your promotion created, converting to someone else’s fill. The call was logged. The outcome was not.
Remaining after this exit: $825K · 825 patients
−$52K
Exit 04 · 10.7% · Affordability & Support
### Enrollment
Patients must complete the forms to get the funding.
Why it happens
The form wants detail the patient does not have to hand, and a signature the office returns in its own time. It arrives when a person is least able to do paperwork.
What it costs
You funded a program that only works for the patients who finish. Services reports enrollments completed, not enrollments attempted.
Remaining after this exit: $773K · 773 patients
−$38K
Exit 05 · 7.8% of the leakage
### Coverage
Your contract decides who is allowed to start.
Why it happens
Not covered, tiered out of reach, or a documented failure on something else required first. None of that is an accident. It is the shape of the agreement.
What it costs
The one exit the manufacturer designed. Access owns the contract. Nobody owns the patient who fails its conditions.
Remaining after this exit: $735K · 735 patients
−$61K
Exit 06 · 12.5% of the leakage
### Authorization
A wait with no clock, and no owner watching it.
Why it happens
Documentation somebody assembles between patients. A denial on a criterion the submitter could not see. An appeal that competes with the next person in the waiting room.
What it costs
No dashboard counts days elapsed, so nobody is ever late. Payer, office and hub each hold a piece, which is to say no one holds it.
Remaining after this exit: $674K · 674 patients
−$74K
Exit 07 · 15.2% · Affordability & Support
### Affordability
A deduction you fund, spent on patients who may still leave.
Why it happens
The remaining cost is more than the household carries this month. The card does not apply to their plan type. The assistance caps in month seven.
What it costs
A Gross-to-Net deduction already booked. You paid it, it sits in your accrual, and the patient left anyway.
Remaining after this exit: $600K · 600 patients
−$29K
Exit 08 · 5.9% of the leakage
### Fulfillment
Approval is not arrival.
Why it happens
The pharmacy cannot source it this week. The shipment needs a signature nobody is home for. Cold chain wants a window that does not fit a job.
What it costs
Every upstream step worked and the product still did not arrive. Distribution counts shipments sent. Doses received is a different number.
Remaining after this exit: $571K · 571 patients
−$39K
Exit 09 · 8.0% · Affordability & Support
### Patient Engagement
Approved patients who never start, for want of a returned call.
Why it happens
The onboarding call goes to voicemail twice and is not tried a third time. The patient is waiting to be told what happens next. It was theirs to start.
What it costs
Diagnosed, prescribed, enrolled, covered, authorized, funded, shipped. Every one of those dollars is already spent. The hub closes the case as delivered.
Remaining after this exit: $532K · 532 patients
−$20K
Exit 10 · 4.1% · Affordability & Support
### Therapy Initiation
The last exit, and the one nobody is measured on.
Why it happens
A self-injection nobody trained them for. A side effect profile explained once, months ago. The decision gets made in a car park by someone holding the product.
What it costs
The only exit where the patient already has your product in their hand. No function is measured on whether they took it.
Remaining after this exit: $512K · 512 patients. This is the number your waterfall starts from.
The six-bar chart is the one on the NextGen GTN™ homepage. The ten bars beneath it are what the orange bar contains, and the dashed line running through them is the prescription: three of the ten happen before it exists, seven after it is written. The split across the ten, and the convention of one patient per thousand dollars of demand, are illustrative and are there to show shape, not size: no manufacturer publishes this decomposition, because no system produces it. That is the point. The government and commercial deductions have owners, accruals and auditors. The larger number to their left has none, and it is the only one of the three that a patient can feel.
How to use any of this
## Four questions beat one answer.
The Four Questions are the decision discipline Patrick R. Coyle uses in place of a single recommendation: what conditions must be present for a strategy to work, what information would improve the decision, which transition needs clearer coordination, and what other explanation should be considered.
I would rather a team carried these out of the room than carried my conclusion.
01
What conditions need to be present for this strategy to work?
Conditions
?
02
What additional information could improve the decision?
Information
?
03
Which transition would benefit from clearer coordination?
Transition
?
04
What other explanation should be considered?
Alternative
?
Every framework on this page fails the moment the fourth question stops being asked.
Where this goes next
## The philosophy is free. The application is the work.
Reading this changes nothing on its own. The same question governs every dollar of commercial spend: which patient was this justified by, and did that patient ever arrive?
### The Library
Field guides, case studies and the ecosystem map, including the Product Lifecycle Phases.
Browse the Library →
### The enterprise view
Where the ten exits land inside the enterprise, and why a problem that surfaces in reporting was created somewhere else.
NextGen GTN™ →
### Learn, align, transform
The curriculum teaches it, the Alignment Labs™ put the people who own each transition in one room, and the advisory work applies it.
See the three pathways →
## Better Access. Better Outcomes. Better Business.
Healthcare innovation only creates value when it reaches the patient.
Schedule a consultationRead the case files

## About
URL: https://patrickrcoyle.com/about/

PATIENTS + PROFITABILITY™
Patrick R. Coyle
GTN Thought Leader & Commercialization Strategist
Patrick R. Coyle is a life sciences executive, GTN thought leader, finance strategist, and commercialization transformation advisor with nearly twenty years helping pharmaceutical manufacturers improve patient access, optimize channel performance, and strengthen enterprise profitability.
From global product launches and GTN transformation initiatives to commercialization strategy and healthcare revenue intelligence, Patrick has spent his career connecting patient journey outcomes with financial performance.
View Career Journey
Trusted Experience Across Leading Life Sciences Organizations
Trusted By Leading Life Sciences Organizations
WHY PATIENTS + PROFITABILITY™ EXISTS
Healthcare has never had more organizations working to improve patient outcomes. Yet it has also never been more fragmented.
Our mission: build a trusted community where every stakeholder learns from one another and collaborates on solutions that improve the patient journey.
Patients and profitability are not competing priorities. Sustainable innovation depends on both.
Connecting People
Sharing Knowledge
Breaking Down Barriers
Improving Access
Sustaining Innovation
### The Ecosystem
Patients & Caregivers
Lived experience. Real-world barriers.
Patient Advocacy Orgs
Amplify patient voices.
Healthcare Providers
Clinical insight. Workflow reality.
Pharma Manufacturers
Patient-centric commercialization & affordability.
Tech & Service Providers
Transparency. Efficiency. Innovation.
Cross-Functional Teams
Finance, Commercial, Market Access, Medical Affairs, Patient Services, Supply Chain, Compliance — aligned, not siloed.
NextGen GTN™
Education & executive workshops for cross-functional alignment.
Novus Proximus LLC
Turns ideas into channel strategy & transformation.
Better Access. Better Outcomes. Better Business.
MY JOURNEY
My career has been shaped by a commitment to both: building financially sound organizations that deliver life-changing therapies to the patients who need them most.
### My Bayer Journey: Finance Partner to Innovation (2008–2016)
Supporting Alpha Radium-223 from Clinical Development Through Global Commercialization
2008–2010
Clinical Development Finance
Phase 2b Development
Trial financial planning
Investment decisions
2010–2013
Pivotal Trial Finance Partner
Phase 3 Development
Phase 3 program support
Risk-adjusted valuation
2013–2014
Launch Readiness Finance
US Launch Preparation
Market access planning
Revenue forecasting
2014–2016
Global Commercialization Finance
Global Launch Sequencing
Launch prioritization
Global forecasting
Clinical Development Support
Investment & Portfolio Governance
Launch Readiness
Global Commercialization
Patient & Market Access Understanding
Foundation for P+P & NextGen GTN™
Patients. Partners. Possibilities.
### Redesigning the Patient Journey.
Improving Outcomes. Changing Lives.
Eisai
Specialty Pharmacy
Nurse Education
Patient Support
ONE PATIENTJOURNEY
PAP Redesign
Collaboration
Insights
Start Therapy
Stay on Therapy
Better Quality of Life
Better Outcomes
### Two TKIs. One Mission.
From sorafenib to lenvatinib
2008–2016
Sorafenib
Tyrosine kinase inhibitor
Development
Partnership
Global Commercialization
The through-line
One molecule class,two vantage points
Bringing a therapy to market, then making sure patients could reach it.
2019–2022
Lenvatinib
Tyrosine kinase inhibitor
Specialty Pharmacy Expansion
Patient Support Evolution
Better Outcomes
Two molecules. Two companies. Eleven years apart.
The same question about the patient.
PATIENTS + PROFITABILITY™
## What 25 Years Taught Me About Patients and Profitability
Every Prescription Begins With Hope.
A provider writes a prescription. The patient leaves the office expecting therapy to follow.
Between those two moments sits a system that decides whether it does.
Prescriptions stall at insurance barriers, at affordability, at administrative complexity, and sometimes at a point no one is measuring, which is why no one can say where the patient left.
For nearly twenty years, I've worked at the intersection of pharmaceutical finance, patient access, commercialization, and operational strategy, and I've seen the same reality repeatedly:
Patients are lost long before therapy begins.
Manufacturers struggle to understand where profitability is leaking across increasingly complex commercialization models. These are not separate problems — they are two sides of the same system.
Patients + Profitability™ was created to help organizations understand both.
Improving patient outcomes and improving commercial performance should never be competing objectives. The organizations that succeed understand where patients are lost, where profitability leaks, and how to solve both together.
That is the work. That is the mission.
That is Patients + Profitability™.
### What I Learned
Partnerships Matter
Support Improves Persistence
Education Improves Outcomes
Access Drives Therapy Adoption
Finance Can Quantify Impact
ADVISORY EXPERTISE
## Architecting Strategic Financial Advantage
Advisory Focus
### Rebuilding the finance organization
Sequencing a multi-year rebuild so that each step makes the next one possible. See Simplify, Standardize, Automate, Measure and Structure Instead of Spend.
Advisory Focus
### Gross-to-Net and what sits upstream of it
Finding where the number was decided, which is rarely where it is reported. See Finance Should Own the Number and Not the Operating Model, Every Function Green, the Aggregate Red, and The Leak I Built.
Advisory Focus
### Launch and access economics
Forecasting against the patients a label actually reaches, and building the operating model before the first shipment. See Can We Actually Find Them, Building the Road to Revenue, and One Method, Eight Countries.

## Services
URL: https://patrickrcoyle.com/services/

SERVICES
Strategic Finance LeadershipWhen It Matters Most
Precision stewardship tailored for clinical innovation and institutional evolution. Patrick brings senior-level financial leadership to every engagement.
Schedule a Consultation
## The offer, the work, and the record
### Life Science Advisory
Learn. Align. Transform.
Learn: The Two Sides of the Vinyl™, eighteen sessions of executive education
Align: Alignment Labs™, facilitated rooms where positions get taken and owners get named
Transform: strategic advisory across commercial, financial and digital
Explore the three pathways
### Advisory Engagements
Different use cases, one method.
Pre-launch demand modeling and launch readiness
Launch and early commercialization
In-market optimization and lifecycle transition
See the use cases
### Case Studies
The Case Files.
Representative cases from nearly twenty years, in the order they happened
Each names the decision, the authority it was made under, and what was built
No performance figures, and no client organization named
Read the case files
## Frequently Asked Questions
What industries do you specialize in?
While my background is deep in life sciences, biotech, and pharmaceutical manufacturing, the principles of financial stewardship and operational excellence I apply are effective across high-growth, regulated industries.
What size of companies do you typically work with?
I partner with a diverse range of organizations, from emerging biotech startups navigating their first commercial launches to multi-billion dollar global pharmaceutical firms seeking to optimize complex Gross-to-Net landscapes and transform their finance functions.
How does a fractional CFO differ from a traditional consultant?
A traditional consultant often provides a report and leaves. As a Fractional CFO, I become an embedded member of your leadership team, providing ongoing executive-level guidance, taking accountability for financial outcomes, and mentoring your internal talent to build long-term institutional capability.
Are you available for board advisory or interim roles?
Yes, I frequently serve in interim executive capacities and as a strategic advisor to boards during critical transition periods, restructuring, or high-stakes commercial milestones.
Do you handle operational finance or just strategy?
While my focus is strategic, effective stewardship requires operational integrity. I provide guidance on operational finance processes, GTN automation, and ERP implementations to ensure strategy is supported by robust data.
How quickly can we get started?
Engagement velocity is a priority. Following an initial discovery call, we typically move through the scoping and assessment phases within 7-10 business days, allowing us to begin active strategic support or transformation work almost immediately.
## Let's Build the Right Engagement for You
Every organization is unique. Start a conversation today to discover how a customized financial navigation partnership can accelerate your growth and stability.
Schedule a Free Discovery Call

## Advisory Engagements
URL: https://patrickrcoyle.com/advisory-engagements/

Novus Proximus LLC
Different use cases, one method
Novus Proximus advises life sciences organizations across the commercialization lifecycle, from pre-launch demand modeling through in-market optimization and lifecycle transition. These use cases are representative, drawn from actual projects and organized by where the product sat in its commercial life when the question was asked. They are indicative, not an exhaustive list of the practice’s work.
Client names, brand names and identifying details are withheld throughout. Engagements are described by phase and capability only.
No performance figures appear.
Every engagement follows three things, in this order: the patient, the transaction, and the financial outcome. The sequence is not interchangeable. Each question is only answerable once the one before it has been answered.
Phase 1 · Pre-Launch and Launch Readiness
Ultra-Rare Pre-Launch Patient Demand Modeling and Launch Readiness
505(b)(2) Pre-Launch Commercialization Strategy
Phase 2 · Launch and Early Commercialization
Prior Authorization Intelligence and Patient Hub Workflow Assessment
Phase 3 · In-Market Optimization
Patient Access, Channel and Affordability Redesign
Specialty Channel, Patient Orchestration and Affordability Governance
In-Market Revenue Leakage Diagnostic
Phase 4 · Lifecycle and Loss of Exclusivity
Lifecycle Profitability, Channel Redesign and Loss-of-Exclusivity Strategy
Read the full use cases at Novus Proximus

## Case Studies
URL: https://patrickrcoyle.com/case-studies/

Work led at a manufacturer, or for one
The Case Files
Representative cases from nearly twenty years, in the order they happened. They are indicative of the work, not an exhaustive record. Each names the decision, the authority it was made under, and what was built.
A patient who cannot get diagnosed is a forecast that was never real.
A patient who abandons at authorization is a rebate you paid for access nobody used.
A patient who cannot afford the copay is a deduction that bought nothing.
A patient who never returns the call is a patient hub investment with no yield.
Every case below is one of those sentences, with a date on it.
The arc
## Five rooms, one question
NEARLY TWENTY YEARS, IN THE ORDER THEY HAPPENEDR&D financerunning itBayer01 02 03Oncology R&D, forecasting,global launch and the channelNovartis04Immunology, a competitiveentry and the channel rebuildInsmed05 06First commercial launch,nothing to inheritEisai07 08CFO, Americas.The rebuild and the mistakeAdvisory09 10De-identified client work,and the position pieces
Before you read them
## No performance figures appear anywhere in this set.
What I claim
The decision, and the pressure it was made under
The authority I actually held, and what I did not control
The architecture, governance and method I built
What the decision cost
What I would do differently
What I will not claim
Revenue, growth, margin or market share
Forecast accuracy or variance reduction
Any outcome I cannot separate from concurrent market movement
Any figure without a source record, a defined denominator and a documented calculation
The name of a single client
Former employers are named because that is professional history. Clients never are. A claim bounded by its own limits is harder to attack than one that is not.
In career order
## The cases
01
Bayer
### Meeting the Patient Before the Label
What changes at approval is not the product and not the patient. It is who is looking at them, and what they are counted for.
Diagnosis
02
Bayer
### One Method, Eight Countries
Standardizing clinical trial forecasting, and learning the sequence I have used ever since.
Architecture
03
Bayer
### Which Part of What Worked
Global launch sequencing taught me humility. The specialty channel turned out to be the whole thing.
Diagnosis
04
Novartis
### Structure Instead of Spend
A competitive entry turned a category with room in it into a red ocean. The question was whether to answer with money or with architecture.
Architecture
05
Insmed
### Can We Actually Find Them
A label narrower than the trial that supported it, and the question no forecast model asks.
Diagnosis
06
Insmed
### Building the Road to Revenue
A first commercial launch with nothing to inherit, and the governance decision that mattered more than any design choice.
Architecture
07
Eisai
### Simplify, Standardize, Automate, Measure
A multi-year rebuild of a finance organization, run as a sequence rather than as a structure.
Architecture
08
Eisai
### The Leak I Built
I had constructed a Silent Leak™ inside my own finance organization, and I did not see it until it was already there.
Failure
09
Advisory, de-identified
### Every Function Green, the Aggregate Red
A specialty product with acceptable coverage, underperforming its forecast, and a working explanation that was wrong.
Diagnosis and architecture
10
Gross-to-Net
### Finance Should Own the Number and Not the Operating Model
Gross-to-Net is treated as a close process because that is where it becomes visible. It is downstream of everything that created it.
Position
The collection anchor
## Twenty Five Years, One Question
A patient is diagnosed. A treatment exists. Their physician prescribes it. And still they may not receive it.
It did not start in pharma. It started in financial operations, which is to say it started by learning how organizations actually run underneath what they say about themselves. Every number a company reports is the residue of something a person did, and if you follow the number backward far enough you always arrive at a human being.
Follow the patient far enough and you will find the economics. Follow the economics far enough and you have to ask what happened to the patient.
## Which of these is your situation?
Start a conversationBack to the Library

## Speaking
URL: https://patrickrcoyle.com/speaking/

Speaking
Twelve years on the circuit, and still booking
Twenty seven speaking credentials issued by conference organizers between June 2014 and March 2026, across Informa Connect, CBI, IIR and Q1, in every role I have held. Keynotes, moderated panels, workshops, chairing and full course leadership.
27Engagements
12Years, 2014 to 2026
4Organizers
7Roles held while speaking
Book a speaking conversationSee the full record
What I speak about
## One argument, told five ways
Every talk comes back to the same claim: patient friction and revenue leakage are the same event, seen by two departments that rarely speak to each other. The frameworks below are the ways I have found to make that argument land with a room that contains both.
### Patients + Profitability™
Better Access. Better Outcomes. Better Business.™ The sequence runs one way: profitability sustains innovation, innovation creates possibility, and access turns possibility into outcomes. Best suited to a mixed executive audience where Finance and Commercial are both in the room.
### The 10 Exits of Therapy™
Diagnosis, provider access, prescription creation, enrollment, coverage, authorization, affordability, fulfillment, patient engagement, therapy initiation. Ten places a patient can leave, only three of which happen before a prescription exists.
### The 5 Layers of GTN™
Clinical and Product, Access and Policy, Channel and Distribution, Affordability and Support, Financial and Reporting. Where a Gross-to-Net number is actually created, as opposed to where it becomes visible. The technical session, and the one that draws accounting audiences.
### The Silent Leak™
Why a variance that surfaces in reporting was created three layers upstream, and why a finance-only analysis identifies the number without identifying the behavior that produced it. Includes the version where I built one myself and did not see it.
### NextGen GTN™
The curriculum built to teach commercial and finance audiences the same map, so the two functions stop arguing from different datasets. Delivered as a four-part series and as full course leadership.
See the curriculum
### Build it for the room
Most engagements are not one of the above off the shelf. Tell me who is in the room, what decision they are facing, and which functions are represented, and the session gets built to that.
Start there
The frameworks above are my own work, published on PatrickRCoyle.com and NextGenGTN.com. They are offered as authorship statements rather than as independently validated taxonomies.
Formats
## Five roles, and the record for each
Organizers have used me in every one of these. The counts come from the register below, so you can check them.
Speaker
A single session, usually forty five minutes, on one of the frameworks above or on a topic the organizer needs covered.
13 engagements
Moderator and speaker
Running a panel and contributing to it. The combination organizers ask for most often, because a moderator who knows the material can keep a panel from becoming four monologues.
10 engagements
Chairperson
Holding a full program together across a day or more, setting the through line and connecting sessions that would otherwise stand alone.
1 engagement
Workshop leader
A working session rather than a talk. The room leaves with something built, not with slides.
1 engagement
Course leader
Designing and leading a multi-part program under the organizer’s name.
On request
Scheduled
## Where I will be
Confirmed and scheduled engagements. If your event is not on this list and you think it should be, the last section of this page is for you.
2027
### Hub & Specialty Pharmacy Models East
Scheduled · Informa Connect
2027
### Patient Assistance & Access Programs
Scheduled · Informa Connect
2027
### Rare Disease Summit
Scheduled · Informa Connect
From the stage
## Watch a few minutes
Short clips from recent sessions. Where a session has a deck or a longer write-up, the clip links through to it.
▶
### PAPs Under Pressure
Hub & Specialty Pharmacy Models East · March 2026
▶
### Aligning Patient Support Services with GTN
Hub & Specialty Pharmacy Models East · March 19, 2026
▶
### GTN for Patient Access
Hub & Specialty Pharmacy Models East · March 19, 2026
More on YouTube
The record
## Every engagement, dated
Twenty seven credentials issued by conference organizers, newest first, with the role held and the organization I was with at the time. Published in full rather than summarized, so an organizer can check it rather than take my word for it.
Date
Event
Organizer
Role
Affiliation
Mar 2026
Hub & Specialty Pharmacy Models East
Informa Connect
Moderator, Speaker
Baker Tilly
Mar 2026
Life Sciences Accounting & Reporting
Informa Connect
Moderator, Speaker
Baker Tilly
Nov 2025
Pharma/Biotech GTN Summit
Informa Connect
Moderator, Speaker
Baker Tilly
Sep 2025
Finance & Accounting for Bioscience
Informa Connect
Participant
Novus Proximus
Mar 2025
Life Sciences Accounting & Reporting
Informa Connect
Moderator, Speaker
IQVIA
Nov 2024
Pharma/Biotech GTN Summit
Informa Connect
Moderator, Speaker
IQVIA
Sep 2024
Finance & Accounting for Bioscience
Informa Connect
Participant
IQVIA
Mar 2024
Life Sciences Accounting & Reporting
Informa Connect
Moderator, Speaker
IQVIA
Nov 2023
Gross-to-Net Accounting & Accruals Summit
Informa Connect
Moderator, Speaker
IQVIA
Mar 2023
Life Sciences Accounting & Reporting
Informa Connect
Moderator, Speaker
Novus Proximus
Nov 2022
Gross-to-Net Accounting & Accruals Summit
Informa Connect
Moderator, Speaker
Novus Proximus
May 2022
Medicaid & Government Pricing Congress
Informa Connect
Speaker
Eisai
Aug 2021
Life Sciences Accounting & Reporting
Informa Connect
Speaker
Eisai
Mar 2019
Life Sciences Accounting & Reporting
CBI
Speaker
Insmed
Nov 2018
Gross-to-Net Accounting & Accruals Summit
CBI
Moderator, Speaker
Insmed
Nov 2017
Gross-to-Net Accounting & Accruals Summit
CBI
Speaker
Insmed
Jun 2017
BioPharma GTN Boot Camp
CBI
Speaker
Novartis
Nov 2016
Gross-to-Net Accounting & Accruals Summit
CBI
Speaker
Novartis
Jun 2016
8th Semi-Annual Life Science Financial Forum
Q1
Speaker
Bayer
Feb 2016
Accounting & Reporting Congress
CBI
Speaker
Bayer
Nov 2015
Gross-to-Net Accounting & Accruals Summit
CBI
Speaker
Bayer
Nov 2015
R&D Financial Tracking & Analysis Summit
CBI
Speaker
Bayer
Jun 2015
Gross-to-Net Accounting Forum
IIR
Chairperson
Bayer
Mar 2015
Accounting & Reporting Congress
CBI
Speaker
Bayer
Feb 2015
Clinical Trial Budget and Forecasting
CBI
Workshop Leader
Bayer
Nov 2014
Gross-to-Net Accounting & Accruals Summit
CBI
Speaker
Bayer
Jun 2014
Gross-to-Net Accounting Forum
IIR
Speaker
Bayer
An underlined event name opens the write-up for that session. On a narrow screen, the table scrolls sideways.
The Gross-to-Net Accounting & Accruals Summit appears seven times and Life Sciences Accounting & Reporting six times. Repeat invitations across a change of employer are the part of this record I would point at first, because an organizer who invites you back is making a judgment about the room’s response rather than about your title.
Book
## Bringing me in
The most useful thing you can send is not a date. It is who is in the room, what decision they are facing, and which functions will be represented. That is what determines whether a session lands or just fills a slot.
Conference sessions, internal executive briefings, cross-functional workshops and multi-part course programs are all in scope. So is a panel you need chaired by someone who will have read the material.
Book a speaking conversationRead the argument first
Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.

## Commercialization Alignment Labs™
URL: https://patrickrcoyle.com/glossary/commercialization-alignment-labs/

Commercialization Alignment Labs™ are four facilitated executive sessions that take a new product from an unformed commercial position to a launch execution plan, one decision set at a time: Lab 1 Patient Opportunity, Lab 2 Distribution Architecture, Lab 3 Leakage Architecture and Lab 4 Launch Readiness.
## Why it matters
Each Lab produces the decisions the next one depends on. Run out of order, the later sessions spend their time rebuilding what the earlier ones should have settled. The Labs exist because the earliest launch failures leave no artifact: no rejection, no denial, only a population that was never found and a plan that assumed it would be.
## Origin
Created by Patrick R. Coyle. Delivered through Novus Proximus and described on nextgengtn.com alongside the NextGen GTN™ curriculum.
## Read more
Alignment Labs™ on NextGen GTN™
Advisory engagements
## Related terms
The 10 Exits of Therapy™, Product Lifecycle Phases
Part of the Patients + Profitability™ Glossary. Canonical definitions by Patrick R. Coyle; the same terms on nextgengtn.com and novusproximus.com carry these meanings.

## Gross-to-Net
URL: https://patrickrcoyle.com/glossary/gross-to-net/

Gross-to-Net is the difference between a pharmaceutical product’s gross sales at list price and the net revenue the manufacturer actually recognizes after rebates, chargebacks, discounts, fees, returns and government program obligations.
## Why it matters
In the Patients + Profitability™ view, Gross-to-Net is not an accounting output. It is the financial echo of how well the enterprise executed the patient journey: every contracting, channel, affordability and support decision made upstream shows up in it downstream. Finance should own the number, but the operating model that produces it belongs to a cross-functional forum, because the number cannot be fixed inside finance alone.
## Origin
A standard industry term. The interpretation here is Patrick R. Coyle’s, developed across Gross-to-Net advisory and CFO roles and taught through the NextGen GTN™ curriculum.
## Read more
Finance should own the number, not the operating model
Accrual design field guide
NextGen GTN™
## Related terms
The 5 Layers of GTN™, Patient Friction, The Silent Leak™
Part of the Patients + Profitability™ Glossary. Canonical definitions by Patrick R. Coyle; the same terms on nextgengtn.com and novusproximus.com carry these meanings.

## Patient Friction
URL: https://patrickrcoyle.com/glossary/patient-friction/

Patient friction is any barrier, delay, administrative requirement or moment of uncertainty between a prescription and a sustained therapy that causes a patient to stall or stop. Patient friction creates revenue leakage.
## Why it matters
When a patient stops, revenue that was forecast never arrives. Not as a rejection or a denial. It simply never shows up, and nothing in the commercial data set records why. Friction is spread across coverage, prior authorization, benefits verification, affordability, fulfillment and engagement, and most organizations cannot say where the largest drop-off happens or how big it is. Removing friction is therefore both a patient outcome and a Gross-to-Net lever.
## Origin
The one-line thesis of Patrick R. Coyle’s work: patient friction creates revenue leakage.
## Read more
Patient journey optimization
Prior authorization abandonment
## Related terms
The Silent Leak™, The 10 Exits of Therapy™, Gross-to-Net
Part of the Patients + Profitability™ Glossary. Canonical definitions by Patrick R. Coyle; the same terms on nextgengtn.com and novusproximus.com carry these meanings.

## Patients + Profitability™
URL: https://patrickrcoyle.com/glossary/patients-profitability/

Patients + Profitability™ is the philosophy that patient outcomes and sustainable profitability are interdependent rather than opposing, because the patient journey and the economic journey of a therapy are the same journey viewed from opposite sides.
## Why it matters
Innovation creates possibility, access turns it into treatment, treatment creates the opportunity for outcomes, and sustainable economics allow innovation to continue. Break any one link and the loop stops. An innovation nobody can reach produces no outcomes, and outcomes nobody can fund produce no next innovation. The philosophy exists to give commercial, market access, patient services, channel and finance leaders one shared map of a journey each of them owns only a piece of.
## Origin
Created by Patrick R. Coyle. It is the foundation of the Patients + Profitability™ book series and podcast, the NextGen GTN™ curriculum and the Novus Proximus advisory practice.
## Read more
Read the philosophy
The podcast
NextGen GTN™ education
## Related terms
The Silent Leak™, The 10 Exits of Therapy™, Patient Friction
Part of the Patients + Profitability™ Glossary. Canonical definitions by Patrick R. Coyle; the same terms on nextgengtn.com and novusproximus.com carry these meanings.

## Product Lifecycle Phases
URL: https://patrickrcoyle.com/glossary/product-lifecycle-phases/

The Product Lifecycle Phases are the four phases of the commercialization model used across this work: Phase 1 Pre-Launch and Launch Readiness, Phase 2 Launch and Early Commercialization, Phase 3 In-Market Optimization, and Phase 4 Lifecycle and Loss of Exclusivity.
## Why it matters
The phase determines which questions matter. Before launch the question is whether the patients can be found; at launch it is whether coverage converts to starts; in market it is where the largest exit is and who owns it; at loss of exclusivity it is which parts of the architecture still earn their cost. Advisory engagements and education are scoped to the phase, not to a fixed program.
## Origin
The commercialization model used by Patrick R. Coyle across Novus Proximus advisory work and NextGen GTN™ education. The word “stage” is reserved for how a market is segmented and is not used for lifecycle phases.
## Read more
Advisory engagements
Novus Proximus
## Related terms
Commercialization Alignment Labs™, Gross-to-Net
Part of the Patients + Profitability™ Glossary. Canonical definitions by Patrick R. Coyle; the same terms on nextgengtn.com and novusproximus.com carry these meanings.

## The 10 Exits of Therapy™
URL: https://patrickrcoyle.com/glossary/10-exits-of-therapy/

The 10 Exits of Therapy™ are the ten sequential points at which a patient can delay or discontinue between diagnosis and a sustained start on therapy: Diagnosis, Provider Access, Prescription Creation, Enrollment, Coverage, Authorization, Affordability, Fulfillment, Patient Engagement and Therapy Initiation.
## Why it matters
Three of the ten happen before a prescription exists and seven happen after it is written, which is why a forecast built on prescriptions alone misses most of the journey. Each exit is a place a patient can leave and, at the same moment, a place forecast revenue fails to arrive. The framework gives every exit a measurement, so the leak can be seen, sized and assigned to an owner instead of being explained after the fact.
## Origin
Created by Patrick R. Coyle. It is the spine of Side A of the NextGen GTN™ curriculum and of the free guide From Prescription to Treatment.
## Read more
From Prescription to Treatment (free guide)
The philosophy page
NextGen GTN™ Side A
## Related terms
The Silent Leak™, The 5 Layers of GTN™, Patients + Profitability™
Part of the Patients + Profitability™ Glossary. Canonical definitions by Patrick R. Coyle; the same terms on nextgengtn.com and novusproximus.com carry these meanings.

## The 5 Layers of GTN™
URL: https://patrickrcoyle.com/glossary/5-layers-of-gtn/

The 5 Layers of GTN™ are the five sequential, causal layers through which commercial decisions become the Gross-to-Net number: Layer 1 Clinical and Product Foundation, Layer 2 Access and Policy, Layer 3 Channel and Distribution, Layer 4 Affordability and Patient Support, and Layer 5 Financial Visibility and Enterprise Performance.
## Why it matters
Each layer flows into the next. The label and clinical position set what access is possible; access and policy set what contracts and government pricing exposure follow; channel design sets who takes title and what chargebacks look like; affordability and support design determine whether coverage converts to a filled prescription; and only then does the number become visible to Finance. Treating Gross-to-Net as a Layer 5 problem means managing the echo instead of the event.
## Origin
Created by Patrick R. Coyle. Side B of the NextGen GTN™ curriculum follows the five layers; Side A follows the 10 Exits of Therapy™, and the two sides pair by topic.
## Read more
The 5 Layers of GTN™, taught in full
NextGen GTN™ Side B
Why Gross-to-Net variance is never a finance problem
## Related terms
Gross-to-Net, The 10 Exits of Therapy™
Part of the Patients + Profitability™ Glossary. Canonical definitions by Patrick R. Coyle; the same terms on nextgengtn.com and novusproximus.com carry these meanings.

## The Silent Leak™
URL: https://patrickrcoyle.com/glossary/silent-leak/

The Silent Leak™ is the population of patients who leave the path to therapy before any system records them: not denied, never counted, gone before a prior authorization, a claim or a support enrollment was ever created.
## Why it matters
Approval metrics only capture requests that were submitted, so an organization can report a healthy approval rate while losing patients it never saw. Because nothing in the commercial data set records why those patients stopped, the loss surfaces later as an unexplained variance in accruals, true-ups and support spend. It is usually the largest line on the revenue waterfall with no assigned owner. Your approval rate is not your access rate.
## Origin
Named by Patrick R. Coyle from his own experience running a finance organization, described in the case file The Leak I Built. The 10 Exits of Therapy™ are the framework for measuring it.
## Read more
The Leak I Built
Why your forecast population was never real
## Related terms
The 10 Exits of Therapy™, Patient Friction, Gross-to-Net
Part of the Patients + Profitability™ Glossary. Canonical definitions by Patrick R. Coyle; the same terms on nextgengtn.com and novusproximus.com carry these meanings.

# Articles

## Still in the Kitchen, Still Unopened
URL: https://patrickrcoyle.com/still-in-the-kitchen-still-unopened/
Published: 2026-09-14

Therapy initiation is the tenth of the 10 Exits of Therapy™, and it is the only one where every part of the system has done its job and the treatment still has not started.
A treatment that arrives and does not get started is usually waiting on a question rather than a decision. The question is almost always small, almost always answerable in one call, and almost never asked.
## What the questions usually are
They are ordinary. Do I take this with food. What happens if I take it at night instead. Is this the dose we talked about, because the box says something different. Am I supposed to keep this cold. What does it feel like when it starts working. What if it feels like nothing.
Each of these is a two-minute answer from a pharmacist or a nurse. Left unanswered, each is enough to leave a box on a counter for a week, and then a month.
NINE STEPS CLEARED, ONE TO GO
1
2
3
4
5
6
7
8
9
10
Every institution in the chain has done its part.
What is left is a question nobody was asked.
FIGURE 1. The chain delivers a box. It does not deliver a start.
## Why the question does not get asked
Partly because by this point you have spoken to a lot of people and asked a lot of questions, and there is a real fatigue in that. Partly because the question feels too small to bother anyone with.
And partly because the moment the treatment arrives is the moment everyone else considers the matter closed. The prescriber has prescribed, the plan has paid, the pharmacy has dispensed. The only person still standing in the middle of it is you, and the last stretch is unaccompanied.
The question that feels too small to ask is the one most likely to cost you a month. Pharmacists answer these all day and consider it their job.
## What to ask, and in what order
Ask the pharmacist how it is taken and stored. They will tell you at pickup if you ask, and they are usually the most accessible expert in the entire chain.
Ask what the first week is typically like. Not what could go wrong. What is ordinary. Knowing what is expected is what stops an ordinary first week from feeling like a reason to stop.
Ask what is worth calling about, and what number to use. Distinguish the after-hours number from the daytime one. Write both down somewhere that is not your phone.
Ask when you should be back in touch regardless. A date on the calendar turns the next contact from something you have to initiate into something already arranged.
## If it has been sitting there a while
There is no useful amount of guilt to feel about this, and a great many people are in exactly the same position. The treatment is still there and the conversation is still available.
Call the prescriber’s office, say the treatment arrived and you have not started it, and say why if you know why. That last part is the useful bit. Whether the reason is a side effect you read about, a question about the schedule, a cost you had not expected, or just that the moment passed, it is all information they can work with and none of it is unusual to hear.
## Why this exit exists
Therapy initiation sits last in the 10 Exits of Therapy™ because it is the point at which every institutional step has succeeded and the outcome still depends on one more thing happening. The whole chain, working perfectly, delivers a box. It does not deliver a start.
That is the argument the whole series is built on. Access is not the same as approval, and approval is not the same as treatment. The gap between the last institutional step and the first dose is where a great deal of good work quietly stops counting.
Therapy initiation is exit 10 of ten. If your treatment stalled somewhere else, find which one at Where did your treatment stop? Exit 9 is patient engagement. This is the last one. Everything written for patients is gathered on the For Patients page. Terms used here are defined in the glossary.
This is navigation help, not medical advice. It does not replace anything your prescriber or pharmacist tells you, and decisions about diagnosis and treatment belong with your licensed clinician. Who pays for this work is set out in the disclosure.

## Nobody Owns the Second Fill
URL: https://patrickrcoyle.com/nobody-owns-the-second-fill/
Published: 2026-09-14

Patient engagement is the ninth of the 10 Exits of Therapy™, and it is the one where everybody stopped watching because the first part went well.
Starting a treatment is measured by almost everyone in the chain. Continuing it is measured by almost no one, and there is usually no single person whose job it is to notice when a refill does not happen.
## What the system actually counts
A first fill is a visible event. It closes a loop that several people were watching. A prescriber can see it, a pharmacy records it, a plan pays for it, and a support program, if you enrolled in one, marks you as started.
The second fill is a different kind of event. If it does not happen, nothing fires. There is no alert, no follow-up call in most cases, and no person for whom that absence is a task.
COUNTED, AND NOT COUNTED
Measured by somebody
The prescription written
The first fill
The follow-up visit
Each one closes a loop someone was watching.
Measured by nobody
The second fill
The gap after a side effect
The month you meant to call
Each one happens at home, and sets off no alarm.
A treatment that stops quietly looks exactly like a treatment that worked.
FIGURE 1. The start is a visible event. The continuation is not.
## Why people stop, which is rarely the reason assumed
The word usually reached for here is adherence, and it carries a whiff of blame that the facts do not support. When people stop a treatment they were willing to start, the reason is usually practical.
A side effect appeared and there was no obvious person to ask about it. The refill needed a step nobody explained. The cost changed. The reminder went to an old phone number. Life got busy during the exact week it ran out, and by the time it surfaced again, restarting felt like a bigger conversation than it is.
A gap in a treatment is information, not a verdict. The useful response is a phone call, not a resolution to do better.
## What to ask, and in what order
Ask when the refill is due and who starts it. You, the pharmacy, or the prescriber’s office. It varies by treatment and by pharmacy, and assuming it is automatic is the most common way a gap opens.
Ask how many refills are on the prescription. Prescriptions run out. The last refill is a date somebody should know in advance, and that somebody is usually you.
Ask what to do about a side effect before you stop. Get a phone number and a sense of what is worth calling about. Having that in hand before anything happens is what keeps a bad week from becoming a stopped treatment.
Ask whether reminders or automatic refills are available, and set them up. They are ordinary and they work. They also need a current phone number, which is worth checking while you are there.
## If there is already a gap
This is worth saying plainly. If you have missed refills, or stopped, the thing to do is call the prescriber’s office and say so. Not apologize for it. Report it.
They need to know, because the right response depends on how long the gap was and what the treatment is, and that is a clinical judgment rather than something to work out alone. Restarting is a common conversation and it is a shorter one than people expect.
## Why this exit exists
Patient engagement sits ninth in the 10 Exits of Therapy™ because it is the first exit that happens entirely outside any building. Every earlier one has a counter, an office or a phone queue attached to it. This one happens in a kitchen, on a Tuesday, with nobody watching.
It is also the exit that costs the most and gets the least attention, because a treatment that stops quietly looks exactly like a treatment that worked.
Patient engagement is exit 9 of ten. If your treatment stalled somewhere else, find which one at Where did your treatment stop? Exit 8 is fulfillment. Exit 10 is therapy initiation. Everything written for patients is gathered on the For Patients page. Terms used here are defined in the glossary.
This is navigation help, not medical advice. It does not replace anything your prescriber or pharmacist tells you, and decisions about diagnosis and treatment belong with your licensed clinician. Who pays for this work is set out in the disclosure.

## Three Sentences That Sound the Same
URL: https://patrickrcoyle.com/three-sentences-that-sound-the-same/
Published: 2026-09-14

Fulfillment is the eighth of the 10 Exits of Therapy™, and it is the one where everything has been approved and the medicine still is not in your hand.
A pharmacy that cannot fill your prescription is telling you one of three different things, and they are usually said in the same six words. Which one it is decides whether you wait two days, go somewhere else, or need a completely different kind of pharmacy.
## The three sentences
We are out of it. A stock problem. It resolves, usually in days, and another branch of the same chain may have it today.
We do not carry it. A stocking decision. This pharmacy does not keep it and waiting will not change that. You need a transfer, and the useful question is which nearby pharmacy does keep it. We cannot dispense it. A restriction. Some treatments can only be dispensed by a defined set of pharmacies, and no amount of waiting or transferring within ordinary retail will fix it.
THREE SENTENCES, THREE FIXES
“We are out of it.”
Stock. Wait, or transfer to another branch. Usually days.
“We do not carry it.”
Stocking. Transfer to a pharmacy that does. Ask which.
“We cannot dispense it.”
Restricted. Only certain pharmacies are allowed to.
All three are said in the same tone at the same counter.
FIGURE 1. The third one is where weeks go missing, because it is heard as the first.
## Why the third one is the expensive one
The first two are inconvenient. The third is where weeks go missing, because it is the one most often misheard as the first.
Somebody waits, calls back, waits again, then drives to a different branch of the same chain, which also cannot dispense it. By the time anyone establishes that the treatment was never going to come from a retail counter, a month has passed and the prescription may have expired.
The words are almost identical and the consequences are not. Asking which of the three you are hearing is the whole of the work here.
## What to ask, and in what order
Ask which of the three it is, in those terms. Is this out of stock, something you do not carry, or something you are not able to dispense. Pharmacy staff can answer immediately and almost never get asked.
If it is stock, ask when, and whether another branch has it. Ask them to check. Most systems can see neighboring inventory from the counter.
If it is stocking, ask which nearby pharmacy does carry it. They generally know, and a transfer is a call between pharmacies rather than a new prescription.
If it is restricted, call the prescriber’s office and say exactly that. The office will have a route. This is also the point where a support program, if there is one, earns its keep.
## Delivery is part of this
Getting it to you is the second half of fulfillment and it fails separately. A shipment needs a signature nobody is home for. A cold shipment sits on a porch. A delivery window lands on the one day you are out.
If your treatment is shipped rather than picked up, ask who the shipper is, whether a signature is required, and what happens if the first attempt fails. These are answerable in one call and they prevent the entirely logistical version of this problem.
## Why this exit exists
Fulfillment sits eighth in the 10 Exits of Therapy™ because by this point every decision has gone your way. The diagnosis is made, the prescription is written, the plan has agreed to pay. What is left is physical, and physical things run out, are not stocked, or are not allowed to be handed over at that particular counter.
It is the exit that feels the most absurd from the inside, which is precisely why people wait rather than ask. Everything worked. Surely this part is automatic.
Fulfillment is exit 8 of ten. If your treatment stalled somewhere else, find which one at Where did your treatment stop? Exit 7 is affordability. Exit 9 is patient engagement. Everything written for patients is gathered on the For Patients page. Terms used here are defined in the glossary.
This is navigation help, not medical advice. It does not replace anything your prescriber or pharmacist tells you, and decisions about diagnosis and treatment belong with your licensed clinician. Who pays for this work is set out in the disclosure.

## The Number at the Counter
URL: https://patrickrcoyle.com/why-your-prescription-costs-more-in-january/
Published: 2026-09-14

Affordability is the seventh of the 10 Exits of Therapy™, and it is the only one that can change while you are standing still.
If the price jumped and nothing about your medicine changed, your benefit year almost certainly reset. There are three separate places help can come from, and you have to ask for each of them on its own.
## Why January is different
Most plans run on a calendar year. On January 1 your deductible goes back to zero, which means you are paying full negotiated price again until you have spent your way back up to where you were in December. The medicine costs what it always cost. Your share of it is what moved.
This is the single most common reason a treatment that was working in the fall stops in the winter. It is not a price increase and it is not a mistake. It is the design of the benefit, and almost nobody explains it in advance.
THE SAME HELP, TWO DIFFERENT YEARS
Assistance counts toward your deductible
Deductible fills while you are helped
Plan pays
An accumulator is in place
Help runs out
You owe the full deductible, unassisted
This is the day people stop
The money was spent either way. Only one of these years ends with you still on treatment.
FIGURE 1. The same assistance, counted two different ways.
## What an accumulator does
If you use a manufacturer copay card, some plans accept the money and do not count it toward your deductible. That is called an accumulator. The practical effect is that the help runs out mid year and you discover you still owe the whole deductible, at exactly the point you thought you were through it.
Twenty-five states plus the District of Columbia and Puerto Rico now require assistance to count toward your cost sharing. Whether that protection reaches you depends on how your plan is structured, and self-insured employer plans generally sit outside state rules. This is worth one phone call, because the answer changes what you should do next.
The dollars eventually net out somewhere in a ledger. The days you spend off treatment do not come back.
## Three sources of help, and they are separate
Manufacturer copay programs. Run by the company that makes the medicine. Usually the fastest to apply for. If you have Medicare or Medicaid these are generally not available to you, which is a rule about federal programs rather than anything about your situation.
Independent charitable foundations. Separate organizations, usually organized by disease rather than by product. Open to people on Medicare. They run out of funds and reopen, so a no in March can be a yes in June.
The pharmacy itself. Cash price, a different pharmacy, a ninety day fill instead of thirty, or a discount program can each change the number. Ask the pharmacist to run the alternatives rather than assuming the first number is the only one.
People routinely apply to one of the three, get turned down, and stop. They are three different doors and being refused at one tells you nothing about the others.
## What to ask at the counter
Ask the pharmacy to run it again with every card and grant you have on file, because a card that was not attached is the most common reason a price looks wrong. Ask what the cash price is, since occasionally it is lower than the insured price. Ask whether a ninety day supply changes the math.
Then ask your plan the one question that decides your year: does my plan count manufacturer assistance toward my deductible. Write down the answer and who gave it to you.
## Why this exit exists
Affordability is seventh in the 10 Exits of Therapy™ because of everything that had to work before you got here. Diagnosis, a prescriber, a prescription, enrollment, coverage and authorization all cleared. And then a number at a counter, on a day nobody warned you about, ends the treatment anyway.
That is what makes this exit worth naming. Almost nobody who leaves here decided the treatment was not worth it.
Affordability is exit 7 of ten. If your treatment stalled somewhere else, find which one at Where did your treatment stop? Exit 6 is authorization. Exit 8 is fulfillment. Everything written for patients is gathered on the For Patients page. Terms used here are defined in the glossary.
This is navigation help, not medical advice, and it is not financial advice. It does not replace anything your prescriber or pharmacist tells you, and decisions about diagnosis and treatment belong with your licensed clinician. Who pays for this work is set out in the disclosure.

## A Wait With No Clock
URL: https://patrickrcoyle.com/prior-authorization-wait-no-clock/
Published: 2026-09-14

Prior authorization is the sixth of the 10 Exits of Therapy™, and it is the one where everybody assumes somebody else is watching the calendar.
There is a deadline on your request. It starts when the request reaches your plan, not when your prescriber's office says they sent it, and you are entitled to ask for both dates by name.
## What is actually happening while you wait
Your prescriber writes a prescription. Your plan says it will not pay for that medicine until someone explains why you need it. So the office fills out a form, attaches your records, and sends it to the plan for review. That is prior authorization.
The part nobody describes is that this creates three separate waits, and they are invisible to each other. There is the wait for the office to prepare and send the request. There is the wait while the plan reviews it. And there is the wait for somebody to notice a decision came back. You experience all three as one long silence.
WHAT YOU EXPERIENCE AS ONE WAIT
Prescribed
Request sent
Decision made
You hear
The office prepares it
The clock you can ask about
Somebody notices
Only the middle stretch has a deadline attached to it. The two on either side have nobody counting.
FIGURE 1. One silence, three waits. Only the middle one is governed by a rule.
## The clock exists. It starts somewhere you cannot see.
Most health plans operate under a turnaround requirement for prior authorization, and many states set one in law as well. The specific limit depends on your plan type, your state, and whether the request is standard or expedited. What matters more than the number is where the clock starts. It starts when the plan receives a complete request.
That is why "we sent it" is not the same as "the clock is running." A request that is missing a chart note, a lab value or a signature can sit as incomplete without ever starting the timer, and nobody is obliged to tell you that is what happened.
If you do not know the date the plan received your request, you do not know whether you are inside the deadline or outside it.
## What to ask, and who to ask
Two phone calls settle almost every case. One to the prescriber's office, one to the plan, and they ask for different things.
Ask the prescriber's office: on what date was the prior authorization submitted, and is there a reference or tracking number for it. If they cannot produce a date, it may not have gone out. That is worth knowing on day three rather than day thirty.
Ask your plan: what is the decision deadline that applies to this request, and is the request complete. Those are two different questions and you want both answered.
Ask either one: does an expedited review apply to my situation. Expedited timelines are much shorter and usually turn on whether waiting would put your health at risk. Your prescriber is the one who can make that case.
Write down who you spoke to and when. A named person and a date changes the next conversation more than any amount of frustration does.
## If it comes back denied
A denial is a document, not a verdict. Ask for it in writing, because the written denial has to name the reason and the appeal route, and those two things are what your prescriber needs in order to respond. A large share of denials are overturned on appeal, and many are overturned on the first one.
Ask your prescriber's office whether a peer to peer review is available. That is a direct conversation between your prescriber and a clinician at the plan, and it often resolves in one call what a paper appeal takes weeks to do.
## Why this exit exists at all
Authorization sits sixth in the 10 Exits of Therapy™ because of where it falls. You have a diagnosis, a prescriber, a prescription and coverage. Everything upstream worked. And then the process stops inside a review that has no visible owner, and a meaningful number of people stop with it.
Nobody decided you should not have the medicine. The wait simply outlasted the effort it was worth. That is what makes this exit different from a denial, and it is why the dates matter so much.
Authorization is exit 6 of ten. If your treatment stalled somewhere else, find which one at Where did your treatment stop? Exit 5 is coverage. Exit 7 is affordability. Everything written for patients is gathered on the For Patients page. Terms used here are defined in the glossary.
This is navigation help, not medical advice. It does not replace anything your prescriber or pharmacist tells you, and decisions about diagnosis and treatment belong with your licensed clinician. Who pays for this work is set out in the disclosure.

## Patients and Profitability: Why the Most Successful Pharmaceutical Companies Never Choose Between Them
URL: https://patrickrcoyle.com/patients-and-profitability/
Published: 2026-09-13

For most of my career I sat in rooms where the same question eventually surfaced. Are we optimizing for patients, or are we optimizing for the business? I asked it myself for years before I understood that the question was the problem.
Patient outcomes and commercial profitability are not opposing forces. They are two readings of the same discipline. Every durable commercial win in this industry traces back to a real improvement in the patient journey, and every real improvement that never becomes commercially sustainable eventually disappears. Patients give innovation its purpose. Stewardship is what allows innovation to continue. One without the other leaves the work unfinished.
When I began in this industry I assumed my education would be technical. Finance, commercialization, manufacturing, market access, patient services, the disciplines that together allow a scientific discovery to become something tangible in another person’s life. In many ways that is exactly what happened. What I did not expect was that the longer I stayed, the less the important lessons had to do with the mechanics and the more they had to do with the people inside them. What follows is why the false choice persists, what it costs the organizations that accept it, and what the integrated version looks like when a company actually commits to it.
## The false choice, and what it has cost
I want to be fair to where the idea came from. The belief that patient welfare and commercial performance sit at opposite ends of a seesaw did not appear out of nowhere. It grew out of a legitimate concern. Pharmaceutical companies respond to incentives like any commercial enterprise, and there are real, well-documented cases where short-term revenue pressure produced decisions that were not in patients’ interests. Those cases deserve the scrutiny they get, and I would not want to work in an industry where they did not.
But I no longer believe the pullback happens because anyone decided patients matter less. It happens because of how the money is structured, and I have been in the room when it did.
Start with the measurement problem. A patient support program is genuinely difficult to measure, and difficult in a specific way. The return arrives late. It arrives through adherence and persistence rather than through a campaign you can attribute. And it shows up as revenue that was never lost rather than revenue that was gained, which is the hardest kind of result to put in front of a finance committee. So when a budget comes under review, patient support sits in the column of line items that cannot defend themselves with a number.
Then there is where the money actually sits. Commercial does not fund medical affairs. Brand budgets often do, through allocation. A single brand budget can carry opex owned by many different functions, and those owners rarely see one another’s line items. What they share is one brand lead who carries the entire brand P&L. When the totality of that P&L comes under scrutiny, every allocation inside it comes under scrutiny with it, including the ones that were never the brand lead’s idea and are not measured in the brand lead’s terms.
That is the moment the decision actually gets made. Not in a strategy session about patients. In a budget review, by one person accountable for one number, looking at line items that cannot prove themselves.
MANY OWNERS, ONE ACCOUNTABLE NUMBER
Commercial
owns opex
Medical Affairs
owns opex
Patient Support
owns opex
Market Access
owns opex
The brand P&L
One lead accountable for the entire number, including the allocations they did not choose
SCRUTINY ARRIVES HERE
Defends itself with a number
Promotional spend. Field activity. Anything with an
attributable campaign behind it.
Cannot
Patient support. Education. Anything whose return is
revenue that was never lost.
The cut lands on the column that cannot prove itself, and rarely on the line the brand lead would have chosen.
FIGURE 1. Many owners, one accountable number, and one column with no way to defend itself.
What makes that costly rather than merely unfortunate is what the room cannot see. If the people making the decision do not share an accurate picture of how the patient journey actually runs, the decision is made in a vacuum. On the page it looks like a reasonable trim of an unprovable expense. In practice it is a decision about whether a particular person gets a returned phone call, finishes an enrollment form, or starts the therapy their clinician already decided they needed. Nobody in that room intended that outcome. Nobody in that room could see it either.
I want to be careful about the conclusion I draw here, because the easy move is to reach for the return on investment, and I think that argument is only half right. Later in this piece I make the commercial case, and I believe every part of it. But the return is not why you fund patient support. You fund it because it is the right thing to do for someone trying to begin a treatment that has already been chosen for them. The return is real. It simply arrives on a timeline, and through pathways, that an allocation model was never built to see. If the only defense of patient support is its measurable return, it will lose the argument in exactly the quarter where losing it costs the most.
You do not fund patient support because of the return. You fund it because it is right. The return is confirmation, not justification.
The pullback is structural, not moral. An unmeasurable return, an allocated cost and one P&L owner under scrutiny produce the same decision every time, regardless of what anyone believes about patients.
Return on investment is the wrong defense. Fund patient support because it is right, and treat the commercial return as confirmation rather than justification.
A decision made without a shared view of the journey is made in a vacuum. The consequence still lands on a person, whether or not anyone in the room can see them.
## How patient outcomes actually reach the income statement
It is worth being precise about the mechanism, because "patient outcomes drive value" is a platitude until you can trace it to a line item. I spent a long time unable to trace it, which is part of why I am careful about it now.
Start with adherence. A therapy with excellent clinical data and poor real-world adherence will underperform its own trial results, sometimes badly, and that gap lands directly in revenue, in payer negotiations and in the credibility of the brand with prescribers. Money spent removing friction from the patient journey protects the clinical investment that got the product to market in the first place.
The same logic runs through prescriber trust. Clinicians are reasonably skeptical of commercial messaging that feels disconnected from what happens to the people in their waiting room. A company that can show, credibly, that its support infrastructure improves real-world outcomes has turned that credibility into a commercial asset. It shows up in formulary conversations, in peer-to-peer education and in who is willing to speak on the company’s behalf. None of it appears on a promotional return spreadsheet, which is exactly why it stays underfunded.
Then there is market access. Payers have become good at telling the difference between a product with genuine value-based outcomes and a product defending share with promotional spend. Real-world outcomes data is leverage in a value-based contracting conversation, and the reimbursement landscape has been moving in that direction for the better part of a decade.



How friction in the patient journey reaches the income statement
Friction in the patient journey produces three separate commercial effects. Poor adherence causes a therapy to underperform its own clinical data, which shows up as revenue. Weak real-world outcomes evidence weakens the negotiating position with payers, which shows up as price erosion. Visible gaps between the promotional story and what happens to patients cost prescriber trust, which shows up as acquisition cost. All three are recorded in finance as something other than access.


THE INPUT
Friction in the
patient journey




Adherence falls
The therapy underperforms its own data

Outcomes evidence thins
Less to bring to a payer negotiation

Prescriber trust erodes
The story stops matching the experience




Booked as revenue
Explained as soft demand

Booked as price erosion
Explained as payer pressure

Booked as acquisition cost
Explained as a promotion gap

One cause. Three line items. None of them named access.



FIGURE 2. One cause reaches the income statement three different ways, and none of the three is labeled access.
Your approval rate is not your access rate. It describes the prescriptions that survived long enough to be measured.
## Market access and the profitability equation
Nowhere is the false choice more expensive, or more avoidable, than in market access. Access sits at the intersection of clinical evidence, payer economics and patient affordability, and it is routinely treated as a downstream technical function that happens after the real commercial strategy has been settled. That sequencing is the mistake, because access strategy shapes the economics of the entire product lifecycle from the first day of launch.
A company that builds access around genuine affordability builds a position competitors find hard to erode. Not discounting to move volume. Structurally reducing the financial burden that stops patients from starting or continuing therapy. Payers respond to evidence of real-world value. Patients respond to less friction. Commercial teams that design to that reality rather than to short-term list price optimization find their long-term revenue trajectory steadier than that of competitors chasing quarter-over-quarter increases.
I have walked organizations through exactly this transition, from an access function that is reactive and defensive to one designed around what reaching the therapy actually costs a patient in money and in effort. The gains are not marginal, and they compound. Every patient who starts and stays on therapy is both a clinical result and a durable revenue line, and every barrier removed closes a leak that no amount of promotional spend fully offsets.
## Commercial excellence is a patient-centered discipline
In many organizations "commercial excellence" has narrowed to mean sales force effectiveness, targeting algorithms and promotional resource allocation. Those are tools. They are not the discipline.
The discipline starts with an honest account of the patient journey: where patients are lost, why they are lost, and what would have to change to keep them in effective treatment. That reframing changes what gets built. Instead of asking how to get more prescriptions written, the more productive question is why written prescriptions fail to become sustained therapy, and what would close that gap. The second question leads straight into medical affairs collaboration, patient support design and access strategy. Those functions are traditionally walled off from commercial teams, and properly integrated they are the highest-leverage commercial investments available.
Commercial excellence is not sales force effectiveness. It begins with a rigorous reading of the patient journey.
Ask the harder question. Why do written prescriptions fail to become sustained therapy?
Integration is a decision. Commercial, medical affairs and access do not converge by accident.
Ask a commercial leader where their revenue actually leaks and most will point to the patient journey before they point to a competitor. That should settle where the investment belongs.
## The Patients + Profitability™ framework
Across biotech and established pharma I have distilled the integrated approach into four connected pillars. None of them was discovered in a single conversation or a single role. They emerged slowly, through years of listening to people who could see parts of the journey I could not, and each one reinforces the others rather than competing with them for budget.



The four pillars of the Patients + Profitability framework
Four pillars sit in sequence and reinforce one another. Journey diagnosis maps where patients are actually lost. Value-aligned access builds market access around demonstrable patient value rather than list price defense. Integrated commercial execution puts sales, medical affairs and patient support on one shared model of the journey. Outcome-linked leadership accountability reviews patient outcome metrics and commercial performance metrics in the same meeting. Each pillar depends on the diagnosis produced by the first.


EACH PILLAR IS BUILT ON THE ONE BEFORE IT

PILLAR ONE
Journey diagnosis
The real map of where
patients are lost, not the
version in the deck


PILLAR TWO
Value-aligned access
Built on demonstrable
patient value, not on
list price defense


PILLAR THREE
Integrated execution
Commercial, medical and
support run against one
model, not three


PILLAR FOUR
Linked accountability
Outcome metrics and
commercial metrics in
the same review

Every pillar is simple to describe. The hard part is that three of them require structural change.
Leaders usually accept the logic long before the organization is built to execute it. Closing that gap is the actual work.



FIGURE 3. The four pillars run in sequence. Nothing downstream works without the first one.
Journey diagnosis. Before any commercial decision, the organization needs an evidence-based map of the real patient journey. Not the idealized version in a marketing deck. The actual one, with every point of friction, drop-off and delay. Everything downstream rests on this.
Value-aligned access. Access strategy built on demonstrable patient value rather than short-term list price defense, which positions the organization for durable payer relationships and slower price erosion.
Integrated commercial execution. Sales, medical affairs and patient support operating against one shared model of the journey instead of separate departmental targets, which removes both the duplication and the blind spots that siloed execution creates.
Outcome-linked leadership accountability. Incentives and reporting structured so that patient outcome metrics and commercial performance metrics are reviewed together, in the same meeting, by the same people.
## The business case for integration
Skeptical commercial leaders are right to ask for the case rather than the philosophy, and I would rather be asked. What follows is why the investment holds up financially. It is still not the reason to make it. It rests on three dynamics that repeat across therapeutic areas and company sizes.
Adherence protects revenue more cheaply than acquisition builds it. Products with above-average adherence beat their launch projections over multi-year horizons far more reliably than products relying on aggressive new-patient acquisition to offset predictable attrition. Chasing new starts gets more expensive every year as competition increases. Protecting existing therapy relationships is comparatively cheap, and it compounds.
Demonstrated value slows price erosion. Payers negotiate harder against products that cannot show real-world outcome value beyond the trial data. Organizations that invest early in outcomes tracking and support infrastructure arrive at renewal with evidence rather than leverage alone, and that shows up in contract terms.
Prescriber trust lowers acquisition cost. When clinicians see consistent evidence that a company’s support infrastructure improves outcomes for their patients, the cost of earning continued prescribing falls. Trust, once earned, is commercially efficient in a way promotional frequency never is.
None of this requires trading margin for goodwill. It requires recognizing that in this industry patient goodwill is margin. Deferred, compounding, and considerably more durable than the alternative.
Adherence-driven revenue protection consistently outperforms strategies built primarily on new-patient acquisition.
Early outcomes investment strengthens payer negotiations and slows long-term price erosion.
Prescriber trust lowers commercial acquisition cost over time.
Every leadership team I have worked with that treated patient support as a cost center eventually found it had been underfunding its own revenue protection strategy.
## Leadership in an age of dual accountability
None of this happens without deliberate leadership. Frameworks and org charts do not integrate themselves. Someone has to make the explicit and occasionally uncomfortable decision to hold commercial and clinical teams accountable to a shared definition of success rather than letting each function optimize its own narrow measure.
It is one of the harder transitions in the industry, because it usually means restructuring incentive plans, changing how success is reported to boards and investors, and building cross-functional reporting lines that did not previously exist. Letting commercial chase the quarter while medical affairs pursues scientific rigor in parallel, each unaware of how it affects the other, is far easier in the short term. Easier in the short term is precisely the trap that produces the false choice this piece opened with.
The leaders who make the transition tend to share a few habits. They ask for patient journey data in the same meeting where they review commercial performance rather than in a separate quarterly review. They judge a launch on both the clinical adoption curve and the patient retention curve, and treat the second as no less important than the first. And they are willing to bring in an outside read, because the silos that need dismantling are usually held in place by internal history that insiders cannot see around.
## What this adds up to
The companies that define the next decade will not be the ones that resolve the tension between patients and profitability by picking a side. They will be the ones that recognize the tension was never as real as it looked. It was a symptom of organizational fragmentation, not an inherent conflict between two legitimate goals.
Patients + Profitability™ is not an argument for less commercial rigor. It is an argument for pointing that rigor at the right target: a patient journey healthy enough, and frictionless enough, that profitability follows from doing the work well rather than competing with it.
The enterprise develops, manufactures, prices, contracts, distributes and supports. It does not diagnose, prescribe, dispense or treat. Within that boundary there is a great deal it can control, and most of it is currently being measured by someone who is not looking at the patient.
I did not arrive at any of this on my own. I learned it from researchers who spent decades pursuing answers that did not yet exist, from physicians carrying conversations no family hopes to have, and from nurses, pharmacists, patient advocates, manufacturing and finance colleagues who each accepted responsibility for one small part of a journey none of us could see in full. Behind every process, every meeting, every forecast and every operational decision was another person hoping to get back to the life they had.
So my hope for this is not that you agree with every conclusion in it. It is that you start asking your own questions about where your organization loses people, and what it costs when it does. Every one of us is building some part of a path that someone else has to cross.
## Frequently asked questions
### What does Patients + Profitability™ mean in practice?
It means designing commercial strategy, market access and medical affairs collaboration around one shared model of the patient journey, rather than treating patient outcomes and commercial performance as separate priorities owned by separate teams with separate metrics.
### Is focusing on patient outcomes a real strategy or just good messaging?
It can be either, and execution is what separates them. The test is whether patient outcome data actually changes commercial decisions such as targeting, access strategy and resource allocation, or whether it lives in a communications narrative disconnected from how the business runs.
### How does this apply differently to a first-launch biotech than to an established company?
A biotech gets to build its commercial and medical infrastructure without legacy silos to dismantle, but often without the resources for extensive patient support at launch. An established company has the resources and has to actively work against the fragmentation it already carries.
### What is the biggest barrier to integrating patient outcomes into commercial strategy?
Usually not belief. Usually incentives. When commercial leaders are measured on quarterly prescription volume and medical affairs leaders are measured on scientific engagement, neither has an organizational reason to collaborate no matter how much they personally agree with the idea.
### How is this different from a value-based healthcare framework?
Value-based healthcare frameworks are mostly about payer and provider reimbursement models. Patients + Profitability™ is a commercial and organizational operating framework spanning the full patient journey, including access, medical affairs collaboration and commercial execution. Value-based principles are one input to it rather than the whole strategy.
### Where should a leader start?
With an honest patient journey diagnosis. Identify exactly where patients disengage from therapy and why, before making any further structural or strategic decision. That diagnosis is the shared foundation the commercial and clinical teams can then build from together.

The ten places a patient can leave are on the philosophy page. The finance version of this measurement problem is in You Can Be Exactly Right About the Wrong Number, the launch version is in A Launch Does Not Fail in the Forecast, and terms used here are defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop? Who pays for this work is set out in the disclosure.



The patterns described here reflect my own experience advising pharmaceutical and biotech organizations, and are offered as commentary rather than as legal, regulatory, clinical or accounting advice. The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.

## Your Plan Decided Before You Did
URL: https://patrickrcoyle.com/formulary-step-therapy-what-to-ask/
Published: 2026-09-13

Coverage is the fifth of the 10 Exits of Therapy™, and it is the one where a decision about your treatment was made by people who never met you.
Your plan keeps a list of medicines it will pay for and rules about the order you have to try them in. Both are negotiated commercial terms, not clinical findings, and both have a formal route to challenge them.
## What a formulary actually is
A formulary is the list of medicines your plan covers, sorted into tiers that determine what you pay. It is built through negotiation between your plan, its pharmacy benefit manager, and the companies that make the medicines. Clinical evidence goes into that process. So does price.
This matters because of what it means when your prescription is refused. Your plan is not saying the medicine will not work for you. It is saying it has not agreed to pay for that one. Those sound similar at a counter and they are not remotely the same thing.
TWO DECISIONS, NOT ONE
Your prescriber decided
Which medicine fits your condition,
your history and your other treatments.
A clinical judgment.
Your plan decided
Which medicines it pays for, on what
tier, and what you must try first.
A contract term.
vs
You need both. When they disagree, the formal name for the fix is a formulary exception,
and only your prescriber can file it.
FIGURE 1. A clinical decision and a commercial one, and you need both to go your way.
## Step therapy, in plain terms
Step therapy means your plan wants you to try a different medicine first and have it not work before it will cover the one you were prescribed. It is sometimes called fail first, which is a more honest name for it.
There are legitimate reasons a plan does this. There are also cases where you have already tried the medicine it wants, years ago, with a different doctor, and nobody has that record in front of them. If that is you, say so early, because prior experience with a medicine is one of the strongest grounds for an exception.
Your plan is not saying the medicine will not work. It is saying it has not agreed to pay for that one.
## What to ask, and in what order
Ask your plan: is this medicine on the formulary, what tier is it on, and does step therapy or a quantity limit apply. Ask for the formulary document itself. You are entitled to it and it is usually on the plan website.
Ask your prescriber: if the plan wants something else first, is there a clinical reason that is not appropriate for me. That reason is the substance of an exception request.
Ask for the refusal in writing. The written notice has to state the reason and the appeal route. Without it you are arguing with a phone call. With it you have a document and a deadline.
## Exceptions exist, and they are used less than they should be
Every plan has a formulary exception process. Your prescriber files it, explains why the covered alternative is not suitable, and the plan responds within a defined window. It exists precisely because a list written months ago cannot anticipate every patient.
Ask your prescriber's office who handles exception requests. It is often one specific person, and finding them by name is usually the difference between a request that moves and one that does not.
## Why this exit exists
Coverage sits fifth in the 10 Exits of Therapy™ because it is the first point where the obstacle is not medical at all. You have a diagnosis, you have seen the right clinician, a prescription exists and you are enrolled in whatever program applies. Then a document written before anyone examined you decides whether you are allowed to start.
That is a solvable problem far more often than it looks from the pharmacy counter. It just requires knowing that what you are facing is a commercial decision with an appeal route, rather than a medical door that closed.
Coverage is exit 5 of ten. If your treatment stalled somewhere else, find which one at Where did your treatment stop? Exit 4 is enrollment. Exit 6 is authorization. Everything written for patients is gathered on the For Patients page. Terms used here are defined in the glossary.
This is navigation help, not medical advice. It does not replace anything your prescriber or pharmacist tells you, and decisions about diagnosis and treatment belong with your licensed clinician. Who pays for this work is set out in the disclosure.

## The Form Nobody Mentioned
URL: https://patrickrcoyle.com/the-form-nobody-mentioned/
Published: 2026-09-13

Enrollment is the fourth of the 10 Exits of Therapy™, and it is the one where the help already exists and is waiting for a form you were never handed.
Many treatments come with a support program that can help with cost, paperwork, delivery or getting started, and almost all of them are opt-in. Nobody in the chain is assigned to tell you they exist, so a large share of the people they were built for never enroll.
## Why nobody mentions it
This is not indifference. It is a gap in the workflow. The clinician’s job ends at the clinical decision. The pharmacy’s job starts when a prescription arrives. The program sits between those two and belongs to neither.
So the information tends to reach you by accident. A nurse who happens to know. A pharmacist who has seen it before. A card in a box you already opened. If none of those happen, nothing happens.
FUNDED, AND OPT IN
People a program is built for
People who are told it exists
People enrolled
Nothing between these bands
is a decision about you.
It is a step nobody owns.
FIGURE 1. The narrowing is administrative, not a judgment about who qualifies.
## What these programs actually do
They vary, and the variation matters more than the name. Some help with what you pay. Some handle the paperwork when a plan wants a review. Some arrange delivery or training when a treatment needs either. Some do all of it through a single person assigned to your case.
One thing to know before you spend time on it. Help with cost that comes from a manufacturer generally cannot be used by people covered by Medicare, Medicaid, TRICARE or other federal programs. That is a federal rule, not a judgment about you, and it is why the answer to whether you can use one depends on what kind of insurance you have. Independent charitable foundations and free medicine programs work differently and are worth asking about separately.
The program is not a favor you are asking for. It was built and paid for, and the only thing between you and it is usually a form.
## What to ask, and in what order
Ask whether there is a support program for this treatment. Ask the prescriber’s office first. If they do not know, ask the pharmacy. If neither knows, the treatment’s own website will say.
Ask who enrolls me, and whether you do it or I do. This is the question that gets skipped. Some programs need the prescriber to submit, some need you to, many need both, in order.
Ask what the program needs from the prescriber. Usually a signature and some clinical detail. Knowing what is needed lets you ask for it once rather than in three rounds.
Ask how long enrollment takes and what happens in the meantime. There is often an arrangement to cover the gap. It is rarely offered unprompted.
## Enrollment is not the same as coverage
Worth separating these, because they get confused constantly. Your plan decides whether the treatment is covered. A support program decides whether it can help you with what is left over, or with the process.
They run on different timelines, they are decided by different people, and one does not wait for the other. You can start an enrollment while a coverage question is still open, and in most cases you should.
## Why this exit exists
Enrollment sits fourth in the 10 Exits of Therapy™ because it is the last step before the plan gets involved, and it is the one most likely to be skipped entirely rather than done badly.
It is also the exit where the gap between what was built and who uses it is widest. Programs are funded on the assumption that people will find them. Most people do not, and nobody is counting the ones who did not.
Enrollment is exit 4 of ten. If your treatment stalled somewhere else, find which one at Where did your treatment stop? Exit 3 is prescription creation. Exit 5 is coverage. Everything written for patients is gathered on the For Patients page. Terms used here are defined in the glossary.
This is navigation help, not medical advice. It does not replace anything your prescriber or pharmacist tells you, and decisions about diagnosis and treatment belong with your licensed clinician. Who pays for this work is set out in the disclosure.

## The Decision Was Made. The Prescription Was Not Sent.
URL: https://patrickrcoyle.com/decision-made-prescription-not-sent/
Published: 2026-09-13

Prescription creation is the third of the 10 Exits of Therapy™, and it is the one where you watched the decision get made and then never saw what happened to it.
Deciding on a treatment and sending the prescription are two separate events, and only the first one happens in front of you. A surprising share of stalled treatments are sitting in the gap between them.
## Why the gap exists
In the room, a clinician tells you what they are going to prescribe. That is a clinical decision and it is done. What follows is an administrative act, usually performed later, sometimes by someone else, occasionally at the end of a long day.
It can go to the wrong pharmacy. It can go to a pharmacy that cannot dispense it. It can be written and not transmitted. It can be transmitted and rejected, with the rejection landing in a queue nobody is watching that afternoon.
TWO EVENTS, ONE WITNESSED
The decision
You were in the room
The transmission
You were not
Everything that goes wrong here goes wrong in the gap between them.
FIGURE 1. You watched the first one. Nobody tells you about the second.
## Nobody is assigned to tell you
This is the part worth understanding. In most practices there is no step in the workflow that closes the loop with the patient. The prescription is sent, and the next thing anyone hears is either you calling or nothing at all.
So silence after a visit does not mean it worked. It means nothing, and the only person reliably positioned to notice is you.
The decision belongs to your clinician. The confirmation is the only part of this you can do yourself, and it takes one phone call.
## What to ask, and in what order
Ask before you leave the room which pharmacy it is going to. Say the name back. Pharmacy records are full of near-duplicates, and a prescription sitting at a branch across town is one of the most common versions of this failure.
Ask whether this one has to go to a specific pharmacy. Some treatments can only be dispensed by particular pharmacies. Finding that out in the room saves a week.
Ask when it will be sent, not whether. Is it going today gets you a date. Will you send it gets you a yes that commits nobody.
Ask who to call if the pharmacy does not have it. Get a name or a department. The main line of a busy practice is where this problem goes to sit.
## Give it two days, then check
A reasonable rule is to call the pharmacy two business days after the visit and ask whether they have received it. Not whether it is ready. Whether it arrived.
If it did not arrive, call the office and say so plainly. You are not chasing a favor. You are reporting that a step did not complete, which is information they need and usually do not have.
## Why this exit exists
Prescription creation sits third in the 10 Exits of Therapy™ because it is the point where a clinical decision becomes an administrative object, and administrative objects get lost.
It is the cheapest exit to close. There is no appeal to file, no program to enroll in and no committee to convince. There is one phone call, and almost nobody makes it, because they assume the thing they watched happen was the thing that happened.
Prescription creation is exit 3 of ten. If your treatment stalled somewhere else, find which one at Where did your treatment stop? Exit 2 is provider access. Exit 4 is enrollment. Everything written for patients is gathered on the For Patients page. Terms used here are defined in the glossary.
This is navigation help, not medical advice. It does not replace anything your prescriber or pharmacist tells you, and decisions about diagnosis and treatment belong with your licensed clinician. Who pays for this work is set out in the disclosure.

## Booked Out, or Out of Network
URL: https://patrickrcoyle.com/booked-out-or-out-of-network/
Published: 2026-09-13

Provider access is the second of the 10 Exits of Therapy™, and it is where two completely different problems wear the same face.
Not being able to see the right clinician is either a scheduling problem or a contract problem. They feel identical when you are the one waiting, they have different fixes, and the first useful thing you can do is find out which one you have.
## The calendar problem
Specialists in some fields are booked months out. That is a supply problem, it is not personal, and it is not something your plan can fix by phone.
What it does respond to is persistence and flexibility. Cancellation lists are real and they move faster than people expect. So does a willingness to take an early morning slot, a different location in the same practice, or a first visit with a nurse practitioner or physician assistant on the same team.
TWO WALLS, TWO DOORS
A calendar problem
The clinician is in your network.
The next opening is months out.
The fix is a cancellation list and flexibility.
A network problem
There is an opening.
Your plan will not pay for it.
The fix is a written request to the plan.
From the waiting room these look the same. They are not.
FIGURE 1. Same experience, different cause, different fix.
## The network problem
This one is different. There is an appointment available. Your plan just will not pay for it, because that clinician is not contracted with your plan.
Plans are required to maintain a network adequate to the care they cover. When the network does not actually contain someone who treats your condition within a reasonable distance or time, there is a formal route to ask the plan to cover an out-of-network clinician at in-network cost. It is a written request, its name varies by plan, and it is used far less often than it applies.
A network is a list of contracts, not a list of the clinicians qualified to treat you. When the two do not overlap, that is the plan’s problem to solve.
## What to ask, and in what order
Ask the office which problem it is. Are you in network with my plan, and what is your next available appointment. One question, two answers, and it sorts the whole situation.
Ask to be added to the cancellation list, and ask how it works. Some practices call in order, some call whoever answers first. Knowing which changes how available you need to be.
Ask your plan who in network treats this condition, by name and location. Make them produce the list. If it is empty, short, or full of people not taking new patients, that is your evidence for the next question.
Ask the plan for a network adequacy or out-of-network exception, in writing. Ask what it is called on your plan, who reviews it, and how long they have to answer.
## The referral is its own step
Many plans will not pay for a specialist visit without a referral, and a referral is a separate document from the appointment. It can expire. It can be written for a set number of visits. It can name a specific clinician rather than a practice.
If your appointment is far out, check that the referral will still be valid when you get there. This is one of the more common and most avoidable ways a scheduled visit falls apart on the day.
## Why this exit exists
Provider access sits second in the 10 Exits of Therapy™ because the diagnosis can be right and the treatment can exist and neither matters until you are in front of someone who can prescribe it.
It is also the exit where the two underlying causes are most often confused, which means people spend months on the fix for a problem they do not have.
Provider access is exit 2 of ten. If your treatment stalled somewhere else, find which one at Where did your treatment stop? Exit 1 is diagnosis. Exit 3 is prescription creation. Everything written for patients is gathered on the For Patients page. Terms used here are defined in the glossary.
This is navigation help, not medical advice. It does not replace anything your prescriber or pharmacist tells you, and decisions about diagnosis and treatment belong with your licensed clinician. Who pays for this work is set out in the disclosure.

## Before Anything Can Be Prescribed
URL: https://patrickrcoyle.com/before-anything-can-be-prescribed/
Published: 2026-09-13

Diagnosis is the first of the 10 Exits of Therapy™, and it is the only one where nothing has gone wrong yet, because nothing has started.
Everything that follows in your care runs off a diagnosis written in your record. Until something has a name, there is no prescription to fill, no coverage to check and no program to enroll in, and the waiting can look like nothing is happening when quite a lot is.
## What is actually going on while you wait
A clinician who is not naming your condition yet is usually not stuck. They are working through a differential, which is the list of things it could be, ruling them out in an order set by which are most likely, most dangerous and most testable.
That order is rarely explained, which is why the wait can feel arbitrary. It is also why two people with the same symptoms wait very different lengths of time. Yours depends on which tests your case needs, how fast those results come back, and whether anything has to be repeated.
NOTHING DOWNSTREAM CAN START
Diagnosis
not yet made
Provider
waiting
Prescription
waiting
Coverage
waiting
Pharmacy
waiting
Four working steps, all waiting on one that has not happened yet.
FIGURE 1. The rest of the system is functioning. It has nothing to act on.
## The working diagnosis is a real thing
Long before a final answer, most records carry a working diagnosis. It is the clinician’s current best explanation, and it is written down. It can be enough to start certain kinds of treatment and it is often enough to start a referral.
It is also the thing most people never think to ask about. If you know what the working diagnosis is, you know what is being ruled in, and you can ask what would change it.
You are not waiting for certainty. You are waiting for enough certainty to act on, and that threshold is lower than most people assume.
## What to ask, and in what order
Ask what the working diagnosis is today. Not the final one. The one in the record right now. It is a legitimate question and the answer is usually a sentence.
Ask what the next test rules in or out. This turns an open-ended wait into a defined one, and it tells you whether the test is confirming something or eliminating something.
Ask what would have to be true to start treatment sooner. Sometimes the answer is nothing and the wait is unavoidable. Sometimes it is a single result, and knowing that changes what you chase.
Ask who is chasing the results. Offices vary. Some call you, some wait for you to call. Find out which one you are dealing with before you assume silence means no news.
## When the wait is the problem
There is a difference between a wait that is doing something and a wait that has stalled. A test ordered and not scheduled, a referral sent and not acknowledged, a result back and not read. These failures look identical to patience from where you are sitting.
The way to tell them apart is to ask for the date. Not the outcome, the date. When was it ordered, when is it scheduled, when should the result be back. A step with no date attached is usually the step that has stalled.
## Why this exit exists
Diagnosis sits first in the 10 Exits of Therapy™ because it is the only exit where the rest of the system is working perfectly and still cannot help you. Coverage, pharmacy, support programs and prescribers are all waiting on a piece of information that does not exist yet.
It is also the exit with the least visible progress and the most avoidable delay, because so much of the time lost here is administrative rather than clinical.
Diagnosis is exit 1 of ten. If your treatment stalled somewhere else, find which one at Where did your treatment stop? Exit 2 is provider access. Everything written for patients is gathered on the For Patients page. Terms used here are defined in the glossary.
This is navigation help, not medical advice. It does not replace anything your prescriber or pharmacist tells you, and decisions about diagnosis and treatment belong with your licensed clinician. Who pays for this work is set out in the disclosure.

## The Launch Begins Long Before Approval Day
URL: https://patrickrcoyle.com/market-access-before-approval-day/
Published: 2026-09-11

Approval day is the moment everyone celebrates, and it is the wrong milestone to organize a launch around. By the time it arrives, the people who will decide whether patients can actually get the therapy have already made up their minds about it.


Market access is still widely treated as a phase that begins after approval. It does not. Payers form a view of a therapy across pivotal data, publication, congress presentations, guideline signals and competitor positioning, most of which happens years before a commercial team is allowed to make its case. Since 2023, federal law has made it explicit that manufacturers may talk to those decision makers before approval, within defined limits. Most organizations still do not use that window, and the launch pays for it.


## Approval day is a milestone, not a starting line


The ritual is understandable. Approval is the culmination of years of work, enormous expense and genuine scientific risk. It deserves the celebration. What it does not deserve is the role it has been given in the commercial calendar, where it functions as the starting gun for a conversation that should already be well underway.


Treating access as a post-approval activity produces a specific and avoidable failure. The commercial team arrives with a well-built case, delivered to an audience that formed its opinion somewhere around the phase 3 readout. The work is not wasted, but it is doing something much harder than it was designed to do. It is asking people to revise a conclusion rather than helping them form one.





When a payer forms a view, and when the commercial conversation usually starts
Two timelines running from early clinical development to the first year in market. A payer's view of a therapy forms steadily across pivotal data, publication, congress presentations, guideline signals and competitor positioning, well before approval. The commercial conversation in most organizations does not begin until approval day. The gap between the two is where the launch is quietly decided.

HOW A PAYER'S VIEW ACTUALLY FORMS

Pivotal data, publication, congress presentations, guideline signals, competitor positioning
The view is forming here, whether or not anyone from the company is in the room

The view is largely set
WHEN THE COMMERCIAL CONVERSATION USUALLY STARTS

Silence, or internal preparation nobody outside the company ever sees

The pitch begins

APPROVAL DAY

The gap is the whole problem.
By the time the case is made, the audience has already reached a conclusion and is being asked to revise it rather than form it.



FIGURE 1. The view forms on the top timeline. The conversation starts on the bottom one. Everything difficult about a launch lives in the space between them.


## What a payer already believes before you ask


By the time a product reaches approval, the people making coverage decisions have usually already answered four questions for themselves. What problem does this therapy solve, and for whom. How does it compare to what they are already paying for. Roughly what will it cost them across a covered population. And how much administrative friction will it take to control utilization.


None of those answers came from the manufacturer. They came from the published literature, from congress presentations, from analyst coverage, from guideline movement and from competitors who were happy to frame the category first. That is not a failure of payer diligence. It is what happens when one party talks for three years and the other stays silent.


## The exchange is now explicitly permitted


The reason most organizations stayed quiet was never really strategy. It was legal caution. Pre-approval communication sat in genuinely ambiguous territory for years, and the reasonable instinct in ambiguous territory is to say nothing.


That ambiguity has narrowed considerably. Section 114 of the FDA Modernization Act opened the door to health care economic information in 1997, the FDA finalized guidance on payer communications in 2018, and pre-approval information exchange was codified in the Consolidated Appropriations Act of 2023. The result is a defined lane rather than a gray zone.





What pre-approval information exchange permits and what it does not
Under the pre-approval information exchange provisions codified in the Consolidated Appropriations Act of 2023, a manufacturer may share with payers, formulary committees, drug information centers, technology assessment committees and pharmacy benefit managers: product descriptions, anticipated approval timelines, the indications being sought, patient utilization projections, and factual study results that draw no conclusions about safety or efficacy. It does not permit conclusions about safety or effectiveness, promotional claims, or communication to prescribers or the public.


WHAT MAY BE SHARED BEFORE APPROVAL

WHAT STAYS OFF THE TABLE

Product description and the indications being sought
Anticipated timeline to approval
Patient utilization projections
Factual study results, without conclusions drawn


Conclusions about safety or effectiveness
Promotional claims of any kind
Communication to prescribers or the public
Anything that presumes the approval decision


The permitted audience is specific: payers, formulary committees, drug information
centers, technology assessment committees and pharmacy benefit managers.
These are precisely the people whose view is forming while most companies stay silent.



FIGURE 2. The lane is narrow and it is real. Descriptions, timelines, indications sought, utilization projections and factual results, to a defined audience.


Read the left column as a commercial planning document rather than a compliance one. Utilization projections and anticipated timelines are exactly what a formulary committee needs in order to budget, and exactly what it cannot construct on its own. Supplying them early is not promotion. It is removing the guesswork that otherwise gets resolved conservatively, and conservative guesses become restrictive criteria.


## What actually gets decided before approval


Three things are effectively settled before the first commercial meeting, and all three are hard to move afterward.



The comparator. Whichever product the category is measured against becomes the baseline for every value conversation that follows. That frame is usually set in the literature, not in a negotiation.

The budget expectation. A payer that has not been given a utilization projection will build one, and it will build one defensively. That number becomes the anchor.

The control posture. Whether a therapy is treated as something to manage tightly or something to enable is a disposition formed well before the first authorization criteria are drafted.



None of those are contract terms. They are prior beliefs, and they are considerably more durable than contract terms.


## Evidence a payer can use, not evidence that impressed a regulator


There is a translation problem underneath all of this. The evidence package that satisfies a regulator answers a different question than the one a payer is asking. A regulator asks whether the therapy is safe and effective for a defined population. A payer asks what happens to a covered population and a budget over a plan year.


Those are not the same question and the second one is rarely prepared with the same rigor as the first. Building it early is not an additional burden invented by commercial. It is the thing that decides whether the clinical work translates into patients actually starting therapy.


## Where this connects to the patient


Everything above sounds like a payer strategy discussion. It is actually a patient access discussion wearing different vocabulary.


A payer who forms a cautious view of a therapy expresses that caution operationally. It becomes step edits, tighter authorization criteria, narrower initial coverage and longer review cycles. Each of those lands on a specific patient at a specific counter, and each one widens an exit that was already open. The decisions described here are made years earlier and several levels of abstraction away, but they arrive as a delay in somebody's treatment.


Your approval rate is not your access rate. It describes the prescriptions that survived long enough to be measured.


This is the same principle running in reverse. Everything done before approval determines how wide the exits will be after it. What happens to the measurement once the product is in market is a separate problem, and I wrote about that in A Launch Does Not Fail in the Forecast. What a forecast is actually for, once it exists, is a separate question again, and I took that up in The Forecast Is Not the Deliverable.


## The alignment this depends on


This is why I keep returning to Patients + Profitability™. Improving patient outcomes and building a commercially sustainable product are not competing objectives that have to be balanced against each other. They are the same objective measured from two ends, and both of them are decided far earlier than the org chart suggests.


The enterprise's role stays narrow throughout. It develops, manufactures, prices, contracts, distributes and supports. It does not diagnose, prescribe, dispense or treat. What it can do is arrive early enough that the people deciding coverage are working from information rather than from inference.


Companies that treat commercialization as a development-phase discipline do not just launch better. They launch into a market that already understands what the therapy is for, which is the only condition under which a launch ever goes well.



The ten places a patient can leave are on the philosophy page. Terms used here are defined in the glossary, and the rest of the writing is on the blog. The patient-side view of the same ten exits is at Where did your treatment stop? The same problem seen from an emerging company's side, where none of that data exists yet, is set out in Your First Launch.




Background on the pre-approval exchange provisions.


Pre-Approval Information Exchange Aids Manufacturer and Payer Engagement, Avalere Health.

Communicating Healthcare Economic and Pre-approval Information With Healthcare Decision-Makers, Frontiers in Public Health.




The description of permitted pre-approval communication is a general summary of publicly available material and is not legal or regulatory advice. Any specific communication should be reviewed by qualified counsel and the appropriate internal review committee. The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.

## A Launch Does Not Fail in the Forecast. It Fails in the Exits.
URL: https://patrickrcoyle.com/launch-fails-in-the-exits/
Published: 2026-09-11

Half of a launch class misses its first-year forecast. The post-mortems almost always blame the forecast. In my experience the forecast was close to right about the patients. It was wrong about how many of them would make it all the way to a paid dispense.


New product commercialization fails in a specific, repeatable way. A forecast quietly assumes commercial infrastructure that a newly approved product does not have yet: a formulary position, a working authorization pathway, dispensers who know the product, an enrolled support base, and claims history to reconcile against. For the first two or three quarters the product is sold into a market that has none of that, while bridge supply masks the shortfall. By the time the first clean Gross-to-Net read arrives, the decisions that shaped it are already locked.


## Half the class misses, and the diagnosis is usually wrong


Trinity Life Sciences found that half of the 2023 United States launch class underperformed its pre-launch first-year forecast, with 39 percent above it. That split has been roughly stable for years, which tells you something. If the problem were forecasting skill, a decade of better analytics would have moved it. It has not moved much, because the miss is not mostly an estimating error. It is an execution gap that shows up in the same line of the P&L as an estimating error.


A forecast is a statement about patients: how many exist, how many get diagnosed, how many get treated, what share this product wins, what it nets per unit. Every one of those is defensible when the model is built. What the model does not carry is the operational state of the market on the day the product actually arrives.





What a forecast assumes a product has, and what a new product actually has on day one
Five pieces of commercial infrastructure a forecast quietly assumes: a formulary position, a working prior authorization pathway, pharmacy familiarity, an enrolled patient support base, and claims history to reconcile against. An in-market product has all five. A newly approved product has none of them, and each one has to be built while the product is already being sold.


IN MARKET, YEAR THREE

APPROVAL DAY

A formulary position
A working authorization pathway
Pharmacy familiarity
An enrolled support base
Claims history to reconcile against


Tiering, terms and rebates already negotiated
Criteria published, denials already appealed
Dispensers know the product and its handling
Hub, copay and adherence programs running
Two years of actuals behind every accrual


Present
Present
Present
Present
Present


Not yet
Not yet
Not yet
Not yet
None at all




FIGURE 1. The forecast was built on an in-market product's operating conditions. The launch inherits none of them and has to build all five while selling.


Read that right column again. Four of those five gaps close over the first year with ordinary work. The fifth does not close at all. There is no claims history for a product that has never been dispensed, so every early accrual is an assumption, and every variance explanation is a guess dressed as an analysis.


## The exits are widest exactly when the product is newest


The 10 Exits of Therapy™ describe the ten places a patient can leave between diagnosis and a first dose. At launch, four of them are wider than they will ever be again. Coverage has not been established. Authorization criteria are new or absent, so denials are the default rather than the exception. Affordability programs are still enrolling. Fulfillment runs through dispensers who have never handled the product.


The scale of the authorization problem is now documented. A Johns Hopkins analysis published in JAMA in July 2026, covering more than two million fill attempts for single-source brand drugs, found initial rejections rose from 24.3 percent in 2018 to 40.7 percent in 2024. Of those rejected attempts, 48.4 percent were never followed within 90 days by a fill of the prescribed drug or any drug in the same class. The patients who did get treated waited an average of 12 days.





Where a first prescription for a newly launched product stops
A first fill attempt for a single-source brand drug meets an initial rejection in about 41 percent of cases, up from 24 percent in 2018. Of those rejected attempts, 48.4 percent are never followed within 90 days by a fill of the prescribed drug or any drug in the same class. Those that are eventually filled take an average of 12 days. Everything to the right of the rejection is invisible to the manufacturer unless it is deliberately instrumented.

A FIRST FILL ATTEMPT, SINGLE-SOURCE BRAND

Prescription reaches
the pharmacy


INITIAL REJECTION
40.7% in 2024
up from 24.3% in 2018



Filled after an average 12-day delay
The patient waits. The therapy starts late.

48.4% never filled within 90 days
Not the drug, not a same-class alternative

None of this appears in shipment data.
A launch reads demand from what left the warehouse. The rejection happens three steps later, to a patient nobody counted.



FIGURE 2. Roughly two in five first attempts are rejected, and nearly half of those never come back. A launch measuring shipments sees none of it.


Those are market-wide figures across established products. A product in its first months, with no published criteria and no appeal history, does not do better than the average. It does worse, and it does worse at the exact moment when every early data point is being used to calibrate the rest of the launch.


A launch reads demand from what left the warehouse. The rejection happens three steps later, to a patient nobody counted.


## Bridge supply hides the leak for two quarters


Here is the part that makes launch different from everything that follows. Most launches put free product in front of the coverage gap on purpose. Bridge and quick-start programs exist so a patient is not left waiting while a payer decides, and that is the right thing to do for the patient. It also means that for the first two quarters, demand looks real and almost none of it is paid.


So the early signal is clean in the wrong direction. Units are moving. Prescribers are writing. Nothing in the demand data says that authorization is failing, because the patient got the drug anyway. The failure only becomes visible when the free supply tapers and paid claims have to carry the volume, and that is precisely when the first real rebate, chargeback and government pricing actuals start landing.





Why the first clean Gross-to-Net read arrives after the decisions it should have informed
A timeline from approval day through month eighteen. Bridge and quick-start supply covers the first two quarters, so early demand looks strong while almost none of it is paid. Paid claims and the first real rebate and chargeback actuals arrive around months six to twelve. By then the contracting, channel and patient support decisions of Phase 1 are already locked and expensive to reverse.

FROM APPROVAL DAY


Day 0
Month 6
Month 12
Month 18


Bridge and quick-start supply carries most volume

Paid claims become the majority

Gross-to-Net is an assumption carried over from the model

First clean read on actuals


Decisions made in this window
Contract terms, channel design, copay program rules, hub vendor selection, pricing corridor

The evidence arrives here
After the decisions are expensive to reverse

The gap between those two boxes is the launch problem. It is a sequencing problem, not a forecasting problem.



FIGURE 3. The evidence arrives on the far side of the decisions it should have informed. That is the sequencing problem at the center of most launch misses.


By month twelve the contracting terms are signed, the channel is built, the copay program rules are set, the hub vendor is selected and the pricing corridor is established. Those are Phase 1 decisions and they are expensive to reverse. The data that would have informed them shows up in Phase 2.


## What Phase 1 actually decides


Phase 1 Pre-Launch and Launch Readiness is usually described as preparation. It is better understood as commitment. Almost every structural driver of Gross-to-Net for the life of the product gets fixed in that phase, before a single unit is dispensed.



The pricing corridor. List price sets the ceiling on every statutory discount that follows, and it is the one number that cannot be quietly revised later.

Contract architecture. Which payers, which tiers, what rebate structure and what volume commitments. These terms outlive the people who negotiated them.

Channel design. How many distributors, which specialty pharmacies, what fee structure. This determines where visibility ends and where it survives.

Affordability program rules. Eligibility, caps and duration, which decide whether the program supports patients or subsidizes benefit design.

What gets measured. The least reversible decision of all, because a signal nobody instrumented at launch cannot be recovered retroactively.



## What to instrument before approval day


If the sequencing problem is real, the fix is not a better forecast. It is moving the evidence earlier. Four things are worth building before the product ships, because none of them can be reconstructed afterward.



A first-fill funnel, not a shipment report. Attempts, rejections, reasons, appeals, reversals and time to fill. If the only launch metric is units shipped, the leak is invisible by construction.

A paid versus supported split from day one. Report bridge and quick-start volume separately from paid claims in every launch review. Blending them produces a number that is comforting and wrong.

Time to therapy as a tracked measure. Twelve days is a national average. Your own number is knowable and almost nobody measures it during a launch.

A Gross-to-Net accrual built to be revised. Assume the first four quarters are estimates and design the true-up governance before you need it, rather than defending a number that was never more than a placeholder.



## The part that carries over


The enterprise's role here is narrow and worth stating precisely. It develops, manufactures, prices, contracts, distributes and supports. It does not diagnose, prescribe, dispense or treat. Every lever above sits on the supply side of a decision a clinician and a patient make together, which is exactly why removing friction is the only honest way to influence the outcome.


Your approval rate is not your access rate. It describes the prescriptions that survived long enough to be measured.


At launch, that sentence is doing more work than anywhere else in the lifecycle, because so little has survived long enough to be measured yet. A launch does not fail in the forecast. It fails in the ten places a patient can leave, during the one period when nobody can see them leaving.



The ten places a patient can leave are on the philosophy page. Terms used here are defined in the glossary, and the rest of the writing is on the blog. The patient-side view of the same ten exits is at Where did your treatment stop? Which of those exits you can actually see in the first three months after launch, and which stay hidden, is set out in Your First Ninety Days.




Primary sources.


Insurance Denials for Brand-Name Prescription Drugs Rose Sharply From 2018 to 2024, Johns Hopkins Bloomberg School of Public Health, July 2026, on Levy et al., JAMA, July 9, 2026.

Half of the 2023 U.S. Pharmaceutical Launch Class Underperforms Pre-Launch First Year Forecasts, Trinity Life Sciences.




Figures cited are the published findings of the named sources. The operating patterns described reflect my own experience across launches and are offered as commentary, not as legal, regulatory, clinical or pricing advice. The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.

## Rethinking Copay Accumulators: Focus on Days-on-Therapy Over Dollars Spent
URL: https://patrickrcoyle.com/copay-accumulators-days-on-therapy/
Published: 2026-09-11

Copay accumulators are argued about in dollars, which is why the argument never ends. Every party to it can produce a number showing they lost, and none of those numbers describes what happened to the patient.
An accumulator does not reduce what a drug costs. It relocates when the patient pays, moving the full weight of the deductible to the moment manufacturer assistance runs out. The dollars eventually net out somewhere in a ledger. What does not net out is the interval in the middle, when the patient is asked to absorb a cost they had been shielded from and some of them stop filling. Measured in dollars, that year is a dispute. Measured in days on therapy, it is a fact.
## Why the dollar frame produces a stalemate
Run the same accumulator year past three parties and you get three defensible grievances. The manufacturer spent assistance that never reduced the patient's deductible. The plan collected cost sharing against the same prescription twice, once from assistance and once from the patient, which is the design working as intended. The patient reaches the point of exhaustion still owing the entire deductible, and now owes it unassisted.
Each of those is true. None of them is a measure of the outcome, because all three are denominated in money and the thing that actually changed was continuity.
Two ledgers for the same accumulator year
The dollar view shows three parties, each able to demonstrate a loss: the manufacturer spent assistance that did not reduce the patient's deductible, the plan collected cost sharing twice against the same drug, and the patient still owes the full deductible. The days view shows the same year as a therapy timeline, with continuous therapy while assistance lasts, a gap when assistance is exhausted and the deductible is still unmet, and a restart once the deductible is satisfied. Only the second view records what happened to the patient.
THE DOLLAR VIEW
Manufacturer
Assistance spent, none of it
applied to the deductible
Plan
Cost sharing collected once from
assistance, once from the patient
Patient
Full deductible still owed,
now without assistance
Every party can document a loss. Nobody can document the year.
THE DAYS VIEW
On therapy
Assistance absorbing the copay
Gap
Assistance exhausted, deductible unmet
Back on therapy
Deductible satisfied out of pocket
The dollars net out somewhere. The days do not come back.
FIGURE 1. The same accumulator year, recorded two ways. Only one of them registers the interruption.
## What the accumulator actually moves
The mechanism is worth stating plainly, because it is often described as a cost-control tool and it is not. Total spend on the drug is unchanged. Assistance is still spent, the plan still pays its share, the patient still owes their deductible. What changes is the sequence: assistance covers the early fills without reducing the patient's accumulated cost sharing, so the deductible arrives intact at the moment the assistance is gone.
That is a timing decision, and timing is exactly what determines abandonment. A patient who would have absorbed a deductible spread across a year encounters it as a single wall in month four or five. The clinical decision at the counter is not made against an annual total. It is made against one price, on one day.
## The regulatory answer is not coming on schedule
It is tempting to treat this as a compliance question that policy will eventually settle. The current record argues otherwise. Twenty-five states plus the District of Columbia and Puerto Rico now require plans to count copay assistance toward cost-sharing limits, and Avalere's analysis put that at no less than 16.8 percent of the United States commercial market, roughly 34.3 million lives.
Those laws reach state-regulated plans. Self-insured employer plans are governed federally and sit outside them, which is where a large share of commercial coverage actually lives. At the federal level, a district court vacated the 2021 provision permitting accumulators in September 2023, returning the standard to the 2020 rule, and the agency then said it would not enforce pending new rulemaking. That rulemaking has not arrived.
So the practical situation is a benefit design that varies by state, by funding type, and by whether a medically appropriate generic exists. That is not a condition anyone should be waiting out.
Where state copay accumulator bans reach, and where they do not
Twenty-five states plus the District of Columbia and Puerto Rico require plans to count copay assistance toward cost sharing. Those requirements reach at least sixteen point eight percent of the United States commercial market, about thirty-four point three million lives. They apply only to state-regulated plans, so self-insured plans governed by the federal Employee Retirement Income Security Act sit outside them, as do states without a ban. At the federal level the 2021 rule permitting accumulators was vacated in 2023, the earlier 2020 standard applies, and the agency has said it will not enforce pending new rulemaking that has not arrived.
US COMMERCIAL MARKET
16.8%
~34.3M lives
The rest of the market
Self-insured ERISA plans, and states with no ban
State bans reach only state-regulated plans. Self-insured employer plans are federally governed and sit outside them.
STATE LAYER
25 states, plus DC and Puerto Rico, require
assistance to count toward cost sharing.
Different rules, different effective dates.
FEDERAL LAYER
The 2021 rule permitting accumulators was
vacated in 2023. The 2020 standard applies.
Not enforced. No replacement rule.
A benefit design that varies by state, by funding type and by whether a generic exists.
FIGURE 2. Coverage depends on where the patient lives, how their employer funds the plan, and whether a generic exists.
## Days on therapy is the measure both sides can audit
The reason to move to a days-based measure is not that dollars do not matter. It is that days are the only variable in this system that every party can observe the same way and none of them can reframe.
Days covered before the cliff. How long assistance sustained continuous therapy before the patient's exposure changed. This is the part of the program that worked.
Gap length at exhaustion. The interval between the last assisted fill and the next fill of any kind. A gap of zero means the patient absorbed it. A long gap means they did not.
Restart rate. The share of patients who resume after a gap, and how long they take. Non-restart is abandonment with a delay in front of it.
Persistence at twelve months against a matched population. The comparison that isolates the accumulator from everything else happening to the patient.
Those four are auditable from data that already exists in hub and pharmacy reporting. None requires agreement about who bore which dollar.
## What this changes about program design
Once the measure is days rather than dollars, the design questions change with it. A support program calibrated to a dollar cap per patient per year is optimizing the wrong constraint, because the cap does not know where the cliff falls. A program calibrated to continuity spends differently: it front-loads less, it monitors the approach to exhaustion, and it treats the transition itself as the event to manage rather than an accounting boundary.
It also changes what gets escalated. A patient at 80 percent of assistance with a deductible still unmet is a predictable gap, visible weeks before it happens, and nothing in a dollars-based program is built to notice.
The accumulator was designed to change who pays. Its measurable effect is on whether the patient continues.
## The same discipline, one step earlier
This sits in the same place as every other access question. The enterprise develops, manufactures, prices, contracts, distributes and supports. It does not decide what a plan counts toward a deductible. What it can decide is what it measures, and whether its own support programs are instrumented to see a patient stop.
The dollar argument about accumulators will continue, in legislatures and in courts, on a timeline nobody controls. The days argument can be settled internally, with data already in hand, and it is the one that tells you whether the patient is still on therapy.
The ten places a patient can leave are on the philosophy page. The measurement problem this creates in finance is in Bridging the Gap, and terms used here are defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop? Where affordability shows up in the first three months after launch, and what it is safe to conclude from it, is set out in Your First Ninety Days.
Primary sources.
State Copay Accumulator Bans Now Affect At Least 17% of Commercial Lives, Avalere Health, December 2025, using September 2025 enrollment data.
HHS Notice of Benefit and Payment Parameters for 2027, proposed rule, Federal Register, February 2026.
Market and enrollment figures are the published findings of Avalere Health. Regulatory status is described as of publication and is not legal advice. The operating patterns described reflect my own experience and are offered as commentary, not as legal, regulatory, clinical or accounting advice. The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.

## The Many Faces of 340B
URL: https://patrickrcoyle.com/the-many-faces-of-340b/
Published: 2026-09-11

Few programs in healthcare generate as much debate, confusion and financial complexity as 340B. Most of that debate comes from people describing the part of the program they can see.


Ask four stakeholders what 340B is and you get four accurate answers. It is a lifeline for patients who depend on safety-net providers. It is the funding mechanism that keeps those providers solvent. It is a source of opacity and misaligned incentives. It is a revenue engine carrying growing complexity for pharmacies and manufacturers. All four descriptions are true at once, and the gap between them is where the conflict lives.





One program described four ways
340B sits at the center. Around it are four descriptions held by different stakeholders: a lifeline for patients who depend on safety-net providers, a funding mechanism that supports those providers, a market distortion that creates opacity and misaligned incentives, and a revenue engine that adds complexity for pharmacies and manufacturers. All four descriptions are accurate at the same time.










340B
ONE PROGRAM

A lifeline
For patients who depend on safety-net providers

A funding mechanism
Economic support that keeps those providers open

A market distortion
Opacity and incentives pointing in different directions

A revenue engine
Growing complexity for pharmacy and manufacturer

All four are true at the same time



FIGURE 1. Most organizations understand their own face of the program with real precision. Very few understand the other three.


## What the program was built to do


The original purpose was straightforward. Let eligible safety-net providers purchase outpatient drugs at a discount so they could stretch scarce federal resources and extend services to vulnerable populations. Oncology programs funded care for patients who could not otherwise afford treatment. Rural providers extended reach into communities with little else nearby. Uncompensated care got underwritten.


That is one face of 340B, and it is a good one. It is no longer the only one.


## The safety-net view


For disproportionate share hospitals and other covered entities, 340B has become an economic support mechanism rather than a discount program. It offsets declining reimbursement as payer mix shifts, uncompensated care delivered without corresponding payment, labor costs in a market that keeps bidding up clinical staff, and capital needs for growing patient populations.


From inside that position, 340B is not optional. It is operationally necessary, and many would argue that without it portions of the safety net begin to fracture. That view deserves to be understood rather than dismissed, because it is describing something real about how those institutions actually stay open.


## The manufacturer view


Manufacturers see the same program from the other end of the transaction, and what they see is exposure they cannot measure. Eligible utilization cannot be validated at the claim level. Claim-level economics and downstream flows are not visible. Medicaid duplicate discount risk sits unresolved on the balance sheet. Contract pharmacy networks have grown in ways that make patient eligibility difficult to establish.


From that position, 340B stopped looking like a targeted safety-net program some time ago. It looks like a broad commercial channel embedded inside the healthcare system, and the financial consequences run straight through Gross-to-Net.


## Contract pharmacy is where the argument concentrates


No part of the program has generated more controversy. Contract pharmacy arrangements were originally limited in scope. Today some covered entities maintain hundreds of these relationships, and a few maintain thousands.


Supporters point to access. More dispensing locations means more convenience for patients who would otherwise travel to a single hospital pharmacy. Critics point to opacity. A sprawling network makes it harder to establish which patients are being served, where the economics land and whether the arrangement still reflects safety-net intent.


Both concerns can be true at once. The contract pharmacy debate is not binary. It is a reflection of the program's broader complexity, and it is unresolvable as long as the underlying transaction data stays fragmented.





Where the 340B discount goes after the manufacturer funds it
The manufacturer funds the discount and sells at the 340B price to a covered entity. The covered entity dispenses through a contract pharmacy, which takes dispensing and administrative fees. Nothing in the statute requires the discount to reach the patient. Payer and pharmacy benefit manager reimbursement sits across the last three steps. Manufacturer visibility ends at the covered entity.


PAYER AND PBM REIMBURSEMENT SITS ACROSS EVERYTHING DOWNSTREAM

Manufacturer
Funds the discount

Covered entity
Buys at the ceiling price

Contract pharmacy
Dispenses and takes fees

Patient
No required pass-through



Discount funded
340B price paid
Fees taken
Retail price paid


Manufacturer visibility ends here
Everything to the right is inferred, not observed



FIGURE 2. The manufacturer funds the discount and then loses sight of it. Nothing in the statute requires the discount to reach the patient.


## The eligibility question nobody has settled


This is where the program becomes genuinely hard. One of the largest ongoing disputes is over who actually qualifies as a 340B patient, and the operational definitions are far less clear than most people assume.


As health systems expand physician affiliations, integrated delivery networks, specialty referrals and outpatient relationships, the line between a truly underserved patient and a commercially insured patient treated somewhere inside a covered entity ecosystem keeps blurring. The ecosystem widened. The definition did not.





The 340B patient eligibility spectrum and how the covered entity ecosystem widened across it
A spectrum runs from uninsured and underserved patients on the left to commercially insured patients on the right. Three positions sit along it: safety-net, integrated network built from physician affiliations and referrals, and commercial. The covered entity ecosystem originally covered only the safety-net end and has widened to cover most of the spectrum, which is what makes the eligibility definition contested. Three questions follow: program intent, economic fairness, and manufacturer exposure.


WHO COUNTS AS A 340B PATIENT




Safety-net
Uninsured and underserved
Integrated network
Physician affiliations and referrals
Commercial
Insured, inside the ecosystem


Original scope


The ecosystem as it operates today

Program intent
Was the program built to
cover this population?

Economic fairness
Are discounts applied the way
the policy intended?

Manufacturer exposure
Who carries the cost of
eligibility ambiguity?



FIGURE 3. Three questions follow from the same ambiguity, and they are asked by three different parties who rarely agree on the answer.


## The PBM and payer layer


Pharmacy benefit managers and payer economics are now deeply entangled with 340B, which makes the accounting question harder than it looks. Manufacturers fund the discounts and absorb the Gross-to-Net pressure. Covered entities capture program economics. Contract pharmacies capture dispensing economics. PBMs manage the reimbursement flows that sit across all of it.


Patients are the intended beneficiaries. Whether they consistently benefit is a separate question, and the honest answer is that nobody can prove it either way at scale, because no single party holds the whole record.


## Transparency is the actual issue


The future of this debate will not turn on whether the program should exist, or on whether hospitals or manufacturers are right. It will turn on transparency, because most stakeholders still operate with fragmented data, incomplete visibility, disconnected incentives and limited understanding of downstream economic behavior.


Opacity does not just create inefficiency. It creates distrust, political conflict, compliance risk and financial instability across the entire ecosystem.


Every structural complaint about 340B, from either direction, reduces to the same root. No single party can see the whole transaction, so every party assumes the worst about the part it cannot see.


## Where this stands in September 2026


Two things have changed the stakes since this argument started.


The first is scale. HRSA reported that covered entities purchased $100 billion in covered outpatient drugs in calendar year 2025, roughly 23 percent above the prior year, with disproportionate share hospitals accounting for about $79 billion of it. A program of that size is no longer a line item in anyone's model.


The second is mechanism. HRSA's revised 340B Rebate Model Pilot Program takes effect January 1, 2027, and it changes how the discount is delivered for a narrow set of drugs. Covered entities in the pilot will purchase at wholesale acquisition cost and claim the difference back as a rebate, which means the discount becomes a claim rather than a price. That is a direct answer to the transparency problem, and it moves cost and administrative burden onto the entities least able to absorb either. I wrote about what that shift does to Gross-to-Net operations in Government Pricing Is No Longer a Calculation.



Both things are true, and that is the whole problem.

Claim-level data is the only credible route to resolving duplicate discounts and eligibility disputes.

The mechanism that produces that data also puts a cash gap and an administrative cost on safety-net providers.

A solution that fixes transparency by weakening the providers it was written to protect has not actually solved anything.



## What structural evolution would look like


The path forward is not elimination, and it is not preservation of the status quo. It is structural evolution across five fronts.



Better data visibility. Claim-level transparency that lets every party validate utilization and economics rather than infer them.

Clearer patient eligibility standards. Operational definitions that reflect the program's original safety-net intent and survive contact with an integrated delivery network.

Contract pharmacy accountability. Frameworks that match the scale the contract pharmacy ecosystem has actually reached.

Duplicate discount mitigation. Systemic solutions rather than retrospective disputes over overlapping discount obligations.

Aligned incentives. A closer relationship between patient benefit and the economics that drive participation.



Most importantly, the path forward requires acknowledging that there are many faces of 340B. Some are good. Some are problematic. Most are complicated. Reducing the conversation to "340B is broken" or "340B is untouchable" misses the reality entirely. This is not a simple issue. It is an ecosystem issue.


## Patients + Profitability


At the center of every healthcare economic debate is one question. Are we improving the patient journey while creating a system that can sustain itself?


In the long run, patients and profitability are not competing objectives. Organizations that create operational visibility across the full ecosystem, align channel strategy with both patient and financial goals, and build incentives that serve patients rather than work around them will improve outcomes, reduce unnecessary leakage and hold up financially over time.


340B is no exception. The path forward is not simpler. It is smarter.



The companion piece on how the discount mechanism itself is changing is here. What a pharmacy-counter stop does to the rebate number is in You Can Be Exactly Right About the Wrong Number. The ten places a patient can leave are on the philosophy page, and the terms used here are defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop? Reading coverage posture and site-of-care concentration from outside your own data is what NaviCuris is built to do.




Primary sources.


2025 340B Covered Entity Purchases, HRSA.

HRSA Announces Revised 340B Rebate Model Pilot Program, July 31, 2026.

Notice Regarding 340B Rebate Model Pilot Program, Federal Register, August 3, 2026.




This analysis reflects a commitment to understanding the full 340B ecosystem rather than one side of it. Program figures and terms reflect publicly available federal data and notices as of September 11, 2026, and are subject to change, agency discretion and litigation. This article is commentary, not legal, tax, regulatory or pricing advice. The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.

## Government Pricing Is No Longer a Calculation. It Is a Transaction.
URL: https://patrickrcoyle.com/government-pricing-is-a-transaction/
Published: 2026-09-11

Government pricing has spent three decades being treated as arithmetic performed after the quarter closed. On January 1, 2027, it starts behaving like a payment system, and what triggers the payment is a patient who actually received the drug.


Two federal programs are moving the government discount from the front of the transaction to the back of it. Medicare's Maximum Fair Price is already delivered to pharmacies as a retrospective refund rather than a lower acquisition cost. Beginning January 1, 2027, a limited 340B rebate pilot does the same for covered entities, which will buy at wholesale acquisition cost and claim the difference back. In both cases the discount stops being a price and becomes a claim. A claim requires a dispense. A dispense requires a patient who made it all the way through.


## What actually changed


The Medicare Drug Price Negotiation Program is no longer theoretical. Negotiated prices for the first ten Part D drugs took effect January 1, 2026, at roughly a 22 percent average reduction off net prices. Fifteen more Part D drugs follow on January 1, 2027, a group that includes the GLP-1 products, at a projected 44 percent average reduction. The 2028 cycle brings fifteen more and pulls physician-administered Part B drugs into negotiation for the first time. The statutory ceiling itself is a function of how old the product is, set at 75, 65 or 40 percent of non-federal average manufacturer price depending on years since approval.


Alongside that, HRSA announced a revised 340B Rebate Model Pilot Program on July 31, 2026. Applications closed August 24. Approval decisions are due by September 24. The pilot takes effect January 1, 2027, and it is narrow on purpose: it covers only drugs selected for Medicare negotiation in the 2026 and 2027 price applicability years, which HRSA puts at under 5.5 percent of total 340B sales. The other 94.5 percent keeps running on upfront discounts.


The narrowness is not the point. The mechanism is. An earlier version of this pilot was enjoined by the U.S. District Court for the District of Maine on December 29, 2025, on Administrative Procedure Act grounds, largely because covered entities had not been given adequate notice or consideration of the burden. The revision answered that with structure: 90 days advance notice instead of 60, rebates paid at unit level rather than package level, a 15-day inventory transition, mandatory dispute pathways, HIPAA deidentification standards, manufacturer-funded platforms, and removal from the pilot for a manufacturer that runs 5 percent or more of its payments late.



The operating dates that matter.

September 24, 2026. HRSA approval decisions on pilot applications.

January 1, 2027. The pilot takes effect, and fifteen additional Maximum Fair Prices begin.

Ten calendar days. The window a manufacturer has to pay a complete 340B rebate claim, with the clock restarting on an incomplete submission.

Fourteen days. The window a manufacturer has to authorize a Medicare Maximum Fair Price refund after receiving the data, which puts most refunds in a pharmacy's account near 21 days from the date of service.



## The discount used to arrive before the patient. Now it arrives after.


Under the model everyone built their systems around, a covered entity bought at the ceiling price. The discount was embedded in acquisition. There was no gap to finance and no claim to substantiate, because the price itself was the proof.


Under a rebate model, the entity buys at wholesale acquisition cost, dispenses, submits a claim and waits. That gap is short on paper and expensive in practice, because it repeats on every unit, every day, indefinitely. HRSA's own estimate puts the average administrative cost near $34,320 per covered entity per year, and that figure does not include the working capital.





When the government discount arrives, before and after January 1, 2027
Through 2026 a covered entity acquires at the 340B ceiling price, the drug is dispensed, and no cash gap opens. From January 1, 2027 under the rebate pilot the entity buys at wholesale acquisition cost, dispenses, submits a claim, and receives a rebate within ten calendar days, carrying the cash in between.

THROUGH 2026 · THE DISCOUNT ARRIVES FIRST


Acquires at the 340B
ceiling price

Drug is dispensed to
the patient

No cash gap. The price
was the discount.




FROM JANUARY 1, 2027 · THE DISCOUNT ARRIVES LAST


Buys at wholesale
acquisition cost

Drug is dispensed
to the patient

Unit level claim
is submitted

Rebate paid within
10 calendar days





Cash carried by the purchaser until the rebate lands
Clock restarts on an incomplete claim



FIGURE 1. The same discount, moved to the other side of the dispense. Through 2026 the price is the proof. From 2027 the claim is.


That matters commercially, not just operationally. A rural hospital or a grant-funded clinic that cannot comfortably float wholesale acquisition cost has one obvious lever, and it is the formulary. Stocking decisions are where a financing problem turns into an access problem.


The discount did not get smaller. It got slower. Slow discounts are financed by whoever is holding the inventory, and that is rarely the party who negotiated them.


## Three federal prices, one dispense record


The harder problem is not cash. It is proof. Before a manufacturer pays a Maximum Fair Price refund, it has to know whether that unit was already discounted under 340B. Before it pays a 340B rebate, it has to know whether the same unit will be billed to Medicaid. Non-duplication has always been the quiet failure point in government pricing, and it was survivable when the discounts were embedded in a price and reconciled quarterly.


Once the discount is a payment, non-duplication has to resolve at the unit, in days, against a claim. There is only one artifact that can carry that determination, and it is the dispense record. Government pricing has therefore just inherited a dependency on patient-level transaction data that it never had before.





One dispense record now sets three federal prices
A single unit dispensed to a patient creates a claim. That claim passes a non-duplication check, which then determines the Medicaid unit rebate amount, the 340B rebate back to the ceiling price, and the Medicare Maximum Fair Price refund to the dispensing pharmacy.


THE SOURCE RECORD
One unit dispensed
to one patient




THE GATE
Non-duplication
check at unit level
Which program owns this unit?






Medicaid unit rebate amount
No longer capped at the average manufacturer price


340B rebate back to the ceiling price
Paid after purchase, not priced into it


Medicare Maximum Fair Price refund
Paid back to the dispensing pharmacy



FIGURE 2. Non-duplication used to be a quarterly reconciliation. It is becoming a unit level decision made in days.


## Medicaid already taught this lesson


None of this is unprecedented. The Medicaid rebate cap came off on January 1, 2024, and with it went the floor. A unit rebate amount can now exceed 100 percent of average manufacturer price, which means a manufacturer can pay more in rebate than it collected on the sale. The formula no longer has a backstop, so every input feeding it carries real money.


The lesson that generalized out of that change is simple. When a statutory formula loses its ceiling or its floor, data accuracy stops being a compliance chore and becomes a balance sheet item. The rebate model does the same thing to timing that the cap removal did to magnitude.


## Where this lands in the patient journey


This is where government pricing stops being a finance topic. The 10 Exits of Therapy™ describe the ten places a patient can leave between diagnosis and a first dose. Four of them sit directly on top of what a rebate model now measures: Coverage, Authorization, Affordability and Fulfillment.





The 10 Exits of Therapy and the point where a claim first exists
The ten exits in order: Diagnosis, Provider Access, Prescription Creation, Enrollment, Coverage, Authorization, Affordability, Fulfillment, Patient Engagement, Therapy Initiation. Coverage, Authorization, Affordability and Fulfillment are the exits a rebate model touches most directly. No dispense record exists before Fulfillment, so patients who leave earlier generate neither therapy nor evidence.

THE 10 EXITS OF THERAPY

01
Diagnosis

02
Provider
Access

03
Prescription
Creation

04
Enrollment

05
Coverage

06
Authorization

07
Affordability

08
Fulfillment

09
Patient
Engagement

10
Therapy
Initiation


Exits 01 through 07
No dispense record is ever created. There is nothing
to claim, reconcile or defend.

Exits 08 through 10
The record exists. It is what
substantiates the discount.


FIGURE 3. Four of the ten exits sit directly on what a rebate model measures. Nothing before Fulfillment creates a record.


A patient who leaves at Authorization does not generate a dispense. No dispense, no claim. No claim, no rebate, no refund, and nothing to reconcile. The leakage was always real. What is new is that the same friction now removes the evidence that would have supported the discount, so it shows up twice in the same quarter.


Your approval rate is not your access rate. It describes the prescriptions that survived long enough to be measured.


Under a rebate model that sentence describes your government discounts too. A rebate you believe you are owed on a dispense that never happened is not a receivable. It is a forecast.


## What to do before January 1



Confirm scope. The pilot reaches only products selected for Medicare negotiation in the 2026 and 2027 price applicability years. Everything else stays on upfront discounts, so the first question is whether you are in it at all.

Name an owner for the ten-day clock. A payment obligation measured in calendar days does not belong to a quarterly close calendar, and it does not survive being handled as an exception.

Rebuild the Gross-to-Net accrual as a claim-triggered payable. A reserve estimated from history and a payable triggered by a submitted claim behave differently in every month that volume moves.

Get non-duplication logic to unit level now. Resolving it after the first dispute means resolving it in front of a covered entity that has already been paid late.

Treat covered entity liquidity as commercial risk. Model what happens to volume if entities that cannot finance wholesale acquisition cost change what they stock.

Instrument the exits. If you cannot see where patients leave, you cannot forecast what you will owe, what you will reclaim, or which of the two will surprise you first.



## The part that does not change


The statute sets the price. Operations decide whether you ever realize it. Gross-to-Net has always been the financial echo of how well the enterprise executed the patient journey, and the enterprise's job in that journey is narrow and unglamorous. It develops, manufactures, prices, contracts, distributes and supports. It does not diagnose, prescribe, dispense or treat. Everything it can control sits on the supply side of a decision a clinician and a patient make together.


What a rebate model changes is the delay. Friction used to show up as a volume miss two quarters later. Now it shows up as a claim that was never filed, on a payment cycle measured in days. The distance between patient friction and revenue leakage just got a lot shorter.



The ten places a patient can leave are on the philosophy page. The 340B companion piece is The Many Faces of 340B, and the rebate-side version of the same measurement problem is in You Can Be Exactly Right About the Wrong Number. Definitions for the terms used here are in the glossary, and the rest of the writing is on the blog. The patient-side view of the same ten exits is at Where did your treatment stop? Reading government-program utilization and coverage posture by state and by site is what NaviCuris is built to do.




Primary sources.


Notice Regarding 340B Rebate Model Pilot Program, Federal Register, August 3, 2026.

HRSA Announces Revised 340B Rebate Model Pilot Program, July 31, 2026.

Medicare Transaction Facilitator Overview for Dispensing Entities, CMS.

Key Facts About Medicare Drug Price Negotiation, KFF.

Medicaid Drug Rebate Program final rule, CMS.




Program terms described here reflect publicly available federal guidance and notices as of September 11, 2026, and are subject to change, agency discretion and litigation. This article is commentary, not legal, tax, regulatory or pricing advice. Figures cited are the agencies' own published estimates. The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.

## The Frameworks Behind the Profile
URL: https://patrickrcoyle.com/frameworks-behind-the-profile/
Published: 2026-09-02

CEOInsider has published a profile of this work: Following the Patient to Understand the Economics, written by Dennis Olympios.
This post supplies the key. The journey the article follows is Patients + Profitability™, the transition points where patients disappear are The 10 Exits of Therapy™, the unobserved losses are The Silent Leak™, and the layers of Gross-to-Net economics and the alignment work are The 5 Layers of GTN™ and Alignment Labs™. There are no numbers in any of it because I cannot honestly separate outcomes from concurrent market movement.
The four named frameworks behind the published profile
A published executive profile describes this body of work without using any of its framework names, which was a deliberate editorial choice for an audience of chief executives. This post supplies the key. The journey it follows is Patients plus Profitability. The transition points where patients disappear are the 10 Exits of Therapy. The unobserved losses are the Silent Leak. The layers of Gross-to-Net economics and the alignment work are the 5 Layers of GTN and Alignment Labs. The article is careful and accurate, but without the names a reader is left holding the shape of an idea with nowhere to put it.
THE JOURNEYPatients +Profitability™The frame the profilefollows without naming.THE TRANSITIONS10 Exits ofTherapy™The points wherepatients disappear.THE LOSSESThe SilentLeak™What is lost withoutever being observed.THE ECONOMICS5 Layers of GTN™and Alignment Labs™Where the loss lands,and how it gets fixed.The profile describes nearly everything I do without using a single one of my names for it.That was the right editorial call. It just leaves a reader holding the shape of an idea with nowhere to put it.
FIGURE 1. Four names for four things the profile describes accurately and never labels.
It is careful, it is accurate, and it describes nearly everything I do without using a single one of my names for it. That was the right editorial call. The piece was written for chief executives, not for people who already follow this work, and a profile crowded with trademarks reads like a brochure.
But it leaves a reader holding the shape of an idea with nowhere to put it.
So here is the key.
## What the article describes, and what I call it
What the article says
What it is called here
That patient access and commercial performance can be understood through the same treatment journey.
Patients + Profitability™The north star. Not opposing objectives. Interdependent ones.
That some transitions are particularly difficult to observe, and a patient may complete one step but not continue to the next.
The 10 Exits of Therapy™The ten places a patient leaves between diagnosis and therapy initiation.
That these situations do not necessarily indicate anyone acted incorrectly, and that finance may observe the outcome without visibility into every earlier step.
The Silent Leak™Not denied. Never counted. No rejection, no appeal, no variance.
That Gross-to-Net economics reflect contracting, channel design, patient support programs and payer policy, not finance alone.
The 5 Layers of GTN™Where each exit lands inside the enterprise, and who owns it.
That the relevant functions should share information and align assumptions through a regular operating cadence.
Alignment Labs™The people who own each transition, in one room, working from one set of definitions.
That the work is being translated into advisory methods and educational approaches other professionals can apply.
Learn. Align. Transform.The curriculum, the labs and the advisory work, in that order.
## Why there are no numbers in any of it
The profile carries no performance figures, and neither does anything else I publish. That is the standard that governs the case files: I will describe the decision, the authority I actually held, the architecture I built and what it cost. I will not attach a revenue number, a growth number or a forecast accuracy number to it, because I cannot separate those from concurrent market movement, and neither can anyone else who publishes them.
A claim bounded by its own limits is harder to attack than one that is not.
## The four questions
The last section of the profile is the part I would keep if I could keep only one. It is four questions that a team can carry out of a room:
What conditions need to be present for this strategy to work?
What additional information could improve the decision?
Which transition would benefit from clearer coordination?
What other explanation should be considered?
They are now on the philosophy page, because every framework above fails the moment the fourth one stops being asked.
If a hypothesis does not survive the evidence, the hypothesis goes. That is not a caveat attached to the work. It is the work.
Read the full profile:Following the Patient to Understand the Economics, CEOInsider. The patient-side view of the same ten exits is at Where did your treatment stop?
Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.

## Aligning Patient Support Services with Gross-to-Net Strategy
URL: https://patrickrcoyle.com/aligning-patient-support-services-with-gross-to-net-strategy/
Published: 2026-09-02

Gross-to-Net is discussed as an accounting output. It is the financial manifestation of dozens of strategic and operational decisions made long before the first prescription is written.
This post captures a session for Finance and Market Access leaders at Informa Connect on how patient support decisions become Gross-to-Net outcomes. Gross-to-Net is a lifecycle, not a calculation, and value leaks in two places: pharmacy behavior that drifts from manufacturer intent, and payer maximizer programs that shift cost back to the manufacturer. Both stay invisible until accruals rise, so the answer is to design access intentionally and hold every partner to measured accountability.
Hub & Specialty Pharmacy Models East
Informa Connect · March 19, 2026
The 5 Layers of GTN™
## The session
A room with Finance on one side and Market Access on the other, which is the room where this argument is worth making. The subtitle on the title slide was From Commercial Strategy to Journal Entry, and that is the whole distance the session tries to close. Two days earlier at the same conference I moderated a panel on patient assistance programs under pressure. This was the session where I got to make the case directly.
The two places value leaks between patient support and the number
Presented to Finance and Market Access leaders, the argument is that Gross-to-Net is a lifecycle rather than a calculation. Value leaks in two places. Pharmacy behavior drifts from what the manufacturer intended, and payer maximizer programs shift cost back onto the manufacturer. Both remain invisible until accruals rise and somebody asks why. The answer is to design access intentionally and to hold every partner to measured accountability, because the number is the financial manifestation of decisions made long before the first prescription is written.
LEAK ONEPharmacybehaviorDrifts from what themanufacturer intended.LEAK TWOPayer maximizerprogramsShift cost back ontothe manufacturer.WHAT THEY SHAREBoth stayinvisibleUntil the accrual risesand somebody asks why.THE ANSWERDesign access,then measure itEvery partner held tomeasured accountability.Gross-to-Net is a lifecycle, not a calculation. From commercial strategy to journal entry.It is the financial manifestation of decisions made long before the first prescription is written.
FIGURE 1. Neither leak announces itself. Both show up first as an accrual movement nobody can explain.
## The argument
Gross-to-Net is a lifecycle, not a calculation. It runs from new product pricing corridors through GPO contracting, copay programs, distribution and government pricing, and only then into accruals and journal entries. Every upstream choice shapes the financial outcome, and almost none of those choices are made by the people who eventually have to defend the number.
Every early decision embeds a downstream financial consequence.
That produces a specific and predictable failure. Every Gross-to-Net decision becomes a financial liability that Finance inherits, often quarters after the decision was made, by which point the conversation is about the reserve rather than about the behavior that created it. Four functions are each behaving reasonably and on different clocks. Finance forecasts from historical analogs. Market Access negotiates against future market conditions. Trade manages today's operations. Accounting trues up to what actually happened. The tension is structural, not a failure of anyone's judgment.
## What has changed
The advantage no longer comes from spending more on affordability.
Vertical integration has moved the economics of access without any single decision announcing itself. The next advantage does not come from spending more on affordability. It comes from making sure every dollar spent actually reaches the patient, which requires intentional network design, measured independence and leadership-level accountability from the beginning rather than as a correction.
## Where the value leaks
Leakage stays invisible until accruals rise or margins compress.
Two kinds, and they behave differently. Pharmacy leakage happens when dispensing behavior, channel steering or performance incentives drift from what the manufacturer designed. Payer leakage happens when accumulator and maximizer programs exploit copay benefits, moving cost back to the manufacturer without improving what the patient actually pays.
Neither announces itself. Leakage stays invisible until accruals rise, margins compress, or a reconciliation stops tying out. The uncomfortable version of this is that expanding access without embedded controls frequently accelerates liability faster than it accelerates revenue.
## What to do about it
Taking back control of Gross-to-Net does not mean restricting access.
Taking back control does not mean restricting access or cutting patient support. It means designing access intentionally: optimizing GPO contracting to protect pricing integrity, redesigning copay benefits to reduce maximizer exposure, keeping the right to transition a patient support provider whose performance deteriorates, and preserving partner independence so that patient interests stay central while financial exposure is actively managed.
The question has shifted. It used to be, did the program help patients? It is now, can we prove every transaction was appropriate, compliant and defensible?
### Watch
Two short clips from the session.
### Where this connects
The ten places a patient can leave are on the philosophy page. The accrual that inherits all of this is Accrual Design, and what happens when the actuals arrive is True-Up Governance. The full speaking record is on the speaking page. The patient-side view of the same ten exits is at Where did your treatment stop? For a company doing this for the first time, with no launch history to align against, the starting position is set out in Your First Launch.
Slides shown are excerpts from the session deck. Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.

## The Pharmacy of the Future Will Not Compete on Dispensing. It Will Compete on Value.
URL: https://patrickrcoyle.com/pharmacy-of-the-future-competes-on-value/
Published: 2026-09-02

The short version: a pharmacy built on dispensing volume is easy to exploit and hard to defend, and enforcement actions and CMS quality measures already reward outcomes over counts. The pharmacy of the future will be paid for moving patients successfully through therapy, through benefits navigation, adherence support, care coordination and real-world evidence. Dispensing alone will price like a commodity.
Pharmacies have been measured by prescriptions filled, and that measure is now working against them. It is easy to exploit, hard to defend, and it describes none of the work that actually keeps a patient on therapy. Reimbursement is already moving toward the work that does.

What a pharmacy gets paid for, now and next
A pharmacy measured on prescriptions filled is easy to exploit and hard to defend, and dispensing alone will price like a commodity. The alternative is being paid for moving patients successfully through therapy: benefits navigation to get past the coverage wall, adherence support and care coordination to keep patients on therapy once they start, and real-world evidence to prove the outcome happened. Enforcement actions and quality measures already reward outcomes over counts.
PAID FORPrescriptionsfilledEasy to exploit.Hard to defend.PAID FORBenefitsnavigationGetting the patientpast the coverage wall.PAID FORAdherence andcoordinationKeeping them on therapyonce they start.PAID FORReal-worldevidenceProving the outcomeactually happened.Enforcement actions and CMS quality measures already reward outcomes over counts.Dispensing alone will price like a commodity. The rest is what a pharmacy can defend.
FIGURE 1. One of these four is a commodity. The other three are a position.







As our industry pushes toward greater pharmacy independence, increased transparency, and reduced vertical integration, I believe we are asking an important question.




What is the future role of the pharmacy?





For years, pharmacies have largely been measured by prescriptions filled.





I do not believe that is enough anymore.




## A Volume Model Is Easy to Exploit





Start with the uncomfortable part. When the unit of value is the prescription rather than the patient, the system becomes straightforward to game, and a small number of actors do exactly that.





In June 2026, the Justice Department announced its largest coordinated health care fraud action by participation in the department's history. Four hundred fifty-five defendants were charged across 56 federal districts and 45 states and territories, involving more than $6.5 billion in alleged false claims, with 50 state Medicaid Fraud Control Units taking part. Ninety of the defendants were licensed medical professionals, pharmacists among them. The prior year's takedown had alleged $14.6 billion in intended loss.





The pharmacy-specific allegations are worth reading closely, because every one of them describes a dispensing transaction detached from a patient outcome.





Alleged in the 2026 takedown

In New Jersey, a pharmacy owner allegedly paid providers to write prescriptions for high-reimbursement medications the pharmacy itself selected, causing roughly $20.7 million in losses to Medicare and Medicaid.

In New York, pharmacies allegedly received more than $12 million for prescriptions that were never dispensed, or were filled using product obtained from unlicensed black-market suppliers.

In Hawaii, a pharmacy allegedly billed Medicare for drugs it did not dispense and could not support with inventory.







These are allegations, and they describe a small minority of an industry where the overwhelming majority of pharmacists do difficult work with integrity. That is not my point. My point is what the cases have in common. Prosecutors built them by comparing claims data against drug purchases, inventory, prescriber patterns, and proof of delivery. Every scheme lived in the gap between a billed prescription and a treated patient.





A model that pays for units moved will always have that gap. A model that pays for patients successfully treated has nowhere to hide.




## Extraction Is Not Always Criminal





The larger issue is not fraud. It is that value can be extracted from a dispensing-based system entirely lawfully.





The FTC's second interim staff report on pharmacy benefit managers examined 51 specialty generic drugs dispensed between 2017 and 2022. It found that the three largest PBMs marked up numerous drugs at their affiliated pharmacies by hundreds and in some cases thousands of percent above estimated acquisition cost. One pulmonary hypertension generic was marked up more than 7,700 percent for commercial payers in 2022. Across the set, affiliated pharmacies generated over $7.3 billion in dispensing revenue above acquisition cost, growing at a 42 percent annual rate, with an additional $1.4 billion attributed to spread pricing.





The share of specialty generic dispensing revenue going to affiliated pharmacies rose from 54 percent in 2016 to 68 percent in 2023. CVS has disputed the analysis, calling it a selective reading of outliers and noting that specialty generics were under 1.5 percent of its clients' total drug spend across the period.





Take the dispute at face value and the underlying point survives. When margin depends on which pharmacy fills the script and at what markup, the economics reward capturing the transaction. Nothing in that structure rewards whether the patient started therapy, stayed on it, or got better.




## Dispensing Alone Is No Longer a Differentiator





If the pharmacy of the future does not create measurable value for patients, providers, manufacturers, and payers, we will continue to see the market evolve toward alternative models. Direct-to-patient distribution. Manufacturer-supported fulfillment. Cash-pay channels, wherever they offer a better experience.





Dispensing medication alone is becoming less of a differentiator.





Creating a better patient journey is.




## What the Pharmacies That Thrive Will Actually Do





The pharmacies that thrive will be those that become active partners in healthcare, by helping to:






Navigate benefits verification and prior authorization




Improve affordability




Increase adherence and persistence




Generate meaningful real-world evidence




Identify patients at risk of discontinuing therapy




Coordinate care across the healthcare ecosystem








They will not simply move products. They will move patients successfully through therapy.






That is where I believe the opportunity lies.




## This Is Not a Prediction. It Has Already Started.





Here is the part I think gets underweighted in this conversation. Value-based payment tied to pharmacy performance is not something the industry is waiting on. It is already the single largest lever in Medicare Advantage plan economics.





CMS Star Ratings include three Part D medication adherence measures, covering diabetes medications, blood pressure medications, and statins. Each has historically been triple-weighted, carrying three times the influence of an ordinary measure. Together they have accounted for roughly a third of a plan's Part D summary rating. Plans reaching four stars overall become eligible for a five percent quality bonus payment.





Read that again in commercial terms. A plan's bonus payment turns substantially on whether patients have their medication on hand at least 80 percent of the days they should. That is not a dispensing metric. It is a patient journey metric. And the pharmacy is the entity closest to it.





Worth tracking: for measure year 2026 CMS temporarily reduced the three adherence measures to single weight while it phases in sociodemographic risk adjustment, with a return to triple weighting expected for the 2027 Star Ratings. CMS also stopped excluding inpatient and skilled nursing days from the adherence calculation. The weighting moved. The direction did not.






## The Debate Is Not Independent Versus Integrated





As someone who has spent nearly two decades working across commercialization, patient access, and healthcare finance, I do not think the future debate is about independent pharmacy versus integrated pharmacy.





It is about which pharmacy models create the greatest value.





The shift

Reimbursement will increasingly follow value.



Value will not be measured by how many prescriptions leave the shelf.

It will be measured by how many patients achieve better outcomes.








The enforcement data shows what a volume model invites. The FTC data shows what it rewards even when everyone stays inside the law. The Star Ratings data shows that the alternative is already funded and already scored.





Pharmacies that can prove they moved a patient from prescribed to persistent will be able to price that. Pharmacies that can only prove they moved a box will be priced like a box.




That is the future I believe our industry should be designing. And the infrastructure to pay for it already exists.







### Sources and Notes


2026 enforcement action: U.S. Department of Justice, "National Health Care Fraud Takedown Results in 455 Defendants Charged in Connection with Over $6.5 Billion in Alleged Fraud," announced June 24, 2026. Cases in 56 federal districts and 45 U.S. states and territories, with 50 state Medicaid Fraud Control Units participating, the most in department history. Ninety of those charged were licensed medical professionals. More than $182 million in assets was seized.

Pharmacy-specific allegations: DOJ case summaries as reported in Buchanan Ingersoll & Rooney, "DOJ's 2026 Health Care Fraud Takedown: Why Pharmacies Should Act Before an Audit Becomes an Investigation," June 2026. All matters described are allegations. Defendants are presumed innocent unless and until proven guilty.

2025 comparison figure: DOJ, 2025 National Health Care Fraud Takedown, June 30, 2025. Charges against 324 defendants involving over $14.6 billion in intended loss, the largest such action in DOJ history at the time. CMS separately reported preventing over $4 billion in payments on false or fraudulent claims and suspending or revoking billing privileges for 205 providers.

PBM markups and affiliated pharmacy steering: Federal Trade Commission, "Specialty Generic Drugs: A Growing Profit Center for Vertically Integrated Pharmacy Benefit Managers," second interim staff report, January 14, 2025. Analysis covered 51 specialty generic drugs and 882 National Drug Codes dispensed 2017 to 2022 under commercial and Medicare Part D plans managed by Caremark, Express Scripts, and OptumRx. Findings include over $7.3 billion in dispensing revenue above National Average Drug Acquisition Cost, a 42 percent compound annual growth rate, roughly $1.4 billion attributed to spread pricing, and a rise in affiliated-pharmacy share of specialty generic dispensing revenue from 54 percent in 2016 to 68 percent in 2023.

Industry response: CVS Health has publicly disputed the FTC analysis, characterizing it as drawing broad conclusions from selected outliers and noting that specialty generics represented under 1.5 percent of Caremark clients' total drug spend over the study period. The FTC reports are staff reports and remain contested. Readers should weigh both.

Star Ratings and adherence: CMS Medicare Part D Star Ratings include three medication adherence measures for diabetes medications, RAS antagonists, and statins, scored on Proportion of Days Covered with an 80 percent adherence threshold. These measures have historically been triple-weighted and have contributed approximately 31 percent of a plan's Part D summary rating. Plans achieving an overall rating of four stars or higher are eligible for a five percent quality bonus payment. For measure year 2026 CMS temporarily reduced the three measures to single weight while phasing in sociodemographic status risk adjustment, with a return to triple weighting expected for the 2027 Star Ratings, and discontinued the exclusion of inpatient and skilled nursing facility days from the adherence calculation. Weighting varies by rating year; confirm the applicable year in the CMS Star Ratings Technical Notes.

Views expressed here are my own. Nothing in this piece is legal, investment, or clinical advice.







About the Author

Patrick R. Coyle is the originator of the Patients + Profitability™ philosophy and the frameworks built on it, including The 10 Exits of Therapy™ and the 5 Layers of GTN™. He previously served as VP & CFO of Eisai Americas, GTN Practice Lead at IQVIA, and Managing Director of GTN Risk Advisory at Baker Tilly, with senior finance and commercial roles at Novartis, Insmed, and Bayer. He is the Founder and CEO of Novus Proximus LLC.

More frameworks, guides, and tools in the Resource Library. Reach him at hello@patrickrcoyle.com.



The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.
The patient-side view of the same ten exits is at Where did your treatment stop?

## Close Cycle Automation
URL: https://patrickrcoyle.com/field-guide-close-cycle-automation/
Published: 2026-09-01

Automating a close you have not simplified buys you the same close, faster, and makes it permanent.
This field guide sets the sequence: count the manual touches, delete steps before standardizing, standardize toward the more rigorous version, automate only the high-volume rule-based steps, and measure time-to-answer rather than days-to-close. Skip the sequence and you buy an expensive, fast, permanent version of the process you had.
Financial TransformationAny phaseSimplify, standardize, automate, measure
## What this guide is for
You want a shorter close. This guide is about the order of operations, and about the specific ways skipping a step makes the problem permanent rather than solved.
## The failure it addresses
The sequence is simplify, standardize, automate, measure. It only works forwards.
The close-cycle sequence, and why the order is the method
The sequence is simplify, standardize, automate, measure, and it only works in that order. Simplify means counting the manual touches and deleting steps rather than relocating them. Standardize means converging on the more rigorous version of a process rather than the easier one. Automate applies only to steps that are both high volume and rule based. Measure tracks time to answer rather than days to close. Automating a process that was never simplified encodes every workaround into a system, and a workaround inside a platform is far harder to remove than one inside a spreadsheet.
FIRSTSimplifyCount the manual touches.Delete steps, do not move them.SECONDStandardizeToward the more rigorousversion, not the easier one.THIRDAutomateOnly the high-volume,rule-based steps.FOURTHMeasureTime-to-answer, notdays-to-close.It only works forwards. Automation applied to an unsimplified process encodes every workaround into a system.A workaround in a spreadsheet can be argued with. A workaround in a platform has an owner and a budget.
FIGURE 1. Skip a step and you buy an expensive, fast, permanent version of the process you already had.
Automation applied to a process nobody simplified encodes every workaround into a system, and a workaround in a spreadsheet can be argued with while a workaround in a platform has an owner, a budget line and a support contract. Standardization skipped means you have automated one entity's way of doing something and created an exception for every other entity. And measurement placed first produces a scoreboard for a process nobody has fixed, which reliably makes people faster at the wrong thing.
The order is not a preference. Each step is only possible because the one before it ran.
## The use cases you can run
Use case 01
Count the touches
Before anything else, map one close end to end and count every human handoff, every manual journal, every reconciliation done outside the system, and every file that moves by email. Do not design anything yet.
What you needone close, observed rather than described. Ask people to show you, not tell you.
What you getthe actual process, which will not be the documented one.
Use case 02
Delete before you standardize
For each touch, ask what would break if it stopped. A surprising share exists because it once mattered, because one person once asked for it, or because nobody has questioned it since an ERP migration.
What you needthe authority to remove a step, and cover for the person who says out loud that their own task is unnecessary.
What you geta smaller process. Everything downstream costs less because of this step, and it is the one most often skipped.
Use case 03
Standardize on the harder version
Where two entities do something differently, converge them before automating, and converge toward the more rigorous of the two rather than the more common. Converging downward is faster and buys a system that cannot support the entity with the real requirement.
What you needa decision forum with authority over both entities. This is a governance problem wearing a technical costume.
What you getone process, capable of the hardest case it will actually meet.
Use case 04
Automate the boring middle
Automate the steps that are high volume, rule-based and low judgment. Leave judgment where a person can be accountable for it. A close is not slow because judgment is slow. It is slow because judgment is waiting behind data movement.
What you needthe simplified, standardized process and an honest split of which steps involve a decision.
What you gettime returned to the people who make the decisions, which is the entire point.
Use case 05
Measure the right thing last
Not days to close on its own. Measure how long after period end a specific question can be answered reliably, because that is what the rest of the business experiences.
What you needone question the business actually asks every month.
What you geta metric that improves only when the close genuinely improves.
## What good looks like
The process was smaller before it was automated. One version exists across entities and it is the rigorous one. Judgment steps still have people attached. And the measure is answer-time, not close-days.
## What it costs to skip it
An expensive, fast, permanent version of the process you had. Automation makes a process durable, which is exactly why it should be the third step and never the first.
### Where this connects
This sequence is the spine of one of the case files, Simplify, Standardize, Automate, Measure. Where it sits among the pathways is Execute. The patient-side view of the same ten exits is at Where did your treatment stop?
Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer, and no commercial outcome for any named product is attributed to me personally. All trademarks belong to their respective owners.

## True-Up Governance
URL: https://patrickrcoyle.com/field-guide-true-up-governance/
Published: 2026-09-01

A true-up is not a correction. It is the one moment the organization finds out which of its assumptions was wrong, and most organizations spend it arguing about the number instead.
This guide shows how to decompose the variance by driver before booking it, route each component to its functional owner with the assumption quoted, report gross movements before netting, and keep a record of which assumptions failed. Skip it and you repeat the same variance every quarter, paying the full cost of being wrong and collecting none of the information.
Financial NavigationPhases 2 and 3The 5 Layers of GTN™ Layer 05
## What this guide is for
Actuals have arrived and they do not match. This guide is about what to do with that information, and specifically about how to stop the true-up from being the end of the conversation when it is the most useful beginning available.
## The failure it addresses
A true-up gets treated as an accounting event. The difference is quantified, the entry is booked, the rate is adjusted, and the period closes. Everyone involved has done their job correctly and the organization has learned nothing.
Four steps that turn a true-up into information
A true-up should be decomposed by driver before it is booked, so each component can be routed to the function that owns the assumption behind it, with that assumption quoted. Gross movements are reported before netting, because netting can hide two errors that happened to offset each other. Finally the assumptions that failed are recorded, so the same variance is not repeated next quarter. A true-up handled as a pure accounting event costs the money and produces no learning.
STEP 1Decompose bydriverBefore booking it, split thevariance into its causes.STEP 2Route to theownerEach component goes to thefunction, with the assumption quoted.STEP 3Report grossbefore netNetting hides two errors thathappened to cancel out.STEP 4Record whatfailedKeep the list of assumptionsthat did not hold.A true-up treated as an accounting event costs you the money and teaches you nothing.Skip this and you pay the full price of being wrong, every quarter, and collect none of the information.
FIGURE 1. The variance is the price. The decomposition is the only part you get to keep.
The information was in the variance, not in the entry. A variance is the only reliable signal that an assumption held somewhere upstream is no longer true, and it arrives already attributed to Finance because Finance is where it becomes visible. That attribution is the problem. The assumption that failed was almost never Finance's.
There is also a quieter failure. A true-up that nets to something small looks like a good period. It can just as easily be two large movements in opposite directions, one in coverage and one in affordability, cancelling each other out. Netting is how an organization congratulates itself on an accrual that was wrong twice.
## The use cases you can run
Use case 01
Decompose before you book
Split the variance by driver before anything is recorded: volume, mix, rate, lag, and eligibility. Booking first fixes the number and ends the inquiry, because once the entry exists the question feels answered.
What you needthe claim detail behind the variance and the assumption inventory the accrual was built on.
What you geta variance you can attribute to a behavior rather than to a period.
Use case 02
Route each component to its owner
Every decomposed piece goes back to the function that owns the assumption underneath it, with the assumption quoted. Not as blame. As information that function has no other way of receiving, because they do not see the financial consequence of their own operating change.
What you needthe decomposition, and a standing forum where Commercial, Market Access, Trade, Patient Services and Finance all sit.
What you getthe loop closed. This is the single highest-value habit in the whole discipline and it is almost never in place.
Use case 03
Ban the net
Report gross movements, both directions, before any netting. Then net.
What you neednothing but the discipline to do it.
What you getthe two large offsetting errors you were about to miss.
Use case 04
Write the assumption obituary
For every assumption that failed, record what it was, when it stopped being true, how long it took to notice, and what would have made you notice sooner. Keep the file. It becomes the most honest forecasting asset the organization owns.
What you needsomewhere durable to write it, and the willingness to keep a record of being wrong.
What you geta detection-lag number that gets shorter over time, which is a better measure of a finance organization than accuracy is.
## What good looks like
Variances are decomposed before they are booked. Each component has a named owner outside Finance. Gross movements are visible before netting. And the organization can say how long it takes to notice that an assumption has stopped being true, because it measures that.
## What it costs to skip it
The same variance, next quarter, with the same explanation. An organization that trues up without governing the true-up is paying the full cost of being wrong and collecting none of the information.
### Where this connects
The accrual this trues up is Accrual Design. The reason a variance that surfaces in reporting was created three layers upstream is the 5 Layers of GTN™. The room where the routing in use case 02 actually happens is the Alignment Labs™. The patient-side view of the same ten exits is at Where did your treatment stop? What is actually testable at the first three checkpoints after launch is set out in Your First Ninety Days.
Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer, and no commercial outcome for any named product is attributed to me personally. All trademarks belong to their respective owners.

## Accrual Design
URL: https://patrickrcoyle.com/field-guide-accrual-design/
Published: 2026-09-01

An accrual is a claim about behavior that has not happened yet. Most of them are built as a claim about arithmetic instead.
This field guide gives Finance four diagnostics, the assumption inventory, the lag map, the denominator test and the single change test, so every Gross-to-Net rate carries documented behavioral assumptions with a named owner. Skip it and the cost is not the variance. It is the credibility lost explaining variances after the fact.
Financial NavigationPhases 1 and 2The 5 Layers of GTN™ Layer 05
## What this guide is for
You are standing up a Gross-to-Net accrual, or you have inherited one and cannot explain why it moves the way it does. This guide is the set of questions I would ask in the room, in the order I would ask them.
It is not a rate methodology. Rates are the output. Everything below is about the inputs the rate is quietly asserting.
## The failure it addresses
An accrual is usually built by taking historical claims, dividing by historical sales, and calling the result a rate. That arithmetic is correct and the reasoning underneath it is not, because it assumes next period's patients will behave like last period's patients, through a channel that has not changed, under coverage that has not moved.
Four diagnostics for a Gross-to-Net accrual
Four questions to ask of any Gross-to-Net accrual before accepting the rate. First, the assumption inventory: what behavior is the rate asserting and who owns that assumption. Second, the lag map: how long passes between the event and the claim arriving. Third, the denominator test: whether the rate is divided by sales or by the units that can actually generate a claim. Fourth, the single change test: what happens to the rate if one assumption moves. An accrual built by dividing historical claims by historical sales silently asserts that no behavior has changed.
DIAGNOSTIC 1AssumptioninventoryWhat behavior is this rateasserting, and who owns it?DIAGNOSTIC 2Lag mapHow long between theevent and the claim?DIAGNOSTIC 3DenominatortestSales, or the units thatcan actually generate a claim?DIAGNOSTIC 4Single changetestIf one assumption moves,what happens to the rate?An accrual built from history divided by history asserts that nothing behavioral has changed.The cost of skipping this is not the variance. It is the credibility lost explaining it afterward.
FIGURE 1. Rates are the output. These four questions are about the inputs the rate is quietly asserting.
None of those three assumptions is safe, and none of them is written down anywhere. So when the accrual misses, the conversation becomes an argument about the rate rather than an examination of the assumption that produced it. The rate is not the thing that broke.
The deeper version of the same problem is that an accrual can only be built from what was recorded. A patient who left at Exit 05 or Exit 07 never generated a claim, never generated a rejection, and never appeared in the denominator. The accrual is therefore accurate about the population it can see and silent about the population it cannot, and the silence does not look like a gap. It looks like a smaller number.
## The use cases you can run
Use case 01
The assumption inventory
Write down every behavioral assumption the accrual depends on, in plain sentences, before touching a rate. Who is eligible. What share enrolls. What share is approved. What share initiates. What share persists, and for how long. Each sentence is a claim someone in the organization owns, and most of them are owned outside Finance.
What you needthe current model, and one person from Market Access, Patient Services and Trade.
What you getthe list of assumptions, and the name of the function that owns each. The naming is the deliverable. An unowned assumption is the one that fails silently.
Use case 02
The lag map
For each contract type, establish how long it takes a claim to arrive, and whether that duration is stable or drifting. Rebates, chargebacks, copay, fees and returns all lag differently, and a single blended lag hides the one that is moving.
What you needclaim-level submission and payment dates by contract type, over enough periods to see drift rather than noise.
What you geta lag profile per type, and an explicit statement of which ones you are estimating versus which ones you are observing.
Use case 03
The denominator test
Take one rate and ask what population sits underneath it. Then ask which patients could have been in that population but never appeared. This is where Exit 04 through Exit 07 enter the accrual conversation, usually for the first time.
What you needthe enrollment, approval and initiation counts that Patient Services already holds, and the willingness to compare them to the claim counts Finance holds.
What you getthe size of the gap between the population the therapy was intended for and the population the accrual describes. You will not book against it. You will stop assuming it is zero.
Use case 04
The single change test
Take the one thing you know is changing next period, a formulary move, a new hub vendor, a copay program redesign, a channel shift, and trace it through the assumption inventory. If it touches nothing in the model, the model is not sensitive to reality.
What you needthe assumption inventory from 01 and one known upcoming change.
What you geteither a specific adjustment, or the discovery that your model cannot represent the thing you already know is happening.
## What good looks like
Every rate has a written assumption behind it, a named owner outside Finance, and a stated lag. The model can represent a change you already know about. And the accrual review is a conversation about behavior, with Finance holding the pen and other functions holding the assumptions.
## What it costs to skip it
Not the miss. The miss is survivable and gets trued up. What it costs is the year you spend arguing about a rate while the thing that moved it was a coverage change nobody told Finance about, and the credibility Finance loses each time it explains a variance after the fact rather than before.
### Where this connects
The exits that feed this accrual are on the philosophy page. Where they land inside the enterprise is the 5 Layers of GTN™. What happens when the actuals arrive is the next guide, True-Up Governance. The patient-side view of the same ten exits is at Where did your treatment stop?
Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer, and no commercial outcome for any named product is attributed to me personally. All trademarks belong to their respective owners.

## Finance Should Own the Number and Not the Operating Model
URL: https://patrickrcoyle.com/finance-should-own-the-number-not-the-operating-model/
Published: 2026-09-01

Gross-to-Net is treated as a close process because that is where it becomes visible. It is downstream of everything that created it.
Finance should own the number. The operating model belongs to a cross-functional forum with real decision rights, reviewed monthly and reset quarterly. A stable blended Gross-to-Net rate is the metric that creates the most false confidence, because it hides leakage at specific points in the patient journey.
Cross-cuttingPositionThe 5 Layers of GTN™ All layers
## Why it gets treated as a Finance process
Because that is where it becomes visible, and because the calendar rewards it. Accruals are due, auditors ask questions, and the answer has to reconcile. None of that is wrong. It is just downstream of everything that created the number.
## The connections run in one direction
A contracting decision sets rebate economics.
Channel design determines who takes title, and therefore what chargebacks look like.
Both feed the price points that government programs calculate from, which is where Best Price, AMP and ASP exposure originates.
340B compounds the consequences on both the economic and the operational side.
Payer behavior determines whether coverage translates into utilization.
Copay and affordability design determine whether utilization translates into a started patient.
Specialty pharmacy design determines what you can see about any of it.
Every one of those is a commercial decision with a financial echo. Finance records the consequences, months later.
Why Gross-to-Net looks like a Finance process and is not one
The connections run in one direction. A contracting decision sets rebate economics. Channel design determines who takes title and therefore what chargebacks look like. Access and affordability decisions determine who converts and at what cost. All of it arrives downstream as the number, which is where Finance sees it and where the calendar forces an answer. Finance should own the number. The operating model that produces it belongs to a cross-functional forum with real decision rights, reviewed monthly and reset quarterly.
UPSTREAMContractingSets the rebateeconomics.UPSTREAMChannel designDecides who takes title,and what chargebacks look like.UPSTREAMAccess andaffordabilityDetermine who converts,and at what cost.DOWNSTREAMThe numberWhere all of it finallybecomes visible.Gross-to-Net is treated as a close process because that is where it becomes visible, not where it is made.Finance should own the number. The operating model belongs to a forum with real decision rights.
FIGURE 1. Everything that makes the number happens before Finance can see it.
## Ownership and cadence
Finance should own the number and must not own the operating model. The operating model needs a standing cross-functional forum with real decision rights, chaired by someone senior enough that Commercial, Market Access, Trade, Government Pricing, Patient Services and Finance all show up.
Shared accountability is required for anything that changes a price point, anything that changes who takes title, anything that changes patient out-of-pocket, and anything that changes what data the organization will be able to see afterward. That last one is almost always decided by accident.
The essentials are transaction-level visibility rather than summarized reporting, a single set of assumptions that all functions forecast from, controls that are auditable because the process was standardized before it was automated, and a monthly cadence with a quarterly reset. Anything slower and you are reconciling history.
## When the objectives conflict
They conflict constantly, and the honest answer is that you sequence rather than balance. Compliance is not tradeable. After that, I would rather protect access and accept a worse Gross-to-Net rate than protect the rate and lose the patient, because a patient who never starts therapy generates no revenue to have a rate on. That is not idealism. It is arithmetic.
## The metrics that create false confidence
The blended Gross-to-Net rate is the figure most likely to mislead, because a stable aggregate can sit directly on top of real leakage at a specific point in the journey. Gross sales growth has the same problem. So does a coverage percentage, which tells you a formulary decision was won and nothing about whether patients started.
What I would rather a CEO look at is conversion at each stage of the journey, the gap between projection and prediction rather than only what reconciled, and the proportion of approved patients who never activate. That last one is the closest single number to the thesis, and almost nobody reports it.
A stable blended Gross-to-Net rate is not evidence of health. It is the least comfortable assumption I challenge, because it is the one my own side of the table relies on.
Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer, and no commercial outcome for any named product is attributed to me personally. All trademarks belong to their respective owners.
The number itself is taken apart in You Can Be Exactly Right About the Wrong Number. The ten places a patient can leave are on the philosophy page, and terms used here are defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop?

## Every Function Green, the Aggregate Red
URL: https://patrickrcoyle.com/every-function-green-the-aggregate-red/
Published: 2026-09-01

A specialty product with acceptable coverage, underperforming its forecast, and a working explanation that was wrong.
Every function's data looked healthy on its own. Integrated across enrollment, coverage, affordability and dispensing, approvals were not converting to activations because no function owned the transitions between them. The fix was architectural: a channel redesigned around initiation, restructured hub handoffs, a rebuilt affordability bridge and explicit ownership of each transition.
Advisory · De-identifiedDiagnosis and architectureThe Silent Leak™The 10 Exits of Therapy™
## Decision context
A specialty product with acceptable coverage was underperforming its forecast. The working explanation inside the company was a demand problem. That is almost always the first hypothesis, because demand is what Commercial is measured on and it is the thing that can be addressed with spend.
## What the data actually showed
The picture came from stitching together sources that normally live apart: enrollment records from the hub, dispensing and fill data from the specialty pharmacy network, payer coverage status, and affordability program utilization.
Every function reporting green while the aggregate ran red
A specialty product with acceptable coverage was underperforming its forecast. Enrollment, coverage and affordability each reported healthy against their own targets. Integrated across all four steps, approvals were not converting to activations, because no function owned the transitions between them. The internal explanation was a demand problem, which is the first hypothesis in most organizations because demand is what Commercial is measured on and it is the thing spend can address. The actual fix was architectural.
GREENEnrollmentVolume on plan.Nothing to escalate.GREENCoverageAcceptable. Payerswere not the problem.GREENAffordabilityProgram performingagainst its own target.REDThe aggregateApprovals were notconverting to activations.Nobody owned the transitions between the functions, so nobody was measuring the only thing that was broken.The working explanation was a demand problem. Demand is what Commercial is measured on, and spend can address it.
FIGURE 1. Four functions measuring themselves accurately, and nobody measuring the handoffs between them.
Separately, each dataset looked healthy. Coverage had been won. Enrollments were being processed. Fills were occurring. The problem only became visible when they were put in the same view, because the number of patients entering at the top was materially larger than the number reaching a second fill, and the loss was concentrated at specific transitions rather than spread evenly.
## Root cause versus symptom
The symptom was abandonment. The root cause was that no single function could see a patient across the whole path, so nobody was accountable for the transitions. A patient who was approved but never activated was, from Market Access's point of view, a success. From the pharmacy's point of view, that patient had never arrived and therefore did not exist.
The distinguishing test I use is simple. If every function reports green and the aggregate is red, the problem is at the seams, not inside the boxes.
## What changed
The channel architecture was redesigned around initiation rather than around fulfillment convenience, which touched the specialty pharmacy footprint and how patients were routed within it.
The hub services were reworked, and the handoffs moved.
The affordability bridge was redesigned so a covered patient was not still an unstarted patient.
The reporting cadence changed, so the same patient-level view reached Finance, Commercial and Market Access at the same time rather than in three separate versions.
Governance changed, which mattered more than any single design decision. Someone was named as accountable for each transition.
## Duration and indicators
This kind of work takes a quarter to diagnose honestly and several quarters to see move, because persistence is a lagging indicator by definition. The indicators worth watching are time from enrollment to first fill, the proportion of approved patients who never activate, and refill continuation at the second and third fill. What typically does not improve on the same timeline is forecast accuracy, because the forecast was built on the old assumptions and has to be rebuilt rather than corrected.
## Attribution
I am not going to publish the movement in those indicators. They are client-reported, I do not have permission to publish them, and I have no documented calculation package that an outside party could reproduce. Even if I did, I could not honestly separate my contribution from concurrent market growth, clinical evidence, pricing decisions and policy movement.
What I claim is the diagnosis and the architecture. The organization could see something it could not see before, and it assigned ownership to transitions that previously had none.
If every function reports green and the aggregate is red, the problem is at the seams, not inside the boxes.
Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer, and no commercial outcome for any named product is attributed to me personally. All trademarks belong to their respective owners.
The launch version of this pattern is in A Launch Does Not Fail in the Forecast, and the finance version is in You Can Be Exactly Right About the Wrong Number. The ten places a patient can leave are on the philosophy page, with terms defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop?

## The Leak I Built
URL: https://patrickrcoyle.com/the-leak-i-built/
Published: 2026-09-01

I had constructed a Silent Leak™ inside my own finance organization, and I did not see it until it was already there.
When we moved to remote work I solved for infrastructure, and every system reported healthy while the unplanned conversations the organization depended on quietly stopped. I have never again assumed that because the systems are working, the organization is.
Eisai · The mistakeFailureThe Silent Leak™
## What I solved for
Infrastructure. When we sent everyone home, I made sure the systems worked. Connectivity, equipment, escalation paths, access. Measured against what I was solving for, it went well.
## What I missed
The building had been doing something for us that nobody had a line item for. The unplanned conversation. The question asked in a hallway. The thing you notice on someone's face.
A leak with no incident, no metric and no complaint
Moving a finance organization to remote work, the author solved for infrastructure: connectivity, equipment, access and escalation paths. Measured against that goal it went well, and every system reported healthy. What stopped was the unplanned conversation, the question asked in a hallway, the thing noticed on someone face. That capability had no line item, so its disappearance produced no incident, no metric and no complaint. The lesson is that working systems are not evidence of a working organization.
WHAT I SOLVED FORInfrastructureConnectivity, equipment,access, escalation paths.WHAT REPORTEDEvery systemhealthyNo incident. No metric.No complaint.WHAT STOPPEDThe unplannedconversationThe hallway question. Thething you notice on a face.WHAT IT COSTA capabilitynobody ownedIt had no line item, soits absence had no signal.The building had been doing something for us that nobody had a line item for.I have never again assumed that because the systems are working, the organization is.
FIGURE 1. Nothing that mattered here was being measured, which is exactly why it went unnoticed.
That did not survive the move, and it did not announce itself when it went. There was no incident, no metric, no complaint. A capability the organization depended on simply stopped, quietly, while every system I was watching reported healthy.
## What made it worse
When we tried to replace it, I left it to individual judgment. Managers did not all prioritize check-ins the same way or schedule them the same way, which guaranteed the replacement would be uneven. Something that had happened by accident in a building had to be designed on purpose outside of one. Regular, structured, expected.
## Why this is the case study I most want published
I had built a Silent Leak™ inside my own finance organization. Every function was working. Every system was green. The aggregate capability was degrading, in the seam between the boxes, which is the exact failure I spend my professional life describing in other people's commercial organizations.
I did not see it until it was already there. That is the whole point. If it is invisible to someone who has made a career of looking for it, then the claim that it is invisible to a manufacturer's cross-functional leadership is not a sales argument. It is a description.
I have never again assumed that because the systems are working, the organization is.
Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer, and no commercial outcome for any named product is attributed to me personally. All trademarks belong to their respective owners.
What a leak costs once it reaches the number is in You Can Be Exactly Right About the Wrong Number. The ten places a patient can leave are on the philosophy page, and terms used here are defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop?

## Simplify, Standardize, Automate, Measure
URL: https://patrickrcoyle.com/simplify-standardize-automate-measure/
Published: 2026-09-01

A multi-year rebuild of a finance organization, run as a sequence rather than as a structure.
As CFO for the Americas, I ran it in one order every time: simplify, standardize, automate, measure. Automating a broken process does not transform it. It runs the wrong process faster.
Eisai · CFO, Americas organizationArchitectureThe 5 Layers of GTN™ Layer 5
## Decision context
Team development and culture were stagnant. Processes were manual. The systems were outdated across ERP, revenue cycle management and Gross-to-Net.
Why a finance rebuild is a sequence rather than a structure
Facing a stagnant team, manual processes and outdated systems across ERP, revenue cycle management and Gross-to-Net, the tempting move is to buy software, because it is visible, fundable and feels like progress. That is how these programs fail. Automation applied to a broken process runs the wrong process faster, at cost, with more confidence than before. The order used instead was simplify, then standardize, then automate, then measure, run the same way every time across a multi-year rebuild.
THE TEMPTING MOVEBuy softwareVisible, fundable,and it feels like progress.WHAT THAT BUYSThe wrong process,fasterAt cost, with moreconfidence than before.THE SEQUENCESimplify, thenstandardizeDelete before youencode anything.ONLY THENAutomate, thenmeasureA rebuild run as a sequencerather than as a structure.Team and culture stagnant. Processes manual. ERP, revenue cycle and Gross-to-Net all outdated at once.Automating a broken process does not transform it. It is the worst of the outcomes available.
FIGURE 1. Buying the software first is the most fundable way to make the problem permanent.
The tempting move is to buy software. It is visible, it is fundable, and it feels like progress. It is also how these programs fail, because automating a broken process does not transform it. It lets you run the wrong process faster, at a cost, with more confidence than you had before, which is the worst of the available outcomes.
## My authority
The CFO seat, covering the Americas organization, with Site Services also reporting to me. Broad enough that the scope was real and narrow enough that adoption still had to be earned from functions that did not report to me.
## The sequence
Simplify, standardize, automate, measure. In that order, every time. The roadmap expressed it in three phases: stabilize, then prepare and plan, then execute.
Stabilize. Evaluate and design the change management approach. Organizational realignment through consistent messaging, rebuilding trust, and visioning. Cultural work through real job descriptions and an engagement survey. Process improvement starting where the pain was worst.
Prepare and plan. Establish and maintain trust, and open the workstreams: financial planning harmonization, a Gross-to-Net assessment and new launch model, procure-to-pay, travel and expense, contract management consolidation, government reporting and pricing, a program management office build-out, and the people initiatives.
Execute. The deployments, once the organization could absorb them.
## What we built
A program management office from nothing, giving the function strategic planning and governance, a common language, real resource management, and a place where project artifacts lived after the project ended.
A standardized process bank covering GMP, non-GMP, workflow and JSOX.
An accounting and reporting stack built on FloQast, SAP function build-out, Readsoft into accounts payable, ZOption for posting, and smrt for lease contracts.
A planning and analysis stack built on Vinyl for project and purchase order tracking, Planful for master data and scenario planning, and ICyte for Gross-to-Net accrual management.
Commercial systems, with Model N for contract pricing and rebates.
A rebuilt travel and expense model on JTB and Concur, with a benchmarked policy and audit flagging.
## Accountability, adoption, and resistance
Accountability came from making work visible rather than from reporting on it. Talent development came from giving people the part of the problem that was slightly beyond them and staying close enough to catch it. Cross-functional adoption came from arriving with a shared view of a problem rather than a mandate.
The resistance was to the word automation, and it was rational. People hear it as a judgment about whether their expertise is still needed. You do not answer that with reassurance, you answer it with specificity: what is changing, why, what higher-value work becomes possible, and where human judgment remains decisive. The teams that struggled were the ones where I had explained the what and skipped the why.
## What I would do differently
See The Leak I Built. The thing I missed was not in the roadmap.
Control and compliance were never in tension with any of this, because standardization precedes automation in the sequence, and a standardized process is an auditable one.
Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer, and no commercial outcome for any named product is attributed to me personally. All trademarks belong to their respective owners.
The same sequence applied to the number is in You Can Be Exactly Right About the Wrong Number. The ten places a patient can leave are on the philosophy page, and terms used here are defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop?

## Building the Road to Revenue
URL: https://patrickrcoyle.com/building-the-road-to-revenue/
Published: 2026-09-01

A first commercial launch with nothing to inherit, and the governance decision that mattered more than any design choice.
Directing commercialization infrastructure for an emerging biotech, I built the roadmap to revenue, paired third-party logistics with specialty distribution, kept patient services in-house, and stood up an executive pricing committee so access decisions had a standing forum rather than an escalation path. The thing I would do differently is build patient identification into the infrastructure rather than alongside it.
Insmed · Commercial infrastructureArchitectureThe 5 Layers of GTN™ Layers 3 and 5
## Decision context
An emerging company launching its first product does not adapt an existing commercial infrastructure. It builds one, at speed, while the clinical organization is still the center of gravity and while the systems in place were designed to track R&D spend and nothing else.
Building commercial infrastructure with nothing to inherit
An emerging company launching a first product does not adapt an existing commercial infrastructure. It builds one at speed, while the clinical organization is still the center of gravity and the only systems in place were designed to track research spend. The choices were to pair third-party logistics with specialty distribution, to keep patient services in-house rather than outsourcing it, and to stand up an executive pricing committee so that access decisions had a standing forum rather than an escalation path. The governance decision mattered more than any individual design choice, and the thing worth doing differently is building patient identification into the infrastructure rather than alongside it.
NOTHING INHERITEDA first launchSystems built to trackR&D spend and nothing else.DECISION3PL paired withspecialtyLogistics outsourced,distribution specialized.DECISIONPatient serviceskept in-houseThe one capability nothanded to a vendor.DECISIONPricing committeeA standing forum for access,not an escalation path.The governance decision mattered more than any single design choice.What I would do differently: build patient identification into the infrastructure rather than alongside it.
FIGURE 1. Three design decisions and one governance decision. The governance decision is the one that held.
## My authority
This one was mine. My scope covered the commercialization infrastructure: the roadmap to revenue, the third-party logistics build, the specialty distribution network, Gross-to-Net, and in-house patient services inside a limited distribution model.
## What I helped design
The roadmap to revenue, as an actual sequenced plan rather than a launch calendar.
The third-party logistics build and the specialty distribution network, designed together rather than contracted separately.
In-house patient services, kept inside rather than outsourced, on the argument that in a narrow indication the patient-level knowledge is the asset.
The specialty pharmacy selection process, which I supported rather than ran, and the operations that had to stand up behind it.
An executive pricing committee, so that access decisions had a standing forum rather than an escalation path. This is the piece I would defend hardest. A recurring decision that only exists as an escalation gets made late, by whoever is available, under pressure.
The first long-range scenario plan for an evolving pipeline, and portfolio governance that tied program decisions to financial sustainability rather than to advocacy.
## The trade-off
Reach against visibility. A limited distribution model gives you control and data at the cost of convenience for prescribers and patients. In a narrow indication I would make that trade again, and I want to be clear that it is a trade rather than a free choice.
## What I would do differently
I would have built the identification capability into the infrastructure rather than alongside it. Everything above serves a patient who has already arrived.
A finance function earns its seat by arriving with an architecture, not with a variance report.
Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer, and no commercial outcome for any named product is attributed to me personally. All trademarks belong to their respective owners.
What gets built before approval day is in The Launch Begins Long Before Approval Day, and what happens after is in A Launch Does Not Fail in the Forecast. The ten places a patient can leave are on the philosophy page, with terms defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop?

## Can We Actually Find Them
URL: https://patrickrcoyle.com/can-we-actually-find-them/
Published: 2026-09-01

A label narrower than the trial that supported it, and the question no forecast model asks.
When approval defines the market as refractory patients rather than diagnosed ones, the commercial problem stops being demand conversion and becomes patient identification. A label is a market definition, not a regulatory formality, so the capability to find patients has to be built before launch, not after.
Insmed · ArikayceDiagnosisThe 10 Exits of Therapy™ Exits 01, 02, 05
## Decision context
First emerging company I had joined, and its first commercial product. No other franchise to hide inside, no established channel to inherit, no second chance next quarter.
We came out of an advisory committee with a label narrower than the trial that supported it. The approved patient had to be refractory. The patient we had built the launch to find was not the patient we were allowed to treat.
## Why that is harder than it sounds
A refractory patient is defined by a failure that has to happen first. Not by a diagnosis you can query for. You are looking for people identified by something that already went wrong.
The diagnosis may sit in a claim nobody in Commercial ever reads. The signal exists. The organization is not built to see it.
Every commercial assumption built during development pointed at a population the product could no longer be sold into. That is not a plan that needs adjusting. It is a plan that needs replacing, on approval day.
## The realization
Until then I had assumed the hard part was converting demand. After it, I understood that the hard part is often finding the patient at all, and that no forecast model asks that question. This is the experience that most changed how I understand healthcare economics, and it is the reason identification became the thing I could not stop thinking about.
When the label defines a market narrower than the trial
Coming out of an advisory committee with a label narrower than the trial that supported it, the approved patient had to be refractory rather than simply diagnosed. A refractory patient is defined by a failure that has to happen first, which makes them far harder to locate than a diagnosed patient. The commercial problem therefore stopped being demand conversion and became patient identification, a capability that has to be built before launch rather than after it. A label is a market definition rather than a regulatory formality.
WHAT WE BUILT FORThe diagnosedpatientFindable in claims.The launch was aimed here.WHAT THE LABEL SAIDThe refractorypatientDefined by a failure thathas to happen first.THE SHIFTNot demandconversionThe commercial problembecame identification.THE CONSEQUENCEBuild it beforelaunchA label is a market definition,not a regulatory formality.The patient we had built the launch to find was not the patient we were allowed to treat.No forecast model asks whether the approved patient can actually be found.
FIGURE 1. A narrower label does not shrink the market. It changes which capability the launch depends on.
## What I would do differently
The same answer as the immunology launch, which is why it is the answer. Build the patient identification capability before the launch, not after it.
A label is a market definition, not a regulatory formality. It is the single sentence that decides how many patients your business actually has.
Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer, and no commercial outcome for any named product is attributed to me personally. All trademarks belong to their respective owners.
The access version of this question is in The Launch Begins Long Before Approval Day. The ten places a patient can leave are on the philosophy page, and terms used here are defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop?

## Structure Instead of Spend
URL: https://patrickrcoyle.com/structure-instead-of-spend/
Published: 2026-09-01

A competitive entry turned a category with room in it into a red ocean. The question was whether to answer with money or with architecture.
As finance lead I controlled the assumptions everyone argued from, and we used them to reconfigure the channel around the patient journey, rebuild the hub, redesign the affordability bridge and consolidate specialty pharmacy data into one view. Structure took months where spend would have taken weeks, and it held.
NovartisArchitectureThe 10 Exits of Therapy™ Layer 4
## Decision context
A competitive entry changed the category more or less overnight. The instinct in that situation is to spend into the fight, because spend is fast, visible, and defensible in a quarterly review. Structure is none of those things.
Answering a competitive entry with architecture rather than spend
A competitive entry changed the category almost overnight. The instinct is to spend into the fight, because spend is fast, visible and defensible in a quarterly review, and structure is none of those things. The alternative taken was to reconfigure the channel around the patient journey, rebuild the hub, redesign the affordability bridge and consolidate specialty pharmacy data into a single view. No function was behaving incorrectly. Each was optimizing its own segment accurately, which is the harder problem. Structure took months where spend would have taken weeks, and structure is what held.
THE INSTINCTSpend intothe fightFast, visible, defensiblein a quarterly review.WHAT WE DID INSTEADReconfigurethe channelAround the patient journeyrather than the segment.ANDRebuild hub andaffordabilityThe bridge redesigned,the hub rebuilt.ANDOne data viewSpecialty pharmacy dataconsolidated into one place.Nobody in those rooms was wrong. Every function was optimizing its own segment correctly.Structure took months where spend would have taken weeks. Structure held.
FIGURE 1. Spend is defensible in the quarter. Structure is what is still working four quarters later.
Nobody in those rooms was wrong. Every function was optimizing its own segment correctly. That is the harder problem, and it is the one I have worked on ever since.
## My authority
I was the finance lead for the franchise. I did not control Market Access. I did not control the field organization. What I did control was the assumptions everyone was arguing from, and that turned out to be the lever that mattered, because the argument in the room could not be settled while three functions were each right according to their own dataset.
## What I helped change
A reconfigured channel, organized around the patient rather than around our own convenience. That meant reworking the specialty pharmacy footprint and how patients moved within it.
A rebuilt patient hub, treated as the place the journey either works or does not, rather than as a cost line.
A redesigned affordability bridge, so that a covered patient was not still an unstarted patient. Those are different conditions and most organizations report them as the same one.
A specialty pharmacy data architecture that consolidated disparate sub-national data into a single view. This is the piece that made the rest possible.
## The trade-off
Time. Reconfiguring a channel in the middle of a competitive fight costs months you feel you do not have, and the pressure to buy your way out instead is enormous. Functions involved were Market Access, Trade, Patient Services, Commercial and Finance, plus the specialty pharmacy network and the hub vendor. Every one of them had a faster alternative to propose.
## What I would do differently
I would build the patient identification capability before the launch rather than after it. We stood up the machinery to serve patients who reached us, and then went looking for the ones who never did. That is the wrong order, and everything I have built since is an attempt to reverse it.
In a red ocean, your competitor is rarely the reason patients are leaving. Your own friction is.
Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer, and no commercial outcome for any named product is attributed to me personally. All trademarks belong to their respective owners.
The affordability version of this argument is in Rethinking Copay Accumulators. The ten places a patient can leave are on the philosophy page, and terms used here are defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop?

## Which Part of What Worked
URL: https://patrickrcoyle.com/which-part-of-what-worked/
Published: 2026-09-01

Global launch sequencing taught me humility. The specialty channel turned out to be the whole thing.
The discipline in taking a US launch abroad is naming which part of what worked was the part that mattered. The answer was the channel: pharmacy networks, prior authorization, patient support and hub operations, each a place a prescription can fail. Once you can name the places patients leave, you can price them.
Bayer · Global launch and specialty channelDiagnosisThe 5 Layers of GTN™ Layer 3
## Decision context
Moving from a single US launch into global launch sequencing puts a specific temptation in front of you: repeat what worked. The clinical story is the same everywhere. Almost nothing else is.
Naming which part of a US launch was the part that mattered
Moving from a single United States launch into global sequencing creates a specific temptation, which is to repeat what worked. The clinical story is the same everywhere and almost nothing else is. The pathway differs, the payer differs, the site of care differs, and the point at which a patient falls out differs in every market. The part that actually mattered turned out to be the channel: pharmacy networks, prior authorization, patient support and hub operations, each of them a place a prescription can fail. Once the places patients leave can be named, they can be priced.
SAME EVERYWHEREThe clinicalstoryAlmost nothing elsetravels with it.DIFFERENTPathway andpayerDifferent site of care,different rules.DIFFERENTWhere patientsfall outThe exit point movesmarket by market.THE ANSWERThe channel wasthe whole thingNetworks, prior auth, patientsupport, hub operations.A playbook that treats those as implementation detail succeeds in the second market for the wrong reasons.Once you can name the places patients leave, you can price them.
FIGURE 1. The clinical story travels. The channel is what has to be rebuilt in every market.
The pathway is different. The payer is different. The site of care is different. And the point at which a patient falls out is different in every market. A playbook that treats those as implementation detail will succeed in the second market for reasons it does not understand and fail in the fourth for the same reason.
## My authority
I supported the sequencing rather than deciding it. What I could influence was which parts of the US experience were treated as transferable and which were treated as local, and that turns out to be most of the decision.
## What I learned
The discipline is not repeating what worked. It is knowing which part of what worked was the part that mattered, which requires being able to say why it worked, which most launch retrospectives cannot.
The channel is not logistics. Supporting an oncology brand put me inside the specialty pharmaceutical channel and inside patient support programs as they actually operate. Limited distribution, specialty pharmacy, prior authorization, a hub making judgment calls all day, a copay program with its own rules. Each one is a place a prescription can stop moving.
Nobody owns the whole path. Every participant owns one segment and optimizes it honestly. The losses happen between segments, where no function is accountable.
## What I would do differently
I understood the channel as operations at the time. It turned out to be the whole thing. If I had understood that then, I would have spent the following five years mapping exit points instead of arriving at the idea a decade later.
Once you can name the places patients leave, you can price them. Before that, all you have is a variance nobody can explain.
Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer, and no commercial outcome for any named product is attributed to me personally. All trademarks belong to their respective owners.
The channel version of the discount question is in The Many Faces of 340B. The ten places a patient can leave are on the philosophy page, and terms used here are defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop?

## One Method, Eight Countries
URL: https://patrickrcoyle.com/one-method-eight-countries/
Published: 2026-09-01

Standardizing clinical trial forecasting, and learning the sequence I have used ever since.
I owned the methodology but not the country organizations, so one accrual and forecasting method had to earn adoption across eight countries on quality rather than mandate. Standardize before you automate. A process automated before it is standardized just runs the wrong way faster.
Bayer · R&D FinanceArchitectureThe 5 Layers of GTN™ Layer 1
## Decision context
Clinical trial forecasting was fragmented. Country-level accruals were inconsistent with one another, and finance had no direct visibility into how the contract research organizations were executing.
One forecasting method earning adoption across eight countries
Clinical trial forecasting was fragmented, with country-level accruals inconsistent with one another and no direct finance visibility into how the contract research organizations were executing. The problem was not poor work. Several groups were each doing the work reasonably, in several different ways, and nobody could reconcile the results, which is harder to fix than incompetence because there is nobody to correct. Owning the method but not the country organizations meant the method had to earn adoption on quality rather than mandate. The rule that came out of it is to standardize before automating, because a process automated before it is standardized simply runs the wrong way faster.
THE PROBLEMSeveral groups,several methodsEach doing it reasonably.Nobody could reconcile.THE CONSTRAINTI owned themethod, not thecountry organizationsthat had to run it.SO IT HAD TOEarn adoptionOn quality ratherthan on mandate.THE RULE LEARNEDStandardizebefore automatingOr the wrong way justruns faster.That is a harder problem than incompetence, because there is no one to correct.I built a method and then sold it. The version where they build it with me is slower to produce and faster to adopt.
FIGURE 1. Owning the method and not the organization changes what the method has to be good enough to do.
The problem was not that anyone was doing the work badly. Several groups were each doing it reasonably, in several different ways, and nobody could reconcile the results. That is a harder problem than incompetence, because there is no one to correct.
## My authority
I owned the method. I did not own the country organizations that had to adopt it, and I did not own the contracts with the research organizations. Anything I built had to be good enough that people chose it, because I could not require it.
## What I built
A single accrual and forecasting method for US-based clinical trials, documented well enough to be applied the same way by people who had not been in the room when it was designed.
Data tracking that made execution visible to finance directly, rather than inferred from invoices after the fact.
Internal controls, developed, implemented and validated, so the method would survive the people who built it. This is the part that gets skipped and it is the part that determines whether anything lasts.
## The trade-off
Standardization costs local judgment. A country team that had built a good method for its own conditions had to give it up for one that worked acceptably everywhere. That is a real loss and pretending otherwise is how you lose the room.
## What I would do differently
I would have brought the country teams into the design rather than into the rollout. I built a method and then sold it. The version where they build it with me is slower to produce and faster to adopt, and I did not understand that yet.
Standardize before you automate. A process automated before it is standardized just runs the wrong way faster, with more confidence than you had before.
Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer, and no commercial outcome for any named product is attributed to me personally. All trademarks belong to their respective owners.
What the method still cannot see is in You Can Be Exactly Right About the Wrong Number. The ten places a patient can leave are on the philosophy page, and terms used here are defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop?

## Meeting the Patient Before the Label
URL: https://patrickrcoyle.com/meeting-the-patient-before-the-label/
Published: 2026-09-01

What changes at approval is not the product and not the patient. It is who is looking at them, and what they are counted for.
Supporting a program from R&D finance through launch, I carried the clinical understanding of the patient into the commercial models, because the gap between how R&D understands a patient and how Commercial understands a customer was visible to me and almost nobody else. I should have documented that gap so it stopped being tacit.

Bayer HealthCare Pharmaceuticals · Oncology R&DDiagnosisThe 10 Exits of Therapy™ Exits 01, 02

## Decision context

I came into pharmaceuticals through oncology R&D, supporting an alpha-emitting radiopharmaceutical, and followed its pivotal trial from the clinical side into commercial launch.
What actually changes at approval day
Coming into pharmaceuticals through oncology research finance and following a pivotal trial from the clinical side into commercial launch, the product at approval does not change and neither does the patient. What changes is who is looking at that patient and what they are being counted for. Research finance understands a patient. Commercial understands a customer. Most finance people meet a product only after it already has a label, a forecast and a price, so that gap stays tacit rather than documented.
IN R&DA hypothesisbeing testedIn men who had run outof other options.AT APPROVALThe product doesnot changeNeither does thepatient.WHAT CHANGESWho is lookingR&D understands a patient.Commercial understands a customer.ANDWhat they arecounted forThe same person, enteredinto a different model.Most finance people meet a product after it has a label, a forecast and a price.The gap was visible to me and almost nobody else. I should have documented it so it stopped being tacit.
FIGURE 1. The same person, carried across approval day, entered into a completely different model.

That sequence matters more than it sounds. Most finance people meet a product after it has a label, a forecast and a price. I met this one while it was still a hypothesis being tested in men who had run out of options.

## My authority

None of the decisions here were mine to make. I was in R&D finance, supporting a program. What I had was access to both rooms during a period when almost nobody has access to both, and a choice about whether to carry what I learned in one into the other.

## What I built


Continuity of assumption. The commercial model inherited the clinical understanding of the patient rather than replacing it with a market-sized abstraction.

A handoff that was not a handoff. I kept the R&D relationships after the program moved, so the questions that surfaced later had somewhere to go.


## The trade-off

Staying close to a program past the point where your function's involvement formally ends costs time that nobody has budgeted, and it is invisible in any performance review. I would make the trade again, but it is a trade.

## What I would do differently

I would have written the difference down. The gap between how R&D understands a patient and how Commercial understands a customer was visible to me and to almost nobody else, and I treated it as something I understood rather than something the organization needed documented. It is where most of the friction in this industry is born, and I let it stay tacit for years.


The product does not change at approval. The patient does not change at approval. What changes is who is looking at them and what they are counted for.


Former employers and products referenced are matters of professional history. The views expressed are my own and are not made on behalf of any current or former employer, and no commercial outcome for any named product is attributed to me personally. All trademarks belong to their respective owners.

What happens to those patients after approval day is in A Launch Does Not Fail in the Forecast, and the access groundwork is in The Launch Begins Long Before Approval Day. The ten places a patient can leave are on the philosophy page, with terms defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop?

## The Forecast Is Not the Deliverable. The Decision Is.
URL: https://patrickrcoyle.com/beyond-forecasting-accuracy-the-real-objective-of-launch-teams/
Published: 2026-08-31

Forecast accuracy is not the objective of a launch team. It is a precondition, and teams routinely mistake the two.
The objective is knowing which decisions change when the numbers shift, and then acting on them. A forecast nobody acts on is a spreadsheet. It holds potential and produces nothing, because no decision was ever wired to it.
Why forecast accuracy is not the objective of a launch team
Forecast accuracy is often held up as the primary objective of a pharmaceutical launch team. Accuracy is necessary but it is not the goal. The more useful question is which decisions change when the numbers shift, because that is what determines whether the forecast affects pricing, inventory and resource allocation. A forecast that nobody acts on is a spreadsheet. Effective forecasting drives behavior, and if nothing changes when the number changes then the number was decoration.
THE STATED GOALForecastaccuracyPrecision treated as theobjective of the launch team.THE BETTER QUESTIONWhich decisionschange?When the numbers shift,what actually moves?WHAT IT TOUCHESPrice, inventory,resourcingThe three things a forecastis supposed to govern.THE TESTDid anyone act?A forecast nobody acts onis a spreadsheet.Accuracy is necessary. It is not the objective, and teams that chase it alone miss the bigger picture.Effective forecasting drives behavior. If nothing changes when the number changes, the number was decoration.
FIGURE 1. Accuracy is necessary and insufficient. The test is whether any decision moved.
## What accuracy is actually good for
Accuracy matters. A launch team that cannot forecast within a usable range has no basis for planning supply, sizing a field organization or setting a price. None of that is in dispute, and the analytical effort that goes into precision is not wasted.
What accuracy cannot do is tell you what to do differently. It describes a number. It does not describe a choice. Teams that treat precision as the finish line tend to arrive at a defensible figure and no decision attached to it.
## The question worth asking instead
Which decisions change when the numbers shift?
That question forces a forecast to name its own consequences. If demand comes in twenty percent below plan, what happens to pricing strategy, to inventory, to how the field organization is deployed? If the answer is nothing, the forecast was never governing anything. It was reporting.
## What a forecast should be changing
A forecast that is doing its job pulls specific conversations into the room. Market access strategy, because coverage assumptions are usually the largest single driver. Patient access, because the gap between a written prescription and a started therapy is where most volume assumptions quietly fail. And revenue impact, stated plainly enough that somebody has to respond to it.
Tied to decisions, a forecast becomes an instrument. Left untied, it is a static report that gets circulated, admired for its rigor and ignored.
## What the best launch teams do differently
They treat forecasting as a means rather than an end. They build a habit of adjusting strategy when the data moves, rather than defending the original number until the quarter closes. That turns forecasting from a recurring task into something closer to organizational reflex.
The goal was never to predict the number. It was to be able to respond to the market the number is describing, early enough that responding is still cheap.
The launch version of this argument is in A Launch Does Not Fail in the Forecast. The ten places a patient can leave are on the philosophy page, and terms used here are defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop?
The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.

## Talent Knows No Geographic Boundary. Why Does Pharma Still Hire Like It Does?
URL: https://patrickrcoyle.com/pharmatalent-knows-no-geographic-boundary/
Published: 2026-08-30

The short version: pharma is filtering out experienced commercialization talent by ZIP code while automating the desk work that geography was supposed to protect. Hire the best person for the problem, build teams around capabilities rather than locations, and bring people together deliberately when the work requires it.

Filtering out commercialization experience by postal code
There is a population of highly specialized people in the industry who have launched products, built patient support programs, negotiated access strategies, managed Gross-to-Net, designed distribution networks and led finance organizations. Many of them do not live within commuting distance of a headquarters, so they are filtered out on location rather than capability. At the same time the routine desk work that geography was supposed to protect is being automated. What gets screened out is judgment that took decades to build. The alternative is hiring for the problem, building teams around capabilities rather than locations, and bringing people together deliberately when the work actually requires it.
WHO THEY AREExperiencedand specializedLaunches, access, GTN,distribution, Finance.THE FILTERCommutingdistanceNot capability.Postal code.MEANWHILEThe desk workautomatesThe very work geographywas supposed to protect.WHAT IS LEFTJudgment thattook decadesFiltered out beforeanyone reads the resume.Expertise without geographic boundaries. Presence with purpose.Hire for the problem. Build teams around capabilities. Bring people together deliberately when the work requires it.
FIGURE 1. The filter removes the judgment and keeps the work that is being automated anyway.

Expertise without geographic boundaries. Presence with purpose.





There is a group of people in our industry that I think we need to talk about more.




They are experienced. Highly specialized. They have launched products, built patient-support programs, negotiated access strategies, managed GTN, designed distribution networks, led Finance organizations, worked through regulatory complexity and solved problems that sometimes take decades of experience to recognize.




Many of them are also not living within commuting distance of Boston, Cambridge, New Jersey, Philadelphia, San Francisco or one of the other traditional pharmaceutical hubs.




And increasingly, that second fact is outweighing the first.




This is not just anecdotal. In 2025, a BioSpace poll found that roughly eight in ten respondents living outside major biopharma hubs struggled to find work because of their location. In the survey covering that year's hiring plans, only 20 percent of responding employers said they would recruit and hire regardless of location.




There are signs of improvement. BioSpace's 2026 employment research found that figure had risen to 28 percent, and that 35 percent of organizations acknowledged relocation requirements cause them to miss candidates.




That number should make every pharma leader stop for a moment.





What the data says

The location filter is costing the industry people.


8 in 10

Professionals living outside major biopharma hubs who said location made finding work harder.

BioSpace, 2025



20% → 28%

Employers who say they will hire regardless of location. 2025 hiring plans versus 2026 plans.

BioSpace Employment Outlook



35%

Employers who acknowledge they miss out on candidates because of relocation requirements.

BioSpace, 2026


Full citations in the Sources and Notes below.





## What Exactly Are We Optimizing For?




There are jobs in our industry that absolutely require physical presence.




You cannot manufacture a biologic from your kitchen table. You cannot run a laboratory experiment over Teams. Certain clinical, manufacturing, quality and operational activities are inherently tied to a physical environment.




But that does not describe the entire pharmaceutical enterprise.





Market Access. Patient Services. Commercial Strategy. Finance. GTN. Forecasting. Analytics. Trade and Distribution Strategy. Commercial Operations. Data Strategy. Patient Journey Design. Launch Readiness.





Many of these functions spent years proving that meaningful work could happen across geography.




And yet we seem to have arrived at an odd moment.




We are simultaneously talking about using AI, automation and RPA to perform entire workflows without a human being sitting at a desk, while telling an extraordinary human expert that we cannot hire them because their desk is in the wrong state.




There is something inconsistent about that.




## Presence Is Not the Same as Engagement




Being in person does not equal being engaged. And being remote does not equal being disconnected.




I have seen both sides throughout my career.




I have seen people sitting 20 feet apart who barely understand what the other person's function does.




I have also seen teams distributed across the country come together around an important problem and accomplish more in two days than an organization accomplishes in months of standing meetings.




The difference was not geography. It was purpose.




## We Have Been Asking the Wrong Question




That is the distinction I think we lost somewhere in the debate between remote and return to office.






The usual question

Where does this person work?

Optimizes for a ZIP code.


↓


The better question

When does bringing these people together create value?

Optimizes for the work.






And I am certainly not arguing against being together. Quite the opposite.




I think people are yearning for connection.




Something changed after COVID. Teams became more distributed. Relationships became more transactional. Calendars filled with video calls. Some of the informal mentorship, hallway conversations and human connection that helped many of us grow in our careers became harder to find.




Simply mandating three or four days in an office does not automatically bring that back.





Proximity is not the same thing as connection. Connection has to be designed.





## Bring People Together When There Is a Reason





Bring the commercialization team together to make a consequential launch decision.




Bring Finance, Market Access, Patient Services and Commercial together to understand the same patient journey.




Bring leaders together to challenge assumptions.




Bring teams together for workshops, planning, problem-solving, mentorship and relationship building.





And when being together matters, be together. Fully. Intentionally.




Then allow people to go back and do the work.




## The Knowledge Base Is Spreading. The Hiring Model Is Not.




There is another consequence we should consider.




Life sciences talent remains heavily concentrated in traditional clusters. CBRE's 2025 research continues to rank Boston-Cambridge, the San Francisco Bay Area, Washington-Baltimore and New York-New Jersey among the country's dominant R&D talent markets. But the same body of research identifies meaningful life sciences talent in places including Raleigh-Durham, Houston, Indianapolis, Denver-Boulder, Seattle, Madison and Dallas-Fort Worth.





Where the talent actually is

The knowledge base is spreading.

The hiring model often is not.


Established clusters

Boston / Cambridge

San Francisco Bay Area

Washington, D.C. / Baltimore

New York / New Jersey



Meaningful talent also in

Raleigh-Durham  ·  Denver-Boulder  ·  Indianapolis

Seattle  ·  Houston  ·  Madison  ·  Dallas-Fort Worth



Hire the best person for the problem.

Build teams around capabilities rather than ZIP codes.

Source: CBRE, U.S. Life Sciences Talent Trends






And experienced people have moved.




They moved during COVID. They followed spouses. They wanted to raise families somewhere different. They became caregivers. They discovered different communities. Or after twenty years of building expertise, they simply decided that where they wanted to live should not determine whether they could continue contributing to an industry they love.




Some are now being asked to choose between relocating and continuing their careers. Recent cases show this is not theoretical. When EMD Serono began requiring R&D staff at its Billerica, Massachusetts institute to work on site at least three days a week, roughly 70 previously remote employees living more than 50 miles away were given three options: commute, relocate with company support, or resign with severance.




Think about what can be lost when we make that trade. Institutional knowledge. Pattern recognition. Relationships. Mentorship. Judgment. Those are not things you recreate by opening another requisition near headquarters.




## The Contradiction I See From the Outside




I see this from the outside now, too.




As an advisor, I can sit with a pharmaceutical company, help solve an extraordinarily complicated commercialization problem, work alongside its executives, fly in for the moments when being together matters, and then continue the work from somewhere else.




Companies routinely accept that model from external experts. Yet sometimes they will not consider essentially the same geographic arrangement for an employee.




That contradiction is worth examining.




## Expertise Without Boundaries. Presence With Purpose.




Because the future does not have to be remote versus office. There is a much more interesting model.





Hire the best person for the problem.




Build teams around capabilities rather than ZIP codes.




Use technology for what technology does well.




Use AI and automation to remove work that does not require human judgment.




Use our offices for what people do exceptionally well together: debate, create, mentor, challenge, decide and connect.





Then bring people together deliberately at the moments that matter.




## An Industry Built on Finding Rare Things




Pharma is an industry built on finding extraordinarily rare things.





Rare molecules.

Rare mechanisms.

Rare diseases.

Rare patient populations.





Perhaps we should recognize that extraordinary talent can be rare, too.




And when we find it, the first question should not be whether it lives close enough to headquarters. It should be: what could this person help us accomplish?




Talent knows no geographic boundary. Maybe our organizations should not either.




### Sources and Notes


Difficulty finding work outside hubs: BioSpace, "Getting Jobs Outside of Major Biopharma Hubs Proves Tough, BioSpace Finds," February 2025.

Employer willingness to hire regardless of location: BioSpace 2026 U.S. Life Sciences Employment Outlook, reported in "Employers Warm Up to Remote Workers Again," February 2026. In a survey of 136 professionals with insight into talent acquisition or workforce planning, 28 percent said they would recruit and hire remote candidates regardless of location, up from 20 percent in the prior survey covering 2025 hiring plans and 16 percent in the survey before that. A further 52 percent who prefer local hiring said they would still consider remote hires for certain roles.

Candidates missed due to relocation requirements: Same BioSpace report. When asked whether their organization misses out on candidates because of relocation requirements, 35 percent said yes.

Talent market concentration: CBRE, U.S. Life Sciences Talent Trends 2025. Boston-Cambridge, the San Francisco Bay Area, Washington D.C.-Baltimore and New York-New Jersey remained the top-ranked U.S. clusters for life sciences R&D talent for the fourth consecutive year. CBRE analyzed the 100 largest U.S. life sciences markets; subsequent CBRE research notes gains in emerging markets including Madison and Dallas-Fort Worth, and rising venture investment in Houston, Chicago and Denver-Boulder.

EMD Serono: Reported by BioSpace, "Out of sight, out of work? What's driving remote job cuts." EMD Serono, the U.S. healthcare unit of Merck KGaA, filed a WARN Act notice regarding R&D staff reporting to its Billerica, Massachusetts research institute. Employees were required to work on site at least three days per week, and 70 remote staff living more than 50 miles away were given the option to commute, relocate with company-provided support, or resign with severance. The company cited collaboration as the reason for the requirement.

Views expressed here are my own. Nothing in this piece is legal or employment advice.






About the Author

Patrick R. Coyle is the originator of the Patients + Profitability™ philosophy and the frameworks built on it, including The 10 Exits of Therapy™ and the 5 Layers of GTN™. He previously served as VP & CFO of Eisai Americas, GTN Practice Lead at IQVIA, and Managing Director of GTN Risk Advisory at Baker Tilly, with senior finance and commercial roles at Novartis, Insmed, and Bayer. He is the Founder and CEO of Novus Proximus LLC.

More frameworks, guides, and tools in the Resource Library. Reach him at hello@patrickrcoyle.com.



 
The ten places a patient can leave are on the philosophy page, terms used here are defined in the glossary, and the rest of the writing is on the blog. The patient-side view of the same ten exits is at Where did your treatment stop?
The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.

## You Can Be Exactly Right About the Wrong Number
URL: https://patrickrcoyle.com/rebate-accuracy-and-prior-authorization/
Published: 2026-08-24

Gross-to-Net teams are measured on rebate accuracy, and most of them are very good at it. The trouble is that accuracy is a statement about arithmetic, not about whether the number being calculated was the right one to begin with.


Every control in a rebate process validates the same thing: that the math is correct on the units you have. Nothing in that process asks whether the units you have are the units you should have had. A prescription stopped at prior authorization never becomes a claim, never enters the eligible population, and therefore never appears in any reconciliation. The calculation stays clean. The number it produces is quietly wrong, and it is wrong in a direction nobody in finance is looking.


## Accuracy is not the same as completeness


Rebate accuracy is a precision measure. It asks whether the contract terms were read correctly, whether the rate was applied to the right base, whether eligibility was determined properly, whether the accrual was trued up against actuals. Those are real disciplines and they deserve the attention they get.


Completeness is a different question entirely. It asks whether the population being measured reflects the demand that actually existed. In a mature process those two questions feel like the same question, because the population is whatever the claims data says it is, and the claims data is the only version of events anyone has.





What rebate accuracy validates, and what it never touches
The rebate calculation chain has five steps: eligible units, contract terms, rate application, accrual and payment. Accuracy controls validate the last four steps thoroughly. Nothing in the chain validates the first step, the population of units that reached a patient at all, because a prescription that was never filled produces no record to reconcile.


NEVER VALIDATED

VALIDATED, RECONCILED, AUDITED, RESTATED IF WRONG

Eligible units
Did the prescription
reach a patient at all?


Contract terms
Tier, eligibility,
effective dates


Rate applied
Correct percentage
to correct base


Accrual
Estimated, trued up
against actuals


Payment
Disputed and
resolved

Every control in this chain answers the same question: is the math right on the units we have?
No control asks whether the units we have are the units we should have had. A prescription that was never filled leaves no record to reconcile.

You can be exactly right about the wrong number, and every audit will agree with you.



FIGURE 1. Four of the five steps are audited to a standard. The first one is not audited at all, because there is nothing to audit.


## What a prior authorization actually does to the number


The scale here is not marginal. The American Medical Association's 2025 physician survey, released in May 2026, found that 95 percent of physicians say prior authorization delays access to necessary care and 79 percent say patients abandon treatment because of authorization challenges. Twenty-six percent reported that prior authorization led to a serious adverse event. Physicians complete an average of 40 prior authorizations a week and spend about 13 hours on them.


Read those numbers as a finance problem rather than an administrative one. Every abandonment in that 79 percent is a unit that was demanded, prescribed and never dispensed. It never enters the rebate calculation, because there is no claim. It never shows up as leakage, because leakage is measured against units that exist.


## Three financial echoes of one denial


A denial does not produce one outcome. It produces three, and each lands somewhere different in the P&L.





One prior authorization denial, three financial echoes
A single denial resolves three ways. The patient waits and eventually fills, which lands as a timing variance. The patient abandons, which lands as a volume miss attributed to demand. The patient is switched to another product, which lands as a mix shift attributed to competition. All three are recorded as something other than what they were.


ONE EVENT
A denial at the
pharmacy counter




The patient waits, then fills
Therapy starts late

The patient abandons
Therapy never starts

The patient is switched
Another product starts instead




Booked as a timing variance
Explained away by quarter-end

Booked as a volume miss
Attributed to soft demand

Booked as a mix shift
Attributed to competition



FIGURE 2. The same event is recorded three different ways, and none of the three names the cause.


The first outcome is survivable. The patient waits, the therapy starts late, and the quarter absorbs a timing variance that gets explained in a footnote. The second and third are the expensive ones, because both get attributed to something they are not. A volume miss reads as soft demand. A mix shift reads as competitive pressure. Neither explanation mentions authorization, so neither generates a fix.


The variance report is not wrong. It is just answering a question nobody asked, using the only data that survived.


## Why finance never sees it


This is a visibility problem with a specific shape. Finance receives claims, chargebacks, rebate submissions and utilization files. Every one of those artifacts is generated downstream of a successful dispense. The failure happens upstream, at a counter, between a pharmacist, a payer system and a patient, and it produces a rejection code that lands in somebody else's data set.


So the information exists. It is sitting in switch data, hub data and pharmacy reject reporting. It is simply not routed to the people building the accrual, and it is not part of the close calendar. That is an organizational choice rather than a technical limitation.


## What to measure alongside accuracy


None of this argues for less rigor on rebate accuracy. It argues for a second measure standing next to it, so the precision has something to be precise about.



Reject and reversal volume by reason code. The raw count of prescriptions that hit a wall, separated by why. This is the denominator that rebate accuracy is silently assuming.

Conversion from approved to filled. An approval is not a dispense. The gap between the two is where the second and third outcomes above live.

Time from first attempt to first fill. Delay is the leading indicator of abandonment, and it is measurable long before the abandonment shows up as a volume miss.

Reconciliation of forecast units to attempted units. Not to dispensed units. Forecasts are built on patients who need the therapy, so the honest comparison is against how many tried.



Put those four next to the accuracy metrics and the variance conversation changes shape. It stops being a debate about whether the accrual was right and becomes a question about where demand went.


Your approval rate is not your access rate. It describes the prescriptions that survived long enough to be measured.


## The same discipline, one step earlier


Gross-to-Net is the financial echo of how well the enterprise executed the patient journey. The enterprise develops, manufactures, prices, contracts, distributes and supports. It does not diagnose, prescribe, dispense or treat. What it can do is refuse to let a measurement system stop at the point where its own data happens to begin.


Rebate accuracy asks whether we paid the right amount on what we sold. The harder and more useful question is whether what we sold reflects what patients were actually prescribed. The first question is closed and well governed. The second one is where the money is.



The ten places a patient can leave are on the philosophy page. The affordability version of the same problem is in Rethinking Copay Accumulators, the government pricing version is in Government Pricing Is No Longer a Calculation, and terms used here are defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop?




Primary source.


AMA Survey: Prior Authorization Reform Pledge Falls Short With Physicians, American Medical Association, May 2026, reporting a 2025 survey of 1,000 practicing physicians.




Survey figures are the published findings of the American Medical Association. The operating patterns described reflect my own experience and are offered as commentary, not as legal, regulatory, clinical or accounting advice. The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.

## Gross-to-Net Was Never About the Numbers. It Was Always Patients + Profitability™.
URL: https://patrickrcoyle.com/gtn-revenue-leakage-patients-profitability/
Published: 2026-08-18

The short version: revenue leakage declines because patient leakage declines first. Gross-to-Net is the financial record of every commercial decision that touched the patient journey, so the fastest way to improve it is to name the three worst friction points in that journey, quantify the net-price impact of each, and remove them.
How patient friction becomes a Gross-to-Net number
The chain runs in one direction. Patient friction, meaning a wall at the pharmacy counter, a wait or a cost, becomes patient leakage when the prescription never becomes a therapy. Patient leakage becomes revenue leakage, which is units that were demanded and never dispensed. All of it is finally recorded as Gross-to-Net, the financial record of every commercial decision that touched the patient journey. Revenue leakage declines because patient leakage declines first, which means the fastest route to a better number is a better journey.
STARTS HEREPatient frictionA wall at the counter,a wait, a cost.BECOMESPatient leakageThe prescription neverbecomes a therapy.BECOMESRevenue leakageUnits that were demandedand never dispensed.RECORDED ASGross-to-NetThe financial record ofevery decision upstream.Revenue leakage declines because patient leakage declines first. Not the other way around.So the fastest way to improve the number is to improve the journey that produced it.
FIGURE 1. Read it left to right. The number at the end is the only part finance can see.






For much of my career, Gross-to-Net was viewed as one of the last stops in the commercialization process. It lived quietly within Finance, emerging at month-end through accruals, reconciliations, rebates, chargebacks, and government pricing calculations. Success was measured by how accurately organizations could explain what had already happened.




At the time, that made perfect sense. GTN reflected the financial consequences of commercial decisions that had already been made.




## What Gross-to-Net Actually Is




It is worth being precise about what Gross-to-Net actually is. GTN is the average net price a manufacturer keeps per unit after all of the drug-channel and healthcare-segment deductions are taken out: rebates, chargebacks, discounts, copay assistance, 340B, fees, and returns. But even that undersells it. GTN is really about recognizing the revenue you expect from a patient before you ever see them show up at a pharmacy or in a clinic. It is a price placed on a relationship that has not yet happened.




The scale is not incidental. Drug Channels Institute estimates that manufacturers' total Gross-to-Net reductions across brand-name drugs reached $416 billion in 2025, up from $356 billion in 2024. That is the annual distance between what the industry lists and what it actually keeps.




Looking back, I believe we misunderstood what GTN really was.




## What We Misunderstood




GTN was never simply measuring financial outcomes. It was measuring the cumulative effect of thousands of commercial decisions made across an organization. Every contracting strategy, every distribution choice, every patient support program, every affordability initiative, every pharmacy relationship, and every payer negotiation ultimately converged in one place. GTN became the financial language of commercialization, even though we continued to treat it as an accounting function.




The industry has spent decades becoming remarkably good at explaining yesterday while investing far less energy in understanding what is happening today.




That distinction is becoming increasingly important.




Commercialization has grown dramatically more complex. Patients navigate increasingly fragmented journeys. Pharmacies have evolved into sophisticated clinical and financial intermediaries. Payers continue to redesign benefit structures. Copay maximizers, accumulators, alternative funding programs, 340B evolution, vertical integration, direct-to-patient models, and artificial intelligence are reshaping the environment faster than many organizations can redesign their operating models.




The scale of those forces is easy to underestimate. Discounted purchases under the 340B program alone reached $100 billion in calendar year 2025, a roughly 23 percent increase over the prior year, according to HRSA. A single one of these dynamics is now larger than the entire net revenue of most manufacturers.




Yet many manufacturers still organize themselves as though each of these challenges belongs to a different department.





Finance measures the outcomes.

Market Access negotiates the contracts.

Trade manages distribution.

Patient Services supports access.

Government Pricing manages compliance.

Commercial Operations manages execution.





Each function performs exceptionally well within its own responsibilities, but the patient experiences none of those organizational boundaries. Neither does the financial outcome. The patient experiences one journey, and the organization ultimately experiences one Gross-to-Net.




## The Future of GTN Is Alignment, Not Accounting




This is why I have increasingly come to believe that the future of GTN has very little to do with accounting.




Its future lies in organizational alignment.




One of the greatest misconceptions in healthcare is that patient access and profitability exist in tension with one another. My experience has consistently suggested the opposite. Organizations that reduce friction throughout the patient journey often create greater predictability throughout the commercial model. Therapy begins sooner. Persistence improves. Forecasts become more reliable. Commercial investments become more intentional. Revenue leakage declines because patient leakage declines first.





Patients and profitability are not competing objectives. They are reflections of the same system functioning well, or functioning poorly.





The industry data supports this. IQVIA Institute research found that roughly 9 percent of new prescriptions are abandoned at the pharmacy counter, but that figure climbs to approximately 45 percent once the patient's out-of-pocket cost exceeds $125, and above 60 percent once it exceeds $500. In the year that analysis covered, that 9 percent amounted to roughly 634 million prescriptions left at the counter. Those are not accounting events. They are patients deciding, at a counter, that they cannot proceed. Every one of them eventually arrives in a forecast.




## What This Looked Like in Practice




Let me make that concrete, because I lived it. One of the first things we did when I became a CFO was step back and look at how the patient journey around one of our medicines had actually evolved, not through any fault of the brand, but in the real world. The therapy had moved into specialty pharmacies that, through no fault of their own, did not yet have deep clinical experience managing a serious adverse event like hand-foot skin reaction. So when a patient developed it, the instinct was to wait for the next oncologist visit rather than to act. And for a patient in pain, waiting too often meant abandonment.




On the P&L, that abandonment looked like softening persistence and a forecast that missed. But that was the echo, not the event. The event was a patient walking away from a therapy that was working. So we treated it as a journey problem rather than a finance problem. We connected those patients directly with support, and we equipped the pharmacies to make the right call to the physician and get the titration right rather than stop, so that a manageable side effect became a dose adjustment instead of a discontinuation. Patients stayed on therapy. Outcomes improved. And the revenue leakage we had been struggling to explain in the accrual simply declined, because the patient leakage declined first.




The most important thing we gave those patients was not persistence, or net price, or a cleaner forecast. It was hope. For anyone who knows the medicine, that word is fitting: HOPE is the name of one of lenvatinib's own trials.




It is worth knowing what that trial actually was. HOPE enrolled 52 patients with anaplastic thyroid cancer across 17 institutions. Anaplastic thyroid cancer is one of the most aggressive malignancies in medicine. One-year survival in the study was under 12 percent. The investigators called it HOPE anyway.




I have thought about that choice for a long time. They did not name the trial for what the data were likely to show. They named it for what they were trying to give the patient.




Somewhere between that trial and the pharmacy counter, we change vocabularies. We begin saying adherence, persistence, conversion, capture, leakage. None of those words are wrong. I use them constantly, and the chart below is drawn in exactly that language. But every one of them describes the patient from the outside, as volume the enterprise is trying to hold onto.




Both descriptions are true. They are the same event viewed from two positions. A patient who stops therapy in month three is a persistence event in a forecast and a person who ran out of reasons to keep going at their own kitchen table. The bucket leaks and someone loses hope. Same moment, described twice.





You do not stop the leak by staring at the leak.





What I have learned is that you can only fix it from one of those two positions. You do not stop the leak by staring at the leak. You stop it by asking why that particular patient ran out of reasons, and then removing whatever it was. Sometimes it is money. Sometimes it is a side effect no one prepared them for. Sometimes it is twelve days of silence after a prior authorization.




Fix those, and the bucket stops leaking. In that order. Never the reverse.




Hope is not a soft word in this business. It is the thing that has to survive every hand-off in the journey. When it does not, nothing downstream works. Not the outcome. Not the forecast. Not the Gross-to-Net.





[caption id="attachment_1919" align="aligncenter" width="1024"] A brand's prescriptions leak at every point of patient friction.[/caption]





## Before AI Can Help, the Organization Has to Agree




Artificial intelligence will undoubtedly accelerate this transformation, but I believe many organizations are asking the wrong question. The conversation often begins with which models to deploy or which processes to automate. Those are important questions, but they are not the first questions.




Before artificial intelligence can make better decisions, organizations must first agree on what defines a better decision.




AI cannot align an organization that remains fundamentally disconnected.




It cannot reconcile competing incentives between Finance, Commercial, Market Access, Trade, Patient Services, Government Pricing, and Operations. It cannot replace leadership. It cannot create a shared understanding of the assumptions that drive commercialization. Those responsibilities remain uniquely human.




What AI can do is amplify organizations that have already achieved alignment. It can connect patient journey signals, pharmacy behavior, payer dynamics, channel performance, affordability programs, forecasting assumptions, and financial outcomes into a continuously learning system that allows leaders to recognize change before it becomes financial leakage. But amplification cuts both ways. Point that same capability at an organization that is not aligned, and it will industrialize the misalignment: faster, at scale, with more confidence and less accountability.




## The Harder Frontier Is Continuity




Which is why the harder frontier is not artificial intelligence at all. It is continuity. As manufacturers finally begin engaging patients directly, they do it through many hands: ten vendors hired to solve ten slices of a single journey, each capable within its own slice and, by design, disconnected from the rest. What breaks is the journey itself. At every hand-off the patient is effectively re-tokenized, a new identifier standing in for them at each vendor, and unless those tokens are deliberately reconciled, the thread of their data is cut, so each touchpoint begins again rather than building on the one before it. Left unmanaged, those seams harden into data gaps. And when you point AI at a process stitched together from gaps, it does not fail quietly; it hallucinates the operation, confidently narrating hand-offs, statuses, and outcomes that never occurred, because no single entity holds the whole. Governance is what closes those seams. It has to be built in by contract, by design, by training, and by culture, all at once, so that one entity maintains continuity across every hand-off, and the intelligence built on top of it is describing something real.




## Human Intelligence First. Then Artificial Intelligence.




This is where most of the industry has the sequence backwards. Nearly every large organization I speak with is out shopping for an AI-enabled GTN solution, whether a model, a platform, or a copilot, as though the technology itself were the missing piece. It rarely is. What is missing, almost always, is the human intelligence to connect the patient and profitability journey in the first place: to define what a good decision looks like, to reconcile the hand-offs, to keep the entire journey in a single frame. That work cannot be bought as software. But do it, and artificial intelligence finally becomes worth deploying, because now the large language models you point at the problem have a coherent, connected reality to learn from. They stop hallucinating, because there are no gaps left for them to invent across, and their output arrives in a form a human can actually read, trust, and act on. The order is everything: Human Intelligence first, to connect the journey; then Artificial Intelligence, to scale it. Reverse it, and all you have automated is the confusion.




## From What Happened to What Should We Do Next




That represents a profound shift in thinking.





For decades we asked, "What happened?"

Increasingly we are asking, "What is happening now?"

Soon the question will become, "What is likely to happen next, and what should we do before it does?"





That evolution is larger than GTN. It represents the emergence of a new commercialization operating model.




## Patients + Profitability™




Over the past several years, my own thinking has continued to evolve beyond GTN itself. I no longer view commercialization as a collection of independent functions. I see it as an interconnected system where every commercial decision ultimately influences both the patient's experience and the financial sustainability of innovation. When those two outcomes improve together, organizations become more resilient, launches become more successful, and innovation becomes more sustainable.




That philosophy became the foundation for everything I have since built. Patients + Profitability™ is the belief that better patient outcomes and stronger financial performance are not competing ambitions. They are the natural result of better commercialization.




## Where to Start on Monday




Prior authorization is the clearest case. A study published in JAMA in July 2026, analyzing more than two million attempts to fill single-source brand-name prescriptions, found that initial rejections rose from 24.3 percent in 2018 to 40.7 percent in 2024. Nearly half of those rejected attempts, 48.4 percent, were never followed by a fill of the prescribed medicine or a same-class alternative within 90 days. The patients who did eventually get treated waited an average of 12 days after that first rejection. Twelve days is not an administrative statistic. It is a patient in pain, waiting.




If you lead a brand or a P&L and you want somewhere to start on Monday, it is simpler than it sounds. Map the three worst points of friction in your patient's journey: the prior authorization that drags, the copay that surprises, the side effect no one prepared them for, the hand-off that quietly drops. Then put a net-price number on each. That number is your Gross-to-Net, told forward instead of backward. Then go fix the friction. The finance tends to take care of itself.




## Where This Is Heading




I believe that is where our industry is heading, not toward better accounting, but toward better alignment. Not toward isolated technologies, but toward intelligent systems that connect every commercial decision back to the patient.


Because GTN was never just about the numbers.




It was always about understanding the journey that created them.




And perhaps, after all these years, that journey has always been about something much bigger than Gross-to-Net.




It has always been about Patients + Profitability™.




### Sources and Notes


Gross-to-Net scale: Drug Channels Institute, "2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges," July 2026. DCI estimates total Gross-to-Net reductions for brand-name drugs of $416 billion for 2025, following $356 billion for 2024.

Prescription abandonment: IQVIA Institute for Human Data Science, "Medicine Spending and Affordability in the U.S.: Understanding Patient Costs for Medicines." Approximately 9 percent of new prescriptions are abandoned; abandonment is under 5 percent at no out-of-pocket cost, approximately 45 percent above $125, and above 60 percent above $500. Abandonment is measured as a prescription not dispensed within 14 days of the initial fill.

340B program scale: Health Resources and Services Administration, 2025 340B Covered Entity Purchases, released July 2026. Covered entities purchased $100 billion in covered outpatient drugs in calendar year 2025, an increase of approximately 23 percent over the $81.4 billion reported for 2024, with disproportionate share hospitals accounting for roughly $79 billion.

Prescriptions abandoned: IQVIA Institute, "Drug pricing's 1% problem," October 2020. Patients abandoned approximately 634 million prescriptions in 2019, representing 9 percent of prescriptions nationally that year.

Prior authorization and rejection rates: Levy JF, Alexander GC, Vabson B, Ippolito BN. "Formulary-Related Insurance Denials of Single-Source Branded Drugs in the United States." JAMA, published online July 9, 2026. Analysis of pharmacy claims from 1.17 million individuals and more than two million fill attempts, January 2018 through September 2024, using IQVIA's Formulary Impact Analyzer. Initial rejections rose from 24.3 percent to 40.7 percent; 48.4 percent of rejected attempts were not followed by a fill of the prescribed drug or a same-class alternative within 90 days; mean delay to fill among those eventually treated was 12 days.

Hand-foot skin reaction with lenvatinib: Kim BH, Yu SJ, Kang W, Cho SB, Park SY, Kim SU, Kim DY. "Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma." Journal of Gastroenterology and Hepatology. 2022 Mar;37(3):428-439. doi:10.1111/jgh.15727. Hypertension, diarrhea, decreased appetite and weight, hand-foot skin reaction, and proteinuria are among the most common adverse events associated with lenvatinib. The consensus emphasizes proactive management and dose adjustment to preserve treatment continuity rather than discontinuation.

HOPE: Higashiyama T, Sugino K, Hara H, et al. "Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)." European Journal of Cancer. 2022;173:210-218. doi:10.1016/j.ejca.2022.06.044. Investigator-initiated, multicenter, open-label, nonrandomized phase II study; 52 patients enrolled across 17 institutions. Registered as NCT02726503 under the acronym HOPE.

The patient experience described in this paper reflects the author's direct operating experience. Clinical management of any adverse event is a decision for the treating physician. Nothing here is clinical, legal, or investment advice.






About the Author

Patrick R. Coyle is the originator of the Patients + Profitability™ philosophy and the frameworks built on it, including The 10 Exits of Therapy™ and the 5 Layers of GTN™. He previously served as VP & CFO of Eisai Americas, GTN Practice Lead at IQVIA, and Managing Director of GTN Risk Advisory at Baker Tilly, with senior finance and commercial roles at Novartis, Insmed, and Bayer. He is the Founder and CEO of Novus Proximus LLC.

More frameworks, guides, and tools in the Resource Library. Reach him at hello@patrickrcoyle.com.

What this looks like inside a rebate process is in You Can Be Exactly Right About the Wrong Number, and the affordability version is in Rethinking Copay Accumulators. The ten places a patient can leave are on the philosophy page, with terms defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop?
The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.

## What Is Pharmaceutical Commercialization? A Complete Executive Guide for Pharmaceutical and Biotech Leaders
URL: https://patrickrcoyle.com/what-is-pharmaceutical-commercialization/
Published: 2026-08-09

Ask ten pharmaceutical executives to define commercialization and you will get ten answers. Launch execution. Sales force deployment. Pricing and contracting. The machinery that turns a molecule into a brand. Each is partly right. None is complete.
Pharmaceutical commercialization is the disciplined work of turning an approved therapy into sustained patient use. It is not a department and it is not a window of time. It is the connective structure between a clinical result and the patients who need it, and between that result and the revenue that funds the next one. It begins well before approval and it does not end at launch.
This guide is for the people who own that structure. Founders building commercial capability for the first time, commercial leaders inheriting a launch plan they did not design, medical affairs and access leaders working out where their function actually sits, and investors trying to judge whether a portfolio company understands what happens after approval.
## What the discipline actually covers
It is easy to mistake commercialization for marketing, and easy to mistake it for sales. Neither survives contact with reality. Marketing builds awareness. Sales drives adoption. Commercialization is the architecture that decides whether awareness and adoption ever become a patient starting, and staying on, effective therapy.
A therapy can have excellent marketing and a capable field team and still fail commercially, because the access strategy, the pricing structure or the distribution model was never built to carry real-world uptake. The scope runs across pricing and access strategy, distribution and channel design, field deployment, medical affairs engagement, patient support and affordability, and the ongoing work of keeping a therapy relevant as competitors, payers and guidelines move.
A scope note worth making, because the industry uses the word inconsistently. Some organizations mean only the launch window, the first twelve to eighteen months. Others mean every commercial activity across the full life of the product. Both usages are defensible. The distinction matters operationally, because an organization that plans only for the launch window, without the governance for what follows, gets caught flat-footed the first time a competitor enters or a formulary reopens.
It is not marketing and it is not sales. Those are instruments. Commercialization is the structure that decides whether they produce anything.
It is cross-functional by definition. Access, distribution, medical affairs and patient support answer to one commercial objective or they answer to four.
Strong execution cannot rescue weak architecture. A field team cannot sell around a pricing decision made two years earlier.
## The four Product Lifecycle Phases
Commercialization is not an event. It runs across four phases, and each one constrains the ones after it. Organizations that treat them as sequential handoffs, passed from team to team with minimal overlap, consistently underperform organizations that run them as one continuous effort.
The four Product Lifecycle Phases and the question each one has to answer
Commercialization runs across four Product Lifecycle Phases. Phase 1 is Pre-Launch and Launch Readiness, which asks whether a prescribed patient can actually start therapy on day one. Phase 2 is Launch and Early Commercialization, which asks whether patients are starting at the rate the model assumed. Phase 3 is In-Market Optimization, which asks whether they are staying on therapy and what the real-world evidence supports. Phase 4 is Lifecycle and Loss of Exclusivity, which asks how the therapy stays clinically and commercially relevant. The pricing and access architecture set in Phase 1 still governs what a patient pays in Phase 4.
PHASE 1
Pre-Launch and
Launch Readiness
Can a prescribed patient
start therapy on day one?
PHASE 2
Launch and Early
Commercialization
Are they starting at the
rate the model assumed?
PHASE 3
In-Market
Optimization
Are they staying on, and
what does the data show?
PHASE 4
Lifecycle and Loss
of Exclusivity
How does it stay relevant
as the market moves?
The pricing and access architecture set in Phase 1 still governs what a patient pays in Phase 4.
Nothing about that decision gets easier to change later. It only gets more expensive.
One system across four phases, not four projects handed between four teams.
FIGURE 1. Four phases, four questions. Each one is constrained by the answers given in the phase before it.
The phases are a shared vocabulary rather than a schedule. In practice they overlap and loop back. What they give a leadership team is a common answer to the question of where the organization actually stands, which is harder to get agreement on than it sounds.
The connective tissue across all four is the patient journey. A pricing decision made in Phase 1 shapes what a patient pays at the counter years later. A distribution model chosen in Phase 1 decides whether a rural patient waits two weeks for a specialty therapy. What a company can claim and how it can promote is governed throughout by regulators, which means the constraint has to be built in from the start rather than applied as a check at the end.
## Why the discipline carries more weight than it used to
Three structural shifts have raised the stakes. The cost of reaching approval has kept climbing, so the return on that investment now rests almost entirely on commercial execution, with very little room to recover a poor launch through volume. Payers have grown more sophisticated about demanding real-world value evidence rather than trial data alone, which means commercial strategy has to be built around outcomes from the beginning rather than retrofitted. And patients have more visibility into their options and their costs than at any previous point, which moves real leverage toward organizations that can show value at the point of care.
Those pressures compound. A therapy that clears every regulatory hurdle and launches on a commercial strategy built for an earlier era, one that assumes payers follow clinical data automatically or that prescriber awareness alone drives adoption, will underperform its own science.
There is a capital dimension that boards feel more sharply than anyone. Commercial performance in the first two to three years is frequently the single largest factor in whether an organization can fund its next program without dilution or unfavorable terms. That is why sophisticated investors now diligence commercial readiness with something close to the intensity they apply to trial design.
I have never seen a therapy fail commercially because the science was weak. I have seen many fail because the organization treated commercialization as something you work out after approval.
## Where it actually breaks
Across the organizations I have advised, the same failures recur regardless of therapeutic area or company size. What is striking is not the failures themselves. It is the distance between where each one originates and where anybody notices it.
Where commercialization failures start and where they get noticed
Four recurring failures each originate in one phase and surface in a later one. Access strategy built after pricing is locked originates in Phase 1 and surfaces in Phase 3 as contract terms nobody can unwind. Patient support sized to a generic benchmark originates in Phase 1 and surfaces in Phase 2 as patients lost while waiting. Functions measured on separate targets originates in Phase 2 and surfaces in Phase 3 as every function green and the aggregate red. No real-world evidence program originates in Phase 2 and surfaces in Phase 4 as a weak position at renewal. In every case the organization sees the symptom one or two phases after the decision that caused it.
WHERE THE DECISION IS MADE
WHERE SOMEBODY NOTICES
Access strategy built after pricing is locked
PHASE 1
Contract terms nobody can unwind
PHASE 3
Patient support sized to a generic benchmark
PHASE 1
Patients lost while waiting to start
PHASE 2
Functions measured on separate targets
PHASE 2
Every function green, the aggregate red
PHASE 3
No real-world evidence program
PHASE 2
Nothing to negotiate with at renewal
PHASE 4
Nobody diagnoses a Phase 1 decision from a Phase 3 report. They diagnose the Phase 3 team.
FIGURE 2. Every one of these is diagnosed downstream of the decision that caused it.
Read that gap carefully, because it explains most of the misdiagnosis in this discipline. The team holding the disappointing number is almost never the team that made the decision producing it. A Phase 1 choice about how patient support was sized shows up as a Phase 2 adoption miss, and the Phase 2 team gets the scrutiny.
Two more failures belong on the list. Patient support infrastructure is often the first line cut under margin pressure, despite being one of the highest-leverage investments available in adherence and therefore in revenue durability. And the operational complexity of specialty distribution is consistently underestimated, because launch timelines get modeled on retail assumptions when the therapy needs cold chain, specialty pharmacy relationships and hub services.
Most failures are structural, not analytical. Organizations can usually name where the patient journey breaks. Naming it is not the hard part.
Symptoms surface one or two phases downstream. Which means the wrong team is usually asked to explain them.
Patient support is cut first and costs most. It is the line item with the widest gap between how it is budgeted and what it protects.
## What commercial excellence actually requires
Commercial excellence gets reduced in practice to field sizing and targeting sophistication. Those matter. They are downstream instruments rather than the discipline itself.
The discipline starts with the ability to see the patient journey and the commercial journey as one connected system, and to build decisions that reflect that rather than optimizing each function on its own. In practice it shows up as specific habits. Pricing and access strategy run through the same planning process as clinical timelines instead of arriving as a downstream negotiation. Success is measured with patient-level outcomes, adherence, time to initiation, persistence, standing next to volume and revenue. And what the organization learns from prescribers and payers actually reaches the people making strategic decisions, rather than dead-ending in a quarterly report nobody outside the originating function reads.
It also requires a particular kind of organizational humility: treating early commercial data as a diagnostic signal rather than a verdict to be defended. The organizations that struggle tend to read early underperformance as a communications problem to be managed. By the time the underlying issue is acknowledged, the payer and competitive positioning that would have made correction cheap has hardened.
Your approval rate is not your access rate. It describes the prescriptions that survived long enough to be measured.
## Leadership is the variable
Leadership decides whether an organization closes these gaps or simply names them in a strategy deck. Commercialization failures are rarely failures of analysis. They are failures of will: an unwillingness to restructure incentives, merge reporting lines that have always been separate, or hold commercial and medical leaders jointly accountable for an outcome neither fully controls.
Incentive design is where good intentions quietly fail. An organization can say sincerely that patient outcomes and commercial performance matter equally, and still pay commercial leaders on quarterly revenue and medical affairs leaders on publication counts. Neither leader is behaving irrationally. They are optimizing exactly what they are measured on. Closing that gap means changing what gets measured, not what gets said at the town hall.
The teams that get this right review patient journey data in the same forum where they review commercial performance. They judge a launch on the retention curve with the same rigor they apply to the adoption curve. And they build cross-functional fluency deliberately, rather than assuming translation between functions happens on its own.
Most commercialization strategies fail in the org chart, not in the market. The market rewards the organization that coordinates. It rarely rewards the one with the smartest individual functions.
## What is changing
Value-based contracting is becoming the default. Payers increasingly structure reimbursement around demonstrated real-world outcomes rather than list price, so an organization without real-world evidence infrastructure negotiates from weakness.
Patient-level data is a commercial asset. Connecting prescribing, adherence and support engagement into one view of the journey is a durable advantage, and it is now reachable much earlier by mid-sized companies that once lacked the infrastructure.
The commercial and medical boundary is blurring. As scientific engagement becomes more central to adoption decisions, integrating medical affairs into commercial planning produces faster and more durable uptake than firewalling the two.
Rare disease models are moving into larger categories. Intensive patient support, direct payer engagement and close real-world monitoring were built for small populations and are being adapted for traditional therapeutic areas.
Global launch is less sequential. Tightening capital markets and shorter exclusivity windows are pushing companies toward near-simultaneous multi-market launches, which requires commercial, regulatory and access strategy to be coordinated globally far earlier than the traditional playbook assumed.
## What this comes down to
Commercialization is too often treated as the execution work that starts once the real work of development is finished. That framing understates one of the most demanding disciplines in the industry, and it is the one that decides whether years of clinical investment become patients who actually receive and stay on effective therapy.
Building the capability is not a matter of hiring a stronger field team or a sharper pricing analyst. It requires treating the patient journey and the commercial journey as one system, led by executives willing to change how their teams are structured and measured, not just what each team is asked to deliver.
The enterprise develops, manufactures, prices, contracts, distributes and supports. It does not diagnose, prescribe, dispense or treat. Commercialization is the whole of what it can control, and most of it is currently being measured by someone who is not looking at the patient.
## Frequently asked questions
### What is pharmaceutical commercialization in simple terms?
It is the complete process of turning an approved therapy into a treatment patients can actually access, afford and stay on. That spans pricing, market access, distribution, prescriber engagement and patient support, not just marketing or sales.
### How is it different from marketing a drug?
Marketing builds awareness of a therapy. Commercialization is the broader structure of pricing, access, distribution and support that decides whether awareness ever becomes a patient successfully starting and remaining on therapy.
### When should commercialization planning begin?
In parallel with late clinical development, not after approval. Pricing architecture, access strategy and distribution planning all take years to build correctly, and each one shapes how the launch performs.
### What is the biggest reason commercialization strategies fail?
Structure rather than analysis. Commercial, medical affairs and access functions operate against separate goals and separate data, so every function can hit its target while the patient journey still breaks.
### How does market access fit into the lifecycle?
It sits at the center, connecting pricing strategy, payer negotiation and patient affordability. Decisions made there shape every later phase, including prescriber adoption and adherence.
### What does commercial excellence require beyond a strong field team?
Treating the patient and commercial journeys as one system. That means aligning pricing and access planning with clinical timelines, measuring patient-level outcomes alongside revenue, and building feedback loops that actually reach decision-makers.
The ten places a patient can leave are on the philosophy page. The Phase 1 version of this argument is in The Launch Begins Long Before Approval Day, the Phase 2 version is in A Launch Does Not Fail in the Forecast, the finance version is in You Can Be Exactly Right About the Wrong Number, and terms used here are defined in the glossary. The patient-side view of the same ten exits is at Where did your treatment stop?
The patterns described here reflect my own experience advising pharmaceutical and biotech organizations, and are offered as commentary rather than as legal, regulatory, clinical or accounting advice. The views expressed are my own and are not made on behalf of any current or former employer. All trademarks belong to their respective owners.